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Abstract 
Head and neck cancer accounts for approximately 6% of diagnosed malignancies 
in the United States, with an estimated 35,000 incidences and over 7,000 deaths every 
year. Head and neck squamous cell carcinoma (HNSCC) comprises the majority of head 
and neck cancers, with a worldwide incidence of more than 500,000 cases. Head and 
neck cancer patients often present in advanced stages of disease, and despite ongoing 
research, survival rates remain lower than other more common malignancies. Cytokines 
and pro-inflammatory factors have been shown to have a critical role in the various steps 
of malignant transformation, including tumor growth, survival, invasion, angiogenesis, 
and metastasis. Mitogen-activated protein kinases (MAPK), such as p38, JNK, and ERK, 
relay information from extracellular signals to the effectors that control these diverse 
cellular processes. Negative regulation of MAPK activity is provided by MAPK 
phosphatases that dephosphorylate MAPK proteins. The founding member of this class of 
phosphatases is dual-specificity phosphatase-1 (DUSP1) and has been shown to be 
crucial for negatively regulating innate immune responses. Initial studies revealed 
significant over-expression of DUSP1 in a range of human epithelial tumors including 
prostate, colon, and bladder, with loss of DUSP1 expression in tumors of higher 
histological grade and in metastases. Based on the above, this study hypothesized that 
DUSP1 is a negative regulator of tumor-promoting inflammation in head and neck 
cancer. To test this hypothesis, we first assessed the effect of Dusp1 deficiency in animal 
models of tumor progression. Dusp1 deficiency enhanced tumor progression in a 
carcinogen-induced model of oral cancer with higher levels of inflammatory infiltrate and 
gene expression. Deficiency in hematopoietic-derived cells by bone marrow transplant 
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did not recapitulate the advanced disease phenotype seen in Dusp1 deficient animals. 
However, Dusp1 deficiency also enhanced the progression of subcutaneous syngeneic 
breast and prostate allograft tumors. Examination of Dusp1 deficient bone marrow 
macrophages revealed enhanced expression of inflammatory cytokine IL-1β after 
stimulation with lipopolysaccharide. Elevated levels of IL-1β were shown to be due to 
increased de novo transcription in addition to enhanced mRNA stability. Inflammasome 
activation was not affected by Dusp1 deficiency. Lastly, in human HNSCC tissues, both 
mRNA and protein DUSP1 was decreased in tumor compared to adjacent non-tumor 
samples, and IL-1β protein was increased. These studies demonstrate DUSP1 expression 
is deregulated in HNSCC and suggests an important role for DUSP1 as a negative 
regulator of tumor-promoting inflammation through suppression of inflammatory 
cytokines, such as IL-1β. Understanding the role of these inflammatory mediators and the 
upstream signaling pathways in the tumor microenvironment in head and neck cancer 
may yield novel therapeutic targets for prevention and treatment.  
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CHAPTER 1. Background & Significance 
 
1.1 Head and neck squamous cell carcinoma 
Importance of the problem 
Head and neck cancers encompass a set of malignancies that affect the oral cavity, 
nasal cavity and sinuses, nasopharynx, oropharynx, laryngopharynx, and salivary glands. 
Head and neck squamous cell carcinoma (HNSCC) comprises over 90% of these cancers 
and is the sixth most commonly diagnosed cancer in the world (1). Of HNSCCs, cancers 
of the oral cavity are the most common, with 263,900 new cases of oral squamous cell 
carcinomas (OSCC) diagnosed worldwide and an estimated 42,000 new cases in the 
United States in 2014 (2, 3). 
Current treatments available to patients diagnosed with HNSCC include surgical 
resection, radiation, and chemotherapies, performed alone or in combination, depending 
upon disease stage. Since the 1960s, great improvements have been in reconstructive 
methods to improve functional outcomes and reduce associated morbidities, yet overall 
survival rates have not significantly changed (4). 
 
Etiological factors in HNSCC 
Tobacco remains an important risk factor for HNSCC, as upwards of 80% of 
cases are attributed, in part, to tobacco exposure (5). Smokers have ten times the risk of 
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HNSCC compared to patients who have never smoked (6). In the United States, public 
health campaigns and significant health education efforts have begun reduce prevalence 
of tobacco use, leading to an overall trend toward decreased HNSCC incidence (5, 6). 
However, tobacco exposure remains an important causative agent in HNSCC for many 
countries outside the developed world.  
Although the national incidence of HNSCC has been decreasing due to changes in 
tobacco use, a rapid increase in oropharyngeal squamous cell carcinoma has been 
reported in a younger population of adults, associated with the presence of the human 
papilloma virus (HPV) (7, 8). Of the 100 characterized HPV subtypes, the predominant 
subtype associated with oncogenesis is HPV-16, which accounts for over 90% of HPV-
associated HNSCC (9, 10). The majority of HPV-associated HNSCCs are found within 
the oropharynx, while the rate is much lower for tumors found within the oral cavity (11). 
 
Signaling pathways deregulated in HNSCC 
HPV-mediated carcinogenesis is driven by the E6 and E7 viral oncoproteins 
expressed by the DNA virus. The ubiquitin ligase E6 inhibits p53 tumor suppressor 
function by targeting it for proteosomal degradation (12), and E7 inhibits the 
retinoblastoma protein (pRB) releasing its inhibition of cyclin-dependent kinase 
inhibitors, including p21, p27, and p16 (13). Overexpression of p16, by 
immunohistochemistry, has become commonly used as a detection tool for identifying 
tissues with HPV infection (14). As HPV-associated HNSCC incidence continues to rise, 
the clinical, pathological, and etiological distinctions with significantly improved 
prognosis and therapeutic outcomes from HPV-negative HNSCC are gaining recognition 
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(15, 16). However, the biological mechanisms underlying these characteristics remain 
unclear.  
HPV-negative HNSCCs typically contain TP53 mutations, the most common in 
HNSCC (17), in addition to mutations in other tumor suppressors which enhance 
genomic instability and resistance to typical cytotoxic regimens (18). In contrast, TP53 
mutations are significantly decreased in HPV-positive HNSCCs concomitant with fewer 
overall mutation rates (19). Unlike HPV-positive HNSCCs, where p16 is overexpressed, 
in HPV-negative HNSCC tissues, exome sequencing studies have found mutation rates 
and copy number losses in the CDKNA gene that encodes both p16INK4A and 
p14INK4B at 7% and 20-30% respectively (20, 21). As data continue to emerge, there is 
a growing appreciation for the distinction between HPV-positive and negative disease in 
HNSCC to support the stratification of patients by HPV status for prognostic and 
predictive assessments. 
HNSCC proliferation is driven predominantly by activation of the epidermal 
growth factor receptor (EGFR), phosphatidylinositol-3-kinase-AKT (PI3K-AKT), and 
Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathways (22). 
EGFR is a cell surface receptor that binds ligands such as epidermal growth factor, 
amphiregulin, and β-cellulin, which initiates receptor dimerization, tyrosine kinase 
activation and autophosphorylation, driving downstream signaling cascades. By driving 
cellular proliferation and survival, EGFR is an oncogene with reports of mutations and 
gene amplification in HNSCC (23, 24). As EGFR expression varies among HNSCC 
tissue sites, with higher levels in the oral cavity and pharynx compared to the larynx (25), 
the signaling pathways within different tumor sites likely vary. 
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Cetuximab is a chimeric monoclonal antibody that targets EGFR and was the first 
approved biologic agent for HNSCC. In patients with locally advanced or recurrent and 
metastatic disease, the addition of cetuximab to radiation or platinum chemotherapies 
improves overall survival (26, 27). However, resistance to cetuximab often develops, due 
to expression of a constitutively active EGFRvIII deletion mutant in the cancer cells (28, 
29). Although antibody and vaccine therapies are being developed to target this mutant 
variant, results have not yet been extended to HNSCC (30, 31).  
A number of cytokine receptors activate intracellular signaling cascades through 
JAKs, non-receptor tyrosine kinases constitutively bound to cytokine receptors that 
transphosphorylate receptors after ligand binding. Activated cytokine receptors 
phosphorylate STAT proteins, which translocate into the nucleus to initiate target gene 
transcription as dimerized transcription factors (32). In HNSCC carcinogenesis, the JAK-
STAT pathway has been shown to promote tumor cell survival and growth as well as 
angiogenesis and suppression of anti-tumor immunity within the microenvironment (33). 
Increased STAT3 expression has been shown in cancer cell lines, human tumor tissues, 
and is an early molecular event in patients with tobacco-associated HNSCC (34, 35). 
STAT5 has also been shown to promote tumor growth as well as epithelial-mesenchymal 
transition in HNSCC and may contribute to chemoresistance (36, 37). In addition to 
efforts to shut down STAT3 signaling downstream of EGFR using kinase inhibitors, such 
as erlotinib (38, 39), a recent in-human trial describes effective downregulation of 
STAT3 target genes in HNSCC tissues using an anti-STAT3 oligonucleotide (40).   
MicroRNAs (miRNAs) are small non-coding RNAs of 18-22 nucleotides in 
length that regulate a host of cellular processes through altering gene expression. After 
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transcription by RNA polymerase II as primary-miRNAs, they are processed within the 
nucleus into pre-miRNAs that are transported into the cytoplasm for further processing 
by the ribonuclease Dicer to form a mature miRNA. Upon association with the RNA-
induced silencing complex (RISC), the miRNA can associate with its target mRNAs 
through interactions most often within the 3’-untranslated region (UTR) to effect gene 
silencing. Partial complementarity with its target mRNA sequence instead results in 
suppression of protein synthesis by translational repression (41).  
Like coding genes, miRNAs have been identified that are oncogenic and 
overexpressed in cancer or tumor suppressive and down-regulated in cancers. In HNSCC, 
the tumor suppressive miRNAs let-7, miR-125a/b, miR-200a, and miR-133a/b have been 
reported to regulate important signaling targets such as oncogenic KRAS, EGFR, the 
EMT-associated transcription factors ZEB1 and ZEB2, and the metabolic regulator 
pyruvate kinase 2, respectively (42-47). Oncogenic miRNAs that are overexpressed in 
HNSCC include miR-106b-25, miR-17-92, miR-106a which downregulate the p21 cyclin 
dependent kinase inhibitor and RB1 (48) as well as miRNA-205 which may target the 
tumor suppressor phosphatase and tensin homolog (PTEN) (49). Although an open-
source database of deregulated miRNAs in HNSCC has been established (50), the 
functional impact of these miRNAs and whether they are suitable targets for therapy have 
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1.2 Mitogen-activated protein kinases and regulation 
Overview of MAPK signaling 
Mitogen-activated protein kinases (MAPKs) comprise a number of signal 
transduction pathways that coordinate cellular responses to a variety of intra- and extra-
cellular stimuli (51, 52). MAPKs phosphorylate serine and threonine residues to regulate 
cellular functions including proliferation, differentiation, survival, and death, through its 
actions on gene transcription, protein translation, stability, localization, and enzymatic 
activity (53, 54). Thus, MAPKs are key players in physiological processes, including 
development, immune and metabolic homeostasis, as well as pathological responses in 
human diseases including obesity, autoimmune disorders, and cancer (55-58). 
MAPK pathways typically include an activation cascade of three members: the 
MAPK kinase kinase (MKKK), a MAPK kinase (MKK), and the MAPK, each of which 
serves as a substrate for the previous kinase for activation (59). Dual phosphorylation of 
both a threonine and a tyrosine residue within the activation loop domain are required. 
The major mammalian MAPK pathways include the extracellular signal-regulated 
kinases (ERKs) 1 and 2, the p38 MAPK family including p38α, p38β, p38γ, and p38δ, 
the c-jun N-terminal kinases (JNKs) 1, 2, and 3, and the ERK5 pathway (60). Other less 
well-characterized MAPKs include ERK3, ERK4, ERK7, and ERK8 (61).  
 
Overview of dual-specificity phosphatases 
The functional outcome of MAPK signaling is controlled, largely in part, by the 
duration of pathway activation (62). Thus, MAPK pathway activation is carefully 
balanced by both the activation of upstream pathway kinases as well as a number of 
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negative regulatory mechanisms. Direct inactivation of MAPK signaling can occur 
through dephosphorylation by specific protein phosphatases at either the threonine or 
tyrosine residue, as phosphorylation of both is required for activation. Dephosphorylation 
can be performed by type 1 and type 2 serine/threonine phosphatases, protein tyrosine 
phosphatases, or dual-specificity tyrosine and threonine phosphatases (DUSPs) (63). 
Although all of these family members may play a role, the largest of these groups are the 
dual-specificity phosphatases and MAPK phosphatases (MKPs).  
 
MAPK phosphatase structure and function 
Within the dual-specificity phosphatases, the MAPK phosphatases are a specific 
sub-family of phosphatases dedicated to MAPK regulation, all of which share a N-
terminal noncatalytic domain and a C-terminal catalytic domain, containing the protein 
phosphatase consensus active site (64). The N-terminal domain serves a number of 
functions, including a docking site for MAPK substrates, and localization sequences (65). 
A kinase interacting domain (KIM) was identified within the N-terminus and shown to be 
responsible for MAPK binding through a cognate MAPK motif (66, 67). MKP-mediated 
dephosphorylation occurs through two separate binding, dephosphorylation, and release 
cycles, first of the tyrosine and then the threonine residue (68, 69). Substrate specificity 
overlap may have risen from gene duplication with divergence across evolution; 
however, tissue and cellular localization, in addition to phosphatase-independent 
mechanisms of regulation must also be considered (70).    
The ten catalytically active MAPK phosphatases in mammalian cells can be 
subdivided into three families based on cellular localization, substrate specificity, and 
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sequence homology. The stress-inducible, nuclear MKPs include DUSP1/MKP-1, 
DUSP2, DUSP4/MKP-2, and DUSP5. ERK-selective, cytoplasmic MKPs include 
DUSP6/MKP-3, DUSP7/MKP-X, and DUSP9/MKP-4. Lastly, the JNK and p38-selective 
MKPs, which are found both in the nucleus and cytoplasm, include DUSP8, 
DUSP10/MKP-5, and DUSP16/MKP-7 (71, 72).  
 
1.3 Dual-specificity phosphatase-1 
The archetype of the MAPK phosphatases is DUSP1/MKP-1, an inducible 
nuclear phosphatase that has been shown to bind and dephosphorylate p38, JNK, and 
ERK MAPKs both in vitro and in vivo (66, 73). However, the KIM of DUSP1 has been 
shown to be necessary only for interaction with p38 and ERK MAPKs. The KIM mutant 
in which the arginine residues have been substituted with alanine can still bind and 
dephosphorylate JNK both in vitro and in vivo with the same efficiency (66). Interaction 
of MKPs with their MAPK substrates has been shown, for DUSP6/MKP-3 as well as 
DUSP1, and DUSP2, to induce conformational changes that enhance enzymatic activity 
(66, 74-77). In the absence of a three-dimensional structural conformation, understanding 
DUSP1 function and activity has come from mutagenesis studies and characterization in 
different cells and tissues.   
 
Regulation of DUSP1 expression 
DUSP1 was initially identified as one of a set of genes expressed during the 
G0/G1 transition in cultured murine cells (78) and is widely expressed in a number of 
tissues (72). The human DUSP1 gene is located in chromosome 5 and contains four 
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exons and three introns, encoding a transcript of approximately 2.4kb shown in Figure 1-
1 (79). Transcription is induced following a variety of stimuli, including growth factors, 
cytokines, lipopolysaccharide (LPS), and other cellular stressors, such as hypoxia, and 
heat shock (65, 80, 81). Transcriptional regulation occurs through regions within the 
DUSP1 promoter and upstream regulatory regions containing cAMP responsive 
elements, glucocorticoid responsive elements, the vitamin D responsive element, as well 
as binding sites for activator protein 1 (AP-1), nuclear factor (NF)-κB, specificity protein 
1 (SP-1), and controlled amino acid treatment (CAAT)-binding transcription 
factor/nuclear factor 1 (CTF/NF-1) (79, 82-86). Epigenetic regulation includes histone 
H3 phosphorylation and acetylation that also modulate stress-induced DUSP1 gene 
transcription (87). More recently, promoter methylation has been described as a 
mechanism of DUSP1 downregulation in both the prostate cancer cell line PC-3 and 
HNSCC tissues (88, 89). 
 
Figure 1-1. Schematic of DUSP1 gene. The DUSP1 gene is located on chromosome 5 
and includes 4 exons and 3 introns. The mature transcript is 2.4kb long. The N-terminus 
contains 2 cdc25-like domains and a noncanonical nuclear localization motif. The C-
terminus contains the phosphatase domain. Adapted from Boutros et al. 2008 (70). 
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As an immediate-early response gene, a number of factors induce transcription of 
DUSP1, including serum in fibroblasts (90), dexamethasone (91, 92) and glucagon in 
hepatocytes (93), insulin in a hepatoma cell line (94), and atrial natriuretic peptide in  
human umbilical vein endothelial cells (95). Stressors such as heat shock in dermal 
fibroblasts (96) and murine macrophages (97), osmotic shock in rat hepatoma (94, 98), 
hypoxia (99, 100), cobalt chloride, a hypoxic mimic (101), and tissue ischemia (102, 103) 
also increase transcription. Similar effects are also seen following exposure to DNA 
damaging agents such as reactive oxygen species from hydrogen peroxide treatment (96), 
ultraviolet radiation (104, 105), and gamma-radiation (106). Although a multitude of 
conditions regulate DUSP1 mRNA, it is unclear whether reported increases are a result of 
de novo synthesis or increased mRNA stability.  
The DUSP1 mRNA has a half-life of 1 to 2h, depending upon the induction 
method (78).  Post-transcriptional regulation of DUSP1 includes negative regulation by 
miR-101, following LPS stimulation, to enhance the strength and duration of the 
inflammatory response (107) and control by the RNA binding proteins Hu antigen R 
(HuR) and nuclear factor 90 (NF90), which enhance DUSP1 transcript stability through 
interactions with the 3’UTR (108). In addition to phosphorylation, DUSP1 can be 
modified following oxidative stress through S-glutathionylation, targeting it for 
proteasomal degradation (109).  
Protein expression of DUSP1 can be increased with exposure to many of the same 
stimuli as those which induce expression, including insulin (110, 111), glucagon (93), 
dexamethasone (91, 92), EGF (112), hypoxia (99, 113-115), and peroxide (116). 
However, it is still unclear whether these increases in protein are due to elevated levels of 
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de novo translation or enhanced protein stabilization. As with transcriptional stimulation, 
these inducing factors are not specific to DUSP1 and increase a large number of targets to 
generate their cellular responses. DUSP1 protein half-life has been reported to be 
between 40min (117) and 2h (85). Modulation of protein half-life is differentially 
regulated by a number of mechanisms. Heat shock has been shown to reversibly 
aggregate DUSP1 protein through HSP72, to preserve its function (118). A p38 inhibitor, 
SB203580, partially blocked cisplatin-induced, ERK-mediated accumulation of DUSP1 
protein, independent of transcriptional effects (119). 
 
Regulation of DUSP1 activity 
The large number of family members and overlapping substrate specificity 
suggest redundancy in the negative regulation of MAPKs by MKPs. However, the 
combination of differing subcellular localization, MAPK specificity, and temporal 
control of activity suggest these phosphatases can modulate MAPK signaling with greater 
finesse than simply turning them on or off. A noncanonical nuclear localization signal 
was identified, through a series of deletion and mutation experiments, in the N-terminus 
of DUSP1 (120), and is conserved among the nuclear MKPs. This LXXLL motif targets 
DUSP1 to the nucleus (120), where it exerts its phosphatase action (72, 120). Spatially, 
MKP binding can serve as an anchor to MAPKs, restricting them to a particular cellular 
compartment for nonenzymatic purposes (121, 122). Reports of cytoplasmic localization 
have been made in different human tumor tissue samples (123). In addition, treatment of 
a human lymphoblastic cell line with nerve growth factor increased DUSP1 mRNA and 
protein levels with translocation of the protein to the mitochondria (124). The 
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significance of these reports and understanding what impact DUSP1 has outside the 
nucleus has yet to be addressed. The C-terminus of DUSP1 contains a region which 
autoinhibits phosphatase activity, as a truncated mutant had higher phosphatase activity 
without change in substrate specificity (125). Determining whether this domain plays a 
part in interaction with other proteins may reveal additional levels of regulation.  
DUSP1 has greater affinity for p38MAPK and JNK than ERK1/2 (126) but also 
minor activity for ERK5 (127). A model of DUSP1 regulation of ERK activity 
independent of dephosphorylation suggests its binding prevents ERK1/2 interaction with 
its downstream targets (112) or translocation into the nucleus. DUSP1 is unable to 
recognize or inactivate p38γ or p38δ (66), despite significant sequence homology to 
p38α. Although initial RNAi experiments suggested DUSP1 could interact with and 
inactivate STAT1 protein to regulate interferon-responses (128), subsequent in vitro 
analyses failed to demonstrate protein-protein interactions or phosphatase activity or 
downregulation of interferon-induced transcription (66). RNAi knockdown of DUSP1 
highlighted phosphorylated-histone H3 at serine 10 as a potential dephosphorylation 
target, in response to thrombin and vascular endothelial growth factor (129). Although 
kinetics demonstrated histone H3 dephosphorylation coincided with DUSP1 expression, 
similar results from Dusp1 deficient mouse embryonic fibroblasts do not support a 
DUSP1-dependent mechanism of action (130). 
Typically, MKPs are expressed at low levels basally and up-regulated following 
exposure to stimuli as an immediate early or delayed early response gene (131, 132). 
Subsequent modulation by MAPKs, such as ERK, forms an autoregulatory feedback loop 
for MAPK signaling (133). ERK phosphorylation of DUSP1 at serine 359 and 364 has 
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been shown to increase protein stability, as a mechanism of negative feedback control 
(134, 135). Alternatively, ERK phosphorylation at residues serine 296 and 323 recruit 
ubiquitin ligases to enhance DUSP1 degradation (136-138). DUSP1 has also been shown 
to be acetylated by p300 acetyltransferase on lysine 57, following Toll-like receptor 4 
(TLR4) stimulation (138). Due to its close proximity to the KIM, substrate specificity for 
p38 is enhanced, increasing its negative feedback effect (139).  
 In summary, MAPK regulation by MKPs depends on a number of factors 
including spatial localization and cellular shuttling of MAPKs, substrate MAPK 
concentration, temporal delays in transcriptional feedback, and other post-translational 
modifications. The unique properties of MKPs place them as central coordinators of 
MAPK signaling and crosstalk with other pathways. Understanding these regulatory 
mechanisms will enable more sophisticated targeting of deregulated pathways in disease.  
 
Phenotype of Dusp1 deficient mice 
When first developed, Dusp1 deficient mice were reported to have no overt 
phenotype, with no differences in cellular proliferation between primary embryonic 
fibroblasts from wild-type or Dusp1 deficient animals (140). Between wild-type and 
knockout littermates, no differences were readily detected during development or in 
adulthood within the neurological, cardiac, endocrinological, and hematological organ 
systems (141).  Subsequent studies have identified an important role for Dusp1 in 
regulation of key cellular processes in these organ systems in pathologic states, detailed 
below.  
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Numerous groups have identified a crucial role for DUSP1 as a negative regulator 
of innate immunity, in models of infection, sepsis, periodontal disease, and arthritis (142-
147). Challenges with endotoxin have demonstrated Dusp1 deficient mice are 
significantly more susceptible to immune activation, with increased leukocyte infiltration, 
severe hypotension, and increased mortality (141-144, 148, 149). In a periodontal model, 
Dusp1 deficient mice developed more severe bone loss with increased inflammatory 
infiltrate and osteoclast formation (150), reversed with adenoviral transfer of Dusp1 into 
the tissues (151). In these models, macrophages from knockout mice express elevated 
levels of cytokines, chemokines, and inflammatory enzymes. In a model of collagen-
induced arthritis, Dusp1 deficient mice displayed increased disease incidence, earlier 
disease onset, and accelerated disease progression, associated with increased serum TNF-
α and IL-6 levels as well as increased inflammatory cell infiltrate and osteoclast 
formation (141, 152).  
In models of Escherichia coli sepsis, Dusp1 deficient mice had more severe 
inflammatory responses with increased mortality but also had impaired bacterial 
clearance (153). Other models of infection include polymicrobial periotonitis (154) and 
pulmonary infection with Chlamydophila pneumoniae (155), which yielded similar 
results. Impaired clearance may be due to excess production of the anti-inflammatory 
cytokine interleukin-10, inhibition of which relieved splenic bacterial load by 
neutralizing antibody or on Dusp1/Il10 double knockout mice in the case of Escherichia 
coli sepsis (153). Dusp1 deficient mice challenged with two strains of the gram-positive 
bacterium Staphylococcus aureus showed no difference in mortality or bacterial burden 
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(156). However, heat-killed bacteria yielded enhanced inflammatory response and 
mortality.  
Additional studies have shown that Dusp1 deficient mice are resistant to diet-
induced obesity, with increased MAPK activity in both skeletal muscle and white adipose 
tissue (157). Recently, JNK activity in macrophages was shown to be necessary for 
insulin resistance induced by high-fat diet, with macrophage-specific JNK deletion 
protecting mice from obesity-induced insulin-resistance, macrophage infiltrate, and pro-
inflammatory polarization (158).  
Few studies have examined the effects of increased Dusp1 expression in animals. 
Constitutive cardiac transgenic mice expressing 4-fold higher levels of Dusp1 die within 
the first two weeks of life in the absence of developmental hypertrophy, whereas mice 
with 2-fold higher levels survive with only moderate cardiac morphology, as determined 
by histology and echocardiography (159).  
Given the phenotype of Dusp1 deficient mice with normal development and 
fertility, it suggests phosphatases are capable of compensating for Dusp1 during 
development. The question remains what compensatory mechanisms are in play and why 
they fail to do so during stress.    
 
Regulation of inflammation by DUSP1 
 The initiation of an inflammatory response can occur when components of the 
bacterial cell wall, such as LPS, engage with host immune cells via Toll-like receptors. 
Resulting activation drives the transcription of pro-inflammatory cytokines through 
activation of NF-κB and the MAPK signaling pathways, detailed above. In addition to 
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transcriptional initiation, p38αMAPK increases mRNA stability of targets (160), via 
MAPKAPK2 (MK2) which phosphorylates RNA binding proteins such as tristetraprolin 
(TTP) (160), heterogeneous nuclear ribonucleoprotein A0 (161), and poly(A)-binding 
protein (162). These RNA binding proteins interact with AU-rich elements within the 
3’UTR of targets such as DUSP1 (163), VEGF (164), and MMP (165, 166), targeting 
them for decay in the absence of an activating stimulus. Activation of toll-like receptors 
also drives DUSP1 expression through the adaptor molecules myeloid differentiation 
factor 88 (MyD88) and toll-interleukin 1 receptor (TIR) domain-containing adaptor 
inducing IFN-β (TRIF) in macrophages (144). As an early response gene, DUSP1 is 
crucial to quell the production of inflammatory cytokines in a timely manner, 
summarized in Figure 1-2. 
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Figure 1-2. DUSP1/MKP-1 negatively regulates inflammatory cytokine production. In 
response to TLR4 activation, signaling cascades induce the phosphorylation of p38 and 
JNK MAPK to stimulate production of inflammatory cytokines and other mediators. The 
induction of DUSP1/MKP-1 dephosphorylates MAPKs to inhibit this process by two 
mechanisms: decreasing transcriptional activation and inhibiting MK2-dependent 
increases in mRNA stability. Adapted from Li et al. 2012 (167). 
 
Glucocorticoids exert an anti-inflammatory effect in macrophages, in part, 
through DUSP1 inactivation of p38 MAPK (168, 169). The upstream region of the 
DUSP1 gene contains functional glucocorticoid response elements at -1.3kb and -4.6kb, 
which function alongside p300 to initiate transcription after glucocorticoid stimulus (82, 
170). In vitro treatment with dexamethasone induces DUSP1 expression, initially 
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identified by microarray analysis (91). Dexamethasone failed to inhibit p38 and JNK 
dephosphorylation in Dusp1 deficient macrophages and had little effect in a dorsal air 
pouch model of inflammation (171). In asthma patients, single nucleotide polymorphisms 
in the DUSP1 gene have been associated with response to inhaled glucocorticoid therapy 
(172). However, dexamethasone also exerts anti-inflammatory effects through alternative 
pathways, as some dose-dependent anti-inflammatory responses are still seen in Dusp1 
deficient animals (173).  
Despite their enhanced susceptibility to innate immune challenges, Dusp1 
deficient mice display normal thymocyte development and have no difference in total 
number or ratio of CD4+ and CD8+ T cells, compared to wild-type mice (147). However, 
T cells from Dusp1 deficient mice display impaired IL-2 release and proliferation, with 
decreased Th1 and Th17 responses following T cell receptor stimulation or exposure to 
antigen, in an influenza vaccination model (147). In a Th17-driven disease model, 
experimental autoimmune encephalomyelitis, Dusp1 deficient mice were relatively 
protected with decreased levels of IFN-γ and IL-17 in infiltrating CD4+ T cells (147). In 
an elegant chimera model, Huang et al. demonstrated Dusp1 deficiency in dendritic cells 
impaired IL-12 production and subsequent Th1 response, while enhancing IL-6 
production and promoting a Th17 response (146). Furthermore, the production of induced 
regulatory T cells was negatively regulated by Dusp1 through inhibition of TGF-β2 
production in deficient dendritic cells (146). 
 These studies demonstrate Dusp1 deficiency, through both enhanced and 
prolonged activation of its MAPK substrates, impacts the duration of inflammation in 
response to innate stimuli. In addition to prolonged inflammation, Dusp1 can also 
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regulate adaptive immunity through the alteration of secreted cytokines, which mediate 
interaction with innate cells and guide the developing immune response. 
 
Expression of DUSP1 in cancer 
As a negative regulator of MAPK signaling, DUSP1 may have a tumor 
suppressive role (123). DUSP1 gene expression has been examined in a number of 
malignant tissues and cell lines. In bladder, breast, prostate, and colon cancers, 
expression of DUSP1 gene was shown to decrease in late stage, more aggressive disease, 
with loss of DUSP1 in nearly 80% of metastatic tissues examined (174). It is unclear 
whether DUSP1 expression is serving a direct role as a metastasis suppressor or the loss 
of DUSP1 is a bystander effect. In vitro studies suggest that DUSP1 expression may 
serve key roles in curtailing filopodia formation and cell motility, in studies of ovarian 
cancer cell lines in which DUSP1 was re-expressed, although the mechanism for this 
phenotype is unclear (175). However, studies of DUSP1 expression in tumor tissues are 
mostly limited to characterization of mRNA levels by in situ hybridization and protein 
levels by immunohistochemistry. The functional role of DUSP1 in cancer remains 
undefined. 
In prostate cancer, DUSP1 mRNA expression decreases with increasing tumor 
grade (174, 176). Similarly, in lymph node metastases of prostate cancer, DUSP1 mRNA 
was absent (176). Both DUSP1 mRNA and protein have been detected in the basal cells 
of prostatic acini (174, 176). In assessing matched patient tissues, an inverse relationship 
was observed between DUSP1 expression and JNK1 activity but not ERK1 (176). Across 
all tumor grades, DUSP1 expression, both mRNA and protein, decreased following 
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hormone ablation. A later study showed similar findings of lower DUSP1 expression in 
hormone-refractory prostate compared to untreated carcinomas and benign hyperplasia 
controls (177).  
In human lobular and ductal breast carcinomas, lesions had higher levels of 
DUSP1 mRNA than the constitutive expression seen in surrounding tissue with loss of 
expression in late stage and metastatic disease (174). However, tissues with positive 
DUSP1 expression strongly correlated DUSP1 with HER2 and EGFR expression as well 
as ERK1/2 (174), which may be due in part to positive feedback regulation of DUSP1 
expression through stimulation of the Raf-MEK-ERK pathway.  
In normal bladder urothelium, DUSP1 mRNA is expressed at only very low 
levels. However, in increasing histological tumor grade, DUSP1 expression is inversely 
related, with more expression in in situ lesions than high-grade carcinomas (174). 
Another group found low DUSP1 expression, in conjunction with high JNK1 expression, 
correlated with higher tumor grade, invasion, and vascularity in human urotehlial 
carcinomas (178). In vitro chorioallantoic membrane assays with cell lines corroborated a 
relationship between low DUSP1 expression supporting JNK-mediated angiogenesis 
(178). 
Human colon adenocarcinomas show a similar pattern of DUSP1 expression 
inversely correlating with tumor histologic grade (174). In the human EB-1 colon cancer 
cell line, p53-dependent expression of DUSP1 could induce apoptosis in response to 
stress (179). In turn, DUSP1 protein inactivation of JNK could allow for the targeting of 
p53 by nonphosphorylated JNK for ubiquitiation and degradation (180).  In human 
gastric adenocarcinomas, DUSP1 expression is increased compared to control tissues 
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from healthy donors, alongside increased ERK1/2 activity (181). However, p38 and 
JNK1/2 activity were not assessed in this study.  
Compared to normal controls or benign lesions, DUSP1 protein expression is 
reduced in low-grade ovarian carcinomas. However, in high-grade lesions, DUSP1 
protein expression greatly varies, with a significant correlation with shorter progression-
free survival, but not overall survival (182). In both cancer cell lines and primary ovarian 
cancer tissues, DUSP1 gene expression was decreased compared to immortalized cell 
lines or normal ovarian control tissues, decreasing with increasing disease stage (175). In 
a xenograft model, nude mice bearing cell lines conditionally expressing DUSP1 had 
decreased tumor burden compared to control cell lines (175).  
In the work by Loda et al., minimal DUSP1 expression was detected in 
hepatocellular carcinomas by in situ hybridization (174). Another group found in DUSP1 
negative tumors, an inverse relationship with increased size and serum levels of the tumor 
burden marker α-fetoprotein compared to DUSP1 positive tumors (183). They also 
suggest DUSP1 may serve as a predictive biomarker for survival post-hepatectomy (183).  
In NSCLC cell lines, DUSP1 expression was increased compared to small cell lung 
cancer cell lines (184). However, there was no relationship between DUSP1 expression 
with other variables such as clinical or pathological stage or MAPK phosphorylation 
status. Overall, increased DUSP1 protein expression correlated with improved survival, 
based on percentage of tumor nuclei staining positive for DUSP1 by 
immunohistochemistry (184).  
Gain of DUSP1 expression has been associated with cancer progression, 
chemoresistance, and poor prognosis (123). This rise in DUSP1 expression may be 
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secondary to increased MAPK activity, as one subset of MAPK-responsive transcripts 
that are elevated in tumorigenesis. When elevated, DUSP1 protein expression can inhibit 
the apoptotic pathways initiated by chemotherapies, through targeting JNK and p38 
MAPKs (119, 185-187).  In a number of tissue contexts, it appears DUSP1 activation is 
necessary for cell survival by inhibiting pro-apoptotic p38 and JNK signaling. Despite a 
substrate preference for JNK (66), induction of DUSP1 gene expression can also occur 
through ERK or p38-dependent pathways (87, 105, 188, 189). In response to ultraviolet 
radiation, p38 activity induces DUSP1 expression to inhibit JNK-mediated apoptosis 
(105, 190). In cortical development, DUSP1 induction also represses JNK signaling, but 
in an ERK-dependent manner, to guide axonal branching (190). In untreated mesangial 
cells, ectopic expression of DUSP1 induced apoptosis. However, in the context of 
hydrogen peroxide treatment, DUSP1 had an anti-apoptotic effect, suggesting DUSP1 
may inhibit basal MAPK activity in the absence of a stress-activated MAPK target (191). 
As a member of several cellular stress-response pathways, DUSP1 expression has 
been suggested to enhance chemoresistance in some cancers (92, 192). Cisplatin is a 
mainstay in chemotherapeutic treatment of HNSCC, as a DNA cross-linking agent that 
blocks transcription and DNA synthesis (193, 194). Cisplatin treatment was shown to up-
regulate DUSP1 expression in human lung and ovarian cancer cell lines (119). Mouse 
embryonic fibroblasts from Dusp1 deficient mice were more sensitive to cisplatin-
induced apoptosis, reversed by treatment with the JNK inhibit SP600125 (119). DNA 
fragmentation was reduced in cells transduced with DUSP1 adenovirus after treatment 
with chemotherapies including paclitaxel, doxorubicin, and mechlorethamine and 
combination regimens as well as in MEFS from wild-type mice compared to Dusp1 
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deficient mice, via JNK inhibition (186). In the breast cancer cell line MDA-MB-231 
paclitaxel-induced caspase-3/7 activation was reduced in the presence of DUSP1 
expression (195). In addition to mediating apoptosis, caspases 3 and 7 can activate p38, 
ERK1/2 and JNK MAPKs through cleavage products of Mst1 (196). Other non-apoptotic 
roles for caspase-3/7 include cellular maturation, differentiation, and cytokine activation 
(197).  
Treatment of the prostate cancer cell line PC-3 with histone deacetylase inhibitor 
trichostatin A (198) and DNA methyltransferase inhibitor decitabine up-regulated 
DUSP1 gene expression (177), suggesting epigenetic regulation is responsible for 
downregulation in these cells and can be reversed with pharmacotherapy. Although 
hormone-refractory prostate carcinomas showed decreased expression of DUSP1 mRNA 
and protein, no differences were detected in untreated prostate carcinomas compared to 
benign prostate hyperplasia control tissues (177).  
Dexamethasone is a glucocorticoid with pleiotropic effects, currently used as an 
antiemetic or to reduce adverse effects or toxicity as a part of a chemotherapeutic 
regimen. Studies have shown dexamethasone treatment prior to chemotherapy with 
paclitaxel or doxorubicin protects breast cancer cells from apoptosis (91), with similar 
effects seen in cell cultures with ectopic DUSP1 expression. This effect was abrogated in 
the presence of siRNA targeting DUSP1. Surprisingly, targeting DUSP1 by RNAi 
increased JNK and ERK1/2 phosphorylation with no effect on p38 activity (92). 
Although these studies suggest DUSP1 plays a part in dexamethasone-induced 
chemoresistance in breast cancer cell lines, the mechanism is still unclear.  
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As many as half of cancer patients receive concurrent radiotherapy with 
chemotherapy (199). In HNSCC, radiation therapy can be given at curative doses for 
early stage disease as well as an adjuvant therapy for more aggressive disease. Gamma-
radiation can also induce DUSP1 expression, in vitro and in irradiated nude mice, 
resulting in ERK1/2 dephosphorylation (106, 200). Ultraviolet radiation-induced 
apoptosis can be inhibited by ectopic DUSP1 expression in the U937 human monocytic 
cell line (104), through the inhibition of JNK1 activity. However, low dose short 
wavelength UVC radiation can decrease DUSP1 gene expression in human fibroblasts 
deficient in transcription-coupled repair (201).  
Originally identified in a set of genes expressed in the G0/G1 cell cycle transition 
(78), DUSP1 has been better characterized as a negative regulator of the G0/G1transition, 
with constitutive expression blocking G1 cycle gene expression, including cyclin D1 
(175, 202, 203). Thus, it is not surprising that in several in vitro systems, DUSP1 
overexpression leads to cell cycle inhibition. Transfection of a phosphatase-dead DUSP1 
dominant-negative mutant enhanced platinum-induced cell death independent of c-Jun-
activation (185). This protective effect may be, in part, due to sequestration of JNK from 
other inactivating phosphatases to promote AP-1-mediated cell cycle progression (204).  
Conditional expression of DUSP1 in U28 and M18 ovarian carcinoma cell lines 
decreased intraperitoneal tumor growth in nude mice, compared to tumors expressing 
vector controls (175). Surprisingly, this effect was not seen in subcutaneous xenografts. 
Similarly, DUSP1 inhibition by RNAi in xenografts of pancreatic cell lines PANC-1 and 
T3M4 also resulted in delayed tumorigenicity in nude mice (205). DUSP1 knockdown 
also impaired anchorage-independent growth of these cell lines in soft agar assays (205). 
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Similar results were seen in transfected cell lines A2780 and UCI101 (175). DUSP1 has 
also been implicated in expression of the melanocyte-specific transcription factor 
Microphthalmia. When overexpressed, DUSP1 rescues Microphthalmia from ERK-
mediated degradation to enhance melanocyte differentiation (206), suggesting induction 
of DUSP1 expression may enhance tumor control, in part, through promoting 
differentiation. The functional impact of loss or gain of DUSP1 expression on 
differentiation and cell cycle progression likely varies across tumor tissues.  
As previously discussed, DUSP1 mRNA and protein are increased in the presence 
of hypoxia or ischemia in a number of systems. Response to VEGF and thrombin 
treatment is reduced in Dusp1 deficient aorta sections, suggesting a supportive role of 
Dusp1 in endothelial sprouting (207). However, in tumor cells, low levels of DUSP1 
expression may promote angiogenesis through p38- and JNK-mediated chemotaxis and 
VEGF response (208, 209). When induced, DUSP1 can inhibit HIF-1 activity through 
inactivation of ERK (114) by reducing phosphorylation of the cofactor p300 (115), an 
acetyltransferase (210). Studies of stress-induced transcriptional activation of DUSP1 
suggest a role of chromatin remodeling through histone H3 phosphorylation and 
acetylation (87), but a clear mechanism has yet to be defined.  
In summary, these studies suggest DUSP1 expression is deregulated in human 
malignancies. In several but not all tumor tissues, DUSP1 expression is lost with disease 
progression and is associated with advanced stage and decreased survival. A number of 
cellular processes, including differentiation, cell cycle progression, and anti-apoptotic 
signal can be altered by modulating DUSP1 levels. However, the functional impact of 
these changes is unclear and warrants further investigation. 
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1.4 Cancer-associated inflammation 
The ability of inflammatory conditions to promote tumor progression has been 
observed in a number of malignancies. These associations include hepatitis infection in 
hepatocellular carcinoma, asbestos and silica exposure with lung carcinoma, 
Helicobacter pylori infection with gastric carcinoma, and Schistosomiasis with bladder 
carcinoma (211-215). In these situations, inflammation occurs initially as a protective 
measure against pathogen exposure or a foreign irritant. As immune cells are recruited, 
an inflammatory response develops with release of cytokines, chemokines, and reactive 
oxidants. Many of these mediators, highly expressed in cases of dysregulated 
inflammation, have been shown to promote tumor growth and invasion, enhance 
mutagenesis, and increase angiogenesis and lymphangiogenesis (216). As such, these 
inflammatory mediators not only support tumorigenesis but may also promote tumor 
progression.  
 
Inflammatory signaling pathways activated in cancer 
The Toll-like receptor family contains highly conserved transmembrane proteins, 
which recognize both microbial products and endogenous molecules released during cell 
death (217). As a first line of defense, these receptors on immune cells activate signaling 
pathways crucial for activation of innate immunity and following induction of adaptive 
immunity (218, 219). TLRs are also expressed on cancer cells, where they may promote 
cell growth, enhance survival and resistance to cytotoxic stressors (217, 220). Previous 
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reports have identified an association between TLR4 expression and HNSCC 
progression, through induction of IL-6, IL-8, VEGF, and GM-CSF (221, 222). Treatment 
of HNSCC cell lines with lipopolysaccharide (LPS) enhanced cell proliferation, 
migration, invasion, and cytokine production (223). Aside from LPS, other endogenous 
ligands for TLR4 include S100A and HMGB1 (217, 224).  
Downstream of the TLR pathway, through adaptor molecule MyD88, NF-κB can 
be activated in both immune and tumor cells to drive expression of inflammatory 
cytokines, prostaglandin synthase enzymes, pro-angiogenic factors, and adhesion 
molecules, as well as pro-survival anti-apoptotic genes. NF-κB is a key regulator of 
innate immunity and inflammation, with dysregulation of NF-κB pathways often 
observed in many cancers (225). The family is composed of NF-κB1 (p105/p50), NF-
κB2 (p100/p52), RelA (p65), and RelB, inactivated in a complex with inhibitor-κB (IκB) 
proteins within the cytoplasm. Upon stimulation, kinase cascades phosphorylate IκB, 
leading to its ubiquitination and proteasomal degradation. The released dimers translocate 
to the nucleus to enact target gene transactivation (226). 
A number of studies have demonstrated that NF-κB activity promotes tumor 
initiation and progression within the lower gastrointestinal tract and liver (225, 227, 228). 
For example, specific inhibition of NF-κB activity within leukocytes, through myeloid-
specific IκKβ deletion, protected animals from colitis-associated cancer (227). MAPK 
cross-talk can occur through MEKK1 activation of IκBα kinase, leading to the 
phosphorylation and degradation of IκBα. The kinase can also be phosphorylated by 
JNK, also targeting it for polyubiquitination and degradation, leading to the activation of 
the NF-κB signaling pathway (229). Blocking NF-κB function in HNSCC results in 
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decreased IL-6 mRNA expression and secretion as well as reduced tumor growth (230, 
231). Inhibition of p65, activating kinase IKK1 or IKK2, and expression of dominant 
negative mutants of IκBα have also demonstrated the pro-survival pro-tumorigenic 
function of this pathway (230, 232).  
Prostaglandin E2 (PGE2) has been shown to be increased in HNSCC tissues. This 
secreted factor promotes tumor growth, inhibits apoptosis, and enhances tumor cell 
invasion, metastasis, and supports angiogenesis (233). Synthesis of PGE2 is regulated by 
the rate-limiting cyclooxygenase (COX) enzymes. Of the two isoforms, COX-2 is up-
regulated in inflammation as well as premalignant and malignant tissues, as a target gene 
of both NF-κB and MAPK pathways. COX-2 has been shown to be overexpressed in 
both oral premalignant lesions as well as HNSCC, with its expression correlated with 
increased invasiveness and angiogenesis (234). In vitro treatment of cell lines of oral 
squamous cell carcinoma, the most common subtype of HNSCC, reduced cellular 
proliferation and expression of matrix metalloproteases (235). However, clinical trials to 
inhibit cyclooxygenase activity to reduce oral leukoplakia have not been effective (236, 
237). A trial with the COX-2 inhibitor celecoxib also failed to demonstrate reduction in 
oral premalignant lesions, with decreased interest as concerns for cardiotoxicity arise 
(236). Early studies of 25-hydroxyvitamin D3 suggested treatment of HNSCC patients 
could impair the recruitment and development of immunosuppressive CD34+ cells within 
the tumor, yet no effect on plasma IL-1β, IL-6, or TGF-β was observed (238).  
 Growing evidence supports the pro-tumorigenic role of inflammation in many 
malignancies, including HNSCC. TLR signaling pathways drive production 
inflammatory mediators, which contribute to disease development and progression, in 
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part through MAPK activation. Thus, there is a need to understand the potential roles of 
MAPK signaling and phosphatase regulation in controlling chronic inflammation-
mediated tumorigenesis as well as anti-tumor immunity. 
 
The HNSCC tumor microenvironment  
Malignancies develop in a multi-factorial process, resulting from the interaction 
of genomic alterations and altered gene expression within the context of a tumor-
supportive microenvironment. The tumor microenvironment is composed of resident 
stromal cell populations, such as fibroblasts and endothelial cells, but also infiltrating 
immune cells, such as macrophages, lymphocytes, natural killer (NK) cells, dendritic 
cells (DCs), eosinophils, and neutrophils (239-241). The relationships between 
inflammatory cells and cancer are complex, with great variability among tumor types, 
tissue sites, and other factors within the microenvironment. Understanding these 
relationships and how they support anti-tumor immunity, enhance disease progression, or 
generate a heterogeneous commixture of the two remains an avenue for exploration.  
 In HNSCC patients with lymph node metastases, there were significantly 
decreased numbers of tumor-infiltrating CD8+ T cells (242). One mechanism of evading 
the adaptive immune system is the secretion of gangliosides by tumor cells which serve 
to down-regulate expression of major histocomptability complex I by T cells (243). The 
secretion of Fas ligand to induce apoptosis in T cells has also been proposed to be another 
mechanism of avoiding cytotoxic killing (244). Intratumoral CD8+ T cells within HNSCC 
also have increased expression of programmed death-1 (PD-1) (245), a signal for immune 
checkpoints to inhibit T cell activation, through interaction with PD-1L, found on 
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HNSCC cells (246). Within HNSCC tissues, immune cell infiltration occurs mostly 
within the underlying stroma, with increasing levels of Foxp3+ T regulatory cells in later 
stages of disease (247). 
In addition to T cells, innate immune cells are powerful players within the tumor 
microenvironment. Dendritic cells are highly specialized antigen-presenting cells, able to 
stimulate adaptive immune T cell responses. In the context of cytokines such as TGF-β 
and IL-10, they can also promote the development of an immunosuppressive environment 
by driving regulatory T cell differentiation (248, 249). In many solid tumors, the majority 
of infiltrating immune cells is comprised of tumor-associated macrophages (TAMs) (240, 
250, 251). Although macrophages have the potential to inhibit tumor progression and 
enhance anti-tumor immunity, TAMs often express factors that both support tumor 
progression directly and also suppress the anti-tumor response. In breast, bladder, and 
ovarian carcinomas, TAMs display a skewed pro-tumor phenotype (252-254). M1-
polarized macrophages produce the pro-inflammatory cytokines IL-12, IL-23, and IFN-γ 
(255). M2-polarized macrophages produce cytokines including IL-10 and TGF-β to 
promote wound healing and angiogenesis. In HNSCC, infiltrating TAMs seem to closely 
resemble the M2 phenotype and in high levels, correlate with increased tumor stage and 
lymph node involvement and extracapsular spread (256-258).  
 
Inflammatory cell recruitment and activation 
Macrophages infiltrating the tumor are derived from monocytes in circulation that 
home to the tumor site and differentiate (254, 259). Chemokines activate the migratory 
response of hematopoietic cells in normal trafficking to sites of inflammation and also for 
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homeostatic migration to lymphoid organs (260, 261). Chemokine receptors, in turn, may 
facilitate a number of processes necessary for metastasis including endothelial 
attachment, cell migration and extravasation, angiogenesis, and pro-proliferative and 
survival signaling (262).  
 CSF-1 is crucial for hematopoiesis and myeloid cell development (263). In 
addition to enhancing monocyte recruitment, it may act secondarily by supporting 
subsequent differentiation into macrophages at the tumor site (264). Although CSF-1 has 
the ability to activate macrophages, promoting phagocytosis and release of cytotoxic 
products, its ability to promote tumor progression suggests a dual role, possibly for its 
secreted rather than membrane-bound form (265). Members of the TGF family have also 
been suggested to participate in monocyte recruitment to tumors. These proteins may 
play a number of roles, regulating the functions of epithelial cells, endothelium, as well 
as immune cells. TGF-β1 in HNSCC was shown to enhance peripheral blood monocyte 
migration and their production of proangiogenic factors, such as IL-8 and vascular 
endothelial growth factor (VEGF) (266, 267). Genetic deletion of TGF-β signaling in a 
mouse model of chemical carcinogenesis in the skin resulted in reduced TAM infiltration 
(268).  
The chemokine C-X-C motif ligand (CXCL) 12 (CXCL12) and chemokine C-X-
C motif receptor (CXCR) 4 (CXCR4) have been identified in HNSCC tissues with some 
associations with poor survival (269-271) and lymph node metastases (271, 272). Interest 
in CXCR4 antagonists as inhibitors of tumor angiogenesis and metastases continues with 
promising results from animal studies (271, 273). A key to unlocking potential 
therapeutic targets in these chemokine networks will be an understanding of the 
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regulatory pathways driving their expression and their function within the tumor 
microenvironment. 
 
Roles of macrophages in cancer 
Differentiated cells of the myeloid monocyte-macrophage lineage display a broad 
diversity with extensive plasticity among phenotypes, which guide the functional 
outcome of interactions with immune cells (274). TAMs constitute the predominant 
leukocyte population within the tumor microenvironment that drives the inflammatory 
response. Based on phenotypic marker expression and functional properties, TAMs 
closely resemble M2-polarized macrophages with some distinctions (253, 275). Focusing 
on M2-polarized cells reveals sub-categories of macrophages, which can drive a 
predominantly T helper 2 response, T regulatory cell response, or B cell response via 
immune complex and LPS stimulation	  (274). 
Within the tumor microenvironment, a number of factors, including IL-10 and 
TGF-β, promote the differentiation of recruited monocytes toward M2-polarized 
macrophages (252, 276). TAMs enhance malignancies through secretion of cytokines, 
growth factors, matrix proteases (277-279), and pro-angiogenic growth factors and 
chemokines (278, 280). In addition, accumulation of TAMs within regions of hypoxia 
promotes a pro-angiogenic switch in those cells (280). Metabolic changes, such as tumor-
secreted lactic acid, can also promote induction of the IL-23/IL-17 inflammatory pathway 
in TAMs, limiting induction of anti-tumor IL-12/Th1 responses (281). TAMs and 
myeloid-derived suppressor cells (MDSCs) themselves express a large repertoire of 
immunosuppressive mediators which inhibit antitumor immunity by targeting cytotoxic T 
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cell activation, as well as further promoting the development of regulatory T cells and 
enhancing M2 polarization (282-285). 
 
Cytokines, chemokines, and inflammatory mediators 
Immune cells impact tumor progression through the release of soluble factors to 
support angiogenesis, tumor cell proliferation, and tissue remodeling (250, 252, 286, 
287). In addition, immunosuppressive effects of these inflammatory mediators inhibit 
potential anti-tumor responses from cytotoxic T lymphocytes, NK cells, macrophages, 
and neutrophils, skewing the immune phenotype to a pro-tumor response (286, 288). 
Chemokines such as IL-8 and CXCL1 recruit neutrophils, monocytes, and endothelial 
cells to promote the inflammatory response as well as local angiogenesis, enhancing local 
invasion and metastasis (289). Chemokines also attract MDSCs, immature myeloid-
lineage cells that have been shown to be important effectors of angiogenesis (282, 290). 
Signaling from these secreted growth factors and other mediators initiate signal 
transduction pathways which can further promotes malignant transformation, such as the 
MAPK, NF-κB, and PI3K/Akt pathways (289).  
By these mechanisms, altered cytokine, chemokine, and growth factor expression 
influences the development of a number of cancers, including HNSCC (291, 292). 
Factors such as IL-1α, IL-6, IL-8, CXCL1, GM-CSF, and VEGF have been identified 
both in secretions from HNSCC cell lines, from within tumor samples, and also in patient 
sera (230, 231, 293). For a number of these secreted factors, increasing levels have been 
associated with disease progression and recurrence, with decreases associated with 
therapeutic response (231). IL-6 has been shown to correlate with poor prognosis in 
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HNSCC (294), in part through induction of VEGF and an invasive phenotype in tumor 
cells (295). Whether targeting these secreted mediators will have a beneficial effect on 
disease progression requires further investigation. 
 
Roles of interleukin-1β  in cancer biology 
 The interleukin-1 family contains IL-1α and IL-1β members that exert potent pro-
inflammatory effects in a pleiotropic manner, produced by macrophages in response to 
inflammatory stimuli. Located on chromosome 2, this gene family produces the pro-
inflammatory cytokines IL-1α and IL-1β, in addition to the antagonist, interleukin 1-
receptor antagonist (IL-1RA).  The agonist members, IL-1α and IL-1β, activate an 
inflammatory response through the IL-1 receptor (IL-1R), but also induce the expression 
of a panel of inflammatory molecules across a diverse panel of stromal and immune cells. 
Low levels of IL-1α expression within healthy cells, released during necrosis may 
activate immune responses (296), through binding IL-1RI on immune surveillance cells, 
bearing MHC class I, B7.1, B7.2, L-selectin, and NKG2D ligands (297, 298). However, 
IL-1β expression is tightly controlled at multiple regulatory points and is only secreted in 
the presence of inflammatory stimuli.  
Genetic knockout mice lacking IL-1β are protected from B16 local and lung 
metastases (299). In models of carcinogen-induced tumorigenesis, both tumor and 
immune cell-derived IL-1β contribute to enhanced tumor cell adhesion and invasion, 
increased angiogenesis within the microenvironment, and local immune suppression 
(300). In prostate cancer, IL-1β was identified as a macrophage-secreted factor with the 
ability to alter androgen receptor signaling modulators to enhance hormonal therapy 
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resistance (301). In human studies, IL-1β polymorphisms were associated with increased 
risk of gastric carcinoma (302). In transgenic mice, expression of human IL-1β within 
stomach tissue generated spontaneous gastric inflammation and cancer, associated with 
the recruitment of MDSCs (303).  
IL-1β has been well characterized as a pro-metastatic factor (304, 305) and is one 
of a number of secreted factors increased in progressing or resistant oral tumors (306, 
307). In HNSCC cell lines, IL-1β exposure promoted epithelial-mesenchymal transitions 
through the up-regulation of Snail, proposed to occur through COX-2 activation (308). In 
oral keratinocytes, the induction of Snail expression was shown to increase pro-
inflammatory cytokine expression (309), generating a cycle of tumor-promoting 
inflammation. Although previous reports have identified IL-1α as a constitutively 
expressed cytokine in a panel of HNSCC cell lines, IL-1β secretion was not detected 
(310), supporting the role of stromal cells as a cellular source of this cytokine in HNSCC. 
Expression of IL-1β is tightly regulated at both the mRNA and protein level. Like 
other early response cytokine genes, IL-1β mRNA can be regulated post-transcriptionally 
through AU-rich elements (AREs) within its 3’ untranslated region (UTR) (311). The 
precise interactions of specific RNA binding proteins and the IL-1β 3’UTR and whether 
other RNA binding factors such as miRNAs are involved in this process have not yet 
been addressed. In addition to post-transcriptional regulation, IL-1β is also regulated 
post-translationally by inflammasome activation. All members of the NLR (nucleotide 
binding, lots of leucine-rich repeats containing) gene family contain a nucleotide-binding 
domain, a leucine-rich repeats (LRR) domain in the C-terminus, and an effector domain 
in the N-terminus, such as CARD or PYRIN (312). In activation complexes, these 
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proteins are key to host responses to pathogen and damage-associated molecular patterns 
(313, 314), including viral DNA (315) and RNA (316), extracellular ATP (317), and 
reactive oxygen species (318). Following activation, the NLR proteins assemble a 
multimeric protein complex, the inflammasome, to cleave pro-caspase-1 into its mature 
form, which in turn cleaves the 36 proform of IL-1β and IL-18 into their mature secreted 
forms (313).	  
Within the NLRP family, genetic variants and experimental deletions have 
identified a regulatory role for these proteins in colorectal carcinogenesis (319-322). 
However, discordant roles for NLRP family members have been identified by different 
research groups. In murine models, deficiencies in Nlrp3 and Casp1 were shown to 
reduce severity of colitis-associated cancer (323, 324), whereas mice lacking Nlrp3, 
Nlrp6, Nlpr12, Pycard, and Casp1 were shown to be more susceptible to the model 
compared to wild-type animals(319, 321, 325-328). Interpretation of results from bone 
marrow-reconstitution experiments should be taken in consideration that previous 
characterizations of engraftment have shown particularly poor reconstitution of intestinal 
lamina propia and intraepithelial lymphocytes despite high splenic reconstitution (329). 
Thus, these discrepancies may be due, in part, to differing roles of inflammasome 
signaling in immune cells versus intestinal epithelium (325), as well as the potential 
impact of varying microflora among animals from different institutions. 
Like, other cytokines, IL-1β expression is deregulated in human cancers. As a 
early pro-inflammatory mediator, IL-1β initiates a downstream cascade of inflammatory 
molecules to potentiate its effect, activating stromal cells, other immune cells, and also 
tumor cells. With increasing interest in the blockade of IL-1β signaling in cancer therapy, 
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the need remains to characterize cellular sources of IL-1β within the tumor and 
surrounding microenvironment and delineate the regulatory mechanisms involved for the 
development of efficient therapeutic targets. 
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1.5 Hypothesis & Specific Aims 
DUSP1 has been shown to be an important regulator of innate immune activity, with 
exuberant over-production of inflammatory cytokines in Dusp1 deficient animals 
following immune challenge. Although levels of DUSP1 expression have been shown to 
be lost in a number of human cancers with advanced tumor stage, whether this change in 
DUSP1 expression is directly related to disease progression or simply a bystander effect 
of altered cancer signaling pathways is unknown. We hypothesized that DUSP1 is a 
negative regulator of tumor-promoting inflammation in head and neck squamous cell 
carcinoma. This hypothesis was tested with the following specific aims.  
Specific Aim 1 addressed how Dusp1 deficiency affects tumor progression in an 
animal model. Wild-type and Dusp1 deficient mice were challenged with 4-
nitroquinoline 1-oxide (4NQO) to initiate the development of oral squamous cell 
carcinoma. The effects of Dusp1 deficiency were examined by assessing disease onset, 
tumor burden, and histological tumor grade. To understand how Dusp1 alters the tumor 
microenvironment, Nanostring analysis and qPCR arrays were performed to quantitate 
the mRNA expression levels of inflammatory mediators in wild-type and knockout tumor 
tissues. Flow cytometry analysis further assessed the numbers of innate and adaptive 
immune cells present within the spleen and draining lymph nodes from tumor-bearing 
wild-type and knockout mice. To determine whether Dusp1 deficiency in the 
hematopoietic compartment was sufficient to recapitulate the enhanced disease 
phenotype observed, bone marrow chimeras were generated from wild-type and Dusp1 
deficient mice, challenged with 4-nitroquinoline 1-oxide, and monitored for disease 
progression. Lastly, tumor progression was assessed using a syngeneic subcutaneous 
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tumor cell injection in wild-type and Dusp1 deficient mice using three different cancer 
cell lines, with enhanced tumor growth in Dusp1 deficient mice inhibited by 
intraperitoneal injections of the p38 inhibitor SB203580.  
Specific Aim 2 addressed the mechanism by which Dusp1 regulates inflammation 
in macrophages. The effect of Dusp1 deficiency on macrophage polarization to M1 or 
M2 phenotypes was examined in vitro. Wild-type and Dusp1 deficient wild-type bone 
marrow-derived macrophages were challenged with inflammatory stimuli including 
lipopolysaccharide and tumor cell-conditioned media to assess expression of Il1b mRNA. 
Total levels of Il1b mRNA and primary mRNA were assessed at steady-state levels by 
qPCR. Rates of mRNA decay were quantified by qPCR following actinomycin D 
treatment. Lastly, the effects of Dusp1 deficiency on inflammasome activation and IL-1β 
secretion were assessed by western blotting and ELISA from primary macrophages. 
Specific Aim 3 addressed how DUSP1 expression is altered in human head and 
neck squamous cell carcinoma. The levels of DUSP1 mRNA and protein were examined 
in matched tissues from human head and neck squamous cell carcinoma tissues and 
adjacent non-tumor tissues. In addition, the mRNA and protein expression levels of IL-1β 
were quantified in these samples. Publicly available datasets from human head and neck 
squamous cell carcinoma tissues were also examined for significant alterations in DUSP1 
expression and IL-1β, identified in the animal model in Specific Aim 1. 
 




CHAPTER 2. Materials and Methods 
 
2.1 Generation of animals 
All animal studies were carried out in accordance with NIH guidelines, in 
compliance with the Guide for the Care and Use of Laboratory Animals, and protocols 
were approved by the Medical University of South Carolina (MUSC) Institutional 
Animal Care and Use Committee. Dusp1-/- (KO) and Dusp1+/+ (WT) mice, on a C57/129 
mixed genetic background were obtained through a Material Transfer Agreement from 
Bristol-Myers Squibb (NY) and bred at MUSC. Every five generations, homozygous 
wild-type and knockout breeder pairs were replaced with littermates from Dusp1-/+ 
heterozygous breeder pairs to prevent genetic drift. Litters from these C57/129 
background mice were used for all experiments with the exception of allograft and 
chimeric experiments, which necessitated a C57BL/6 genetic background. For allograft 
and bone marrow transplants, Dusp1-/- mice were backcrossed to a C57BL/6NCrl 
background (Charles River Laboratories) for ten generations, alternating male and female 
C57BL/6 mates. Homozygous Dusp1-/- and Dusp1+/+ breeder pairs for colony 
maintenance were established from heterozygous Dusp1-/+ breeder pairs. Every five 
generations, Dusp1-/- mice were backcrossed with C57BL/6J mice (The Jackson 
Laboratory) to prevent genetic drift. 
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2.2 Carcinogen-induced oral cancer model 
Male and female mice aged 6-8 weeks old and weighing 16-22g were housed in 
appropriate sterile filter-capped cages and fed and given water ad libitum. A stock 
solution of 4-nitroquinlone 1-oxide (4NQO) (Sigma-Aldrich) dissolved in propylene 
glycol (4mg/mL) was diluted in the drinking water to a final concentration of 25µg/mL 
for mice on a mixed genetic background or 50µg/mL for mice on a C57BL/6 genetic 
background.  4NQO concentration was decreased for mice on the mixed C57/129 genetic 
background, compared to C57BL/6, due to enhanced toxicity in an initial pilot study. 
These results are in accordance with previous reports that mice on a C57BL/6 genetic 
background are more resistant to other models of carcinogenesis. Drinking water was 
protected from light exposure and prepared weekly. Animals were given either water 
with propylene glycol vehicle controls or 4NQO in the drinking water for 16 weeks, after 
which all cages were reverted to regular water and monitored until week 28-32. Animals 
were euthanized at week 28 (C57BL/6 background) or 32 (C57/129 background) or when 
greater than 20% weight loss was documented. Full autopsies were performed, and 
tissues were immediately collected in 10% buffered formalin for histology or snap frozen 
for homogenization. All animals were monitored daily for general behavioral 
abnormalities and any sign of toxicity or illness. 
Weekly examinations were performed under anesthesia [3-5% isoflurane mixed 
with oxygen] to document pathologic changes within the oral cavity. Images were 
recorded using an Olympus SZ40 Stereo Zoom Microscope at 6.7x magnification and 
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Hitachi KP-D20B CCD color camera, and disease onset was determined by a blinded 
observer. Survival rates were estimated from the first date of visible oral tumor 
formation, using the Kaplan-Meier method, and differences between the curves were 
compared using the log-rank test. 
 
 
2.3 Bone marrow transplantation 
Male and female mice aged 8-10 weeks old and weighing 18-24g were used to 
generate bone marrow chimeras through lethal irradiation and hematopoietic 
reconstitution by bone marrow transplant. The day before irradiation of recipient mice, 
access to food but not water was restricted to limit radiation-induced gastrointestinal 
toxicity. Mice received 2 doses of 550 cGy, spaced 4 hours apart, from a JL Shepherd 
Model 143 137 Cesium irradiator. The following day, irradiated mice received 200µL 
injections of 2 x 106 red blood cell-depleted whole bone marrow in phosphate-buffered 
saline (PBS) through the lateral tail vein.  Animals were monitored for signs of radiation-
induced illness and given access to soft gel-based diets for a week following treatment. 
At 6-8 weeks post-transplant, engraftment was assessed by flow cytometry analysis of 
peripheral blood for the markers CD45.2 from Dusp1-/- and Dusp1+/+ mice and the 
congenic marker CD45.1 from C57/Ly5.1 mice (NCI, Frederick). Successful engraftment 
was determined as greater than 80% expression of the donor marker. After validation, 
animals began 4NQO treatment at 50µg/mL for 16 weeks, as described above, followed 
by 12 weeks of regular water. Weights were monitored as a surrogate for disease burden 
throughout the model. 
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2.4 Subcutaneous syngeneic tumor model 
Male and female Dusp1-/- and Dusp1+/+ mice on a C57BL/6 genetic background 
aged 8-10 weeks old and weighing 18-24g were implanted with syngeneic cancer cell 
lines. Animals were anesthetized by isoflurane inhalation (3-5% mixed with oxygen), and 
fur on the dorsal flank was removed with an electric razor. EO771, TRAMP-C2, or 
B16F10 tumor cells were subcutaneously injected in 100 – 200µL volumes of PBS over 
the right flank using 27 gauge x ½” tuberculin needles. After injections, animals were 
monitored daily for signs of illness. Tumor progression was monitored by assessing 
tumor volume, calculated as (length x width2)/2 with digital calipers every other day. 
Animals were sacrificed if tumor volume exceeded 1500mm3 or tumors developed 
extensive non-healing ulcerations. During tissue collection, tumor tissues were split and 
either fixed in 10% buffered formalin for 48 hours or snap frozen in liquid nitrogen. 
Animals were also examined for any signs of metastatic lesions or other illness. 
 
2.5 Human tissue samples 
Previously collected snap-frozen tissues from patients diagnosed with head and 
neck squamous cell carcinoma were acquired from the MUSC Hollings Cancer Center 
Tissue Biorepository in compliance with protocols approved by the MUSC Institutional 
Review Board. Tissue samples were collected fresh from the surgical pathology grossing 
room. A representative sample of the tissue sample was placed in Optimum Cutting 
Temperature (OCT) compound with the remaining tissue frozen in liquid nitrogen. Tissue 
pathology and tumor percentage within the representative frozen section was verified by 
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hematoxylin and eosin (H&E) staining by the Tissue Biorepository research pathologist. 
Non-tumor adjacent tissue was obtained from the same patient during the same surgical 
procedure and underwent the same collection procedure. The non-tumor adjacent tissue 
was also verified by H&E staining to contain no abnormal pathology. 
 
2.6 Histology 
Formalin-fixed paraffin-embedded tissues were used for histological scores and 
immunohistochemistry. Tissues were sectioned at 7µm thickness by rotary microtome 
and placed onto glass slides before drying overnight. Slides were deparaffinized in three 
five minute washes of xylene and rehydrated through three five minute washes of 100%, 
95%, and 90% ethanol before staining. Tissue sections were stained with hematoxylin 
and eosin before examination by two pathologists, blinded to experimental group. 
Histological scores were graded as normal, hyperplasia, dysplasia, in situ squamous cell 
carcinoma, or invasive squamous cell carcinoma. For tissue samples with multiple 
lesions, the most severe histological score was used for analysis. Inflammation was 
scored on a 0–4 scale (0, normal mucosa; 1, minimal inflammation (occasional scattered 
granulocytes and leukocytes); 2, mild inflammation (scattered granulocytes with 
occasional infiltrates); 3, moderate inflammation (scattered granulocytes with patchy 
infiltrates); and 4, severe inflammation (multiple extensive areas with abundant 
granulocytes and marked infiltrates), as previously described (330). For animals with 
multiple lesions of varying inflammation, the highest inflammation score was used for 
analysis. 
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2.7 Immunohistochemistry 
Tissue slides were deparaffinized and rehydrated, as described above, before 
performing antigen retrieval in ethylenediaminetetraacetic acid (EDTA) buffer (1mM 
EDTA, 0.05% Tween-20, pH 8.0) or in citrate buffer (10mM sodium citrate, 0.05% 
Tween-20, pH 6.0) at 100°C for 30min. Sections were blocked in 10% goat serum in PBS 
and incubated with the following primary antibodies in blocking buffer at 4°C overnight: 
F4/80 at 1:500, phospho-p38 MAPK, phospho-ERK1/2, phospho-SAPK/JNK (Cell 
Signaling) at 1:1000, Ki67 (Abcam) at 1:100, and isotype controls (Santa Cruz) at 
corresponding µg/mL dilutions to the primary antibody. After washing in PBS, slides 
were sequentially incubated with biotinylated secondary antibody at 1:200 and avidin-
biotin complex (Santa Cruz) at 1:1:50 before developing in 3,3-diaminobenzidine (Vector 
Labs), according the manufacturers’ protocols. Slides were washed, counterstained with 
Gill’s hematoxylin No. 2 (Sigma-Aldrich), dehydrated overnight, and transferred to 
xylene before mounting with CytoSeal mounting media (ThermoScientific).  
Staining was scored by a research pathologist, blinded to animal identification and 
experimental group. Immunohistochemistry scores were calculated by the Quick-Score 
method of multiplying the intensity coefficient and the frequency of positivity coefficient 
(331). The intensity coefficient was scored as 0 (negative), 1 (low), 2 (moderate) or 3 
(strong), and the positivity coefficient was scored based on the percentage of positively 
staining cells (0 = no positive staining, 1 = 1-19% positive, 2 = 20-39% positive, 3 = 40-
59% positive, 4 = 60-79% positive, and 5 = 80-100% positive). The resulting product was 
categorized from 0 to 5 yielding the IHC staining score as follows: 0 = negative score, 1 
= 1-3, 2 = 4-6, 3 = 7-9, 4 = 10-12, and 5 = 13-15. For F4/80+ cell counts, tumor-positive 
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fields of view were acquired at 10X magnification and quantified using Viziopharm 
acquisition and analysis software v. 4.48.201 (Hoersholm, Denmark), in a blinded 
manner, and expressed as the number of positive cells in each histologically defined area.  
 
 
2.8 Primary bone marrow-derived macrophage isolation 
Bone marrow cells were obtained from age and sex-matched 8-12 week-old 
Dusp1-/- and Dusp1+/+ mice. Animals were euthanized by CO2 inhalation, followed by 
cervical dislocation. After spraying with 70% ethanol, six bones from each mouse, 
humerus, femur, tibia, were removed and cleaned with a Kimwipe to remove muscle and 
connective tissue. Bones were sprayed with 70% ethanol and moved to a sterile cell 
culture dish. In the cell culture hood, one epiphysis was removed from each bone, and the 
bones were placed, three to a tube, cut side down, into sterile 0.5 mL tubes within a 1.5 
mL tube. The 0.5 mL tubes each contained a small hole bored using a heated 20 gauge 
needle. Bone marrow cells were flushed by centrifuging the tubes for a 5 second pulse in 
a tabletop centrifuge. Following isolation, red blood cells were lysed with ammonium 
chloride potassium (ACK) lysis buffer for 2 minutes before plating remaining cells.  
Isolated bone marrow cells were differentiated for 6-7 days in Iscove’s Modified 
Dulbecco’s Medium (IMDM, Life Technologies) or α-minimum essential media (α-
MEM, Life Technologies) supplemented with 2mM glutamine, 10% HyClone 
characterized endotoxin-free fetal bovine serum (FBS) (ThermoScientific), penicillin 
(100U/mL, Sigma-Aldrich), streptomycin (100µg/mL, Sigma-Aldrich), and 10ng/mL 
macrophage colony-stimulating factor (M-CSF, R&D Systems). During differentiation, 
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bone marrow cells were plated in untreated plastic tissue culture dishes with media 
replenishment every two days. Bone marrow-derived macrophages were released from 
culture dishes with Cellstripper solution (Cellgro) and plated the day prior to treatment. 
All inflammasome treatments were performed in serum-free IMDM supplemented with 
10ng/mL M-CSF. All other treatments were performed in complete α-MEM diluted 5-
fold in serum-free α-MEM. 
 
2.9 Macrophage polarization 
Primary bone marrow-derived macrophages were cultured, as described in section 
2.8, and plated the day prior to treatment in α-MEM with 10% FBS, antibiotics, and 
10ng/mL M-CSF. Macrophages were plated at a density of 1.5 x 106 cells in 2mL media 
in a 6-well dish. Treatments were performed for 24 hours in low serum α-MEM, 
prepared from complete media diluted 5-fold in serum-free α-MEM, containing either 
LPS (100ng/mL) and recombinant mouse interferon-γ (IFN-γ, 20ng/mL, R&D Systems) 
or recombinant mouse IL-4 (10ng/mL, R&D Systems), to polarize cells to a M1 or M2 
phenotype, respectively. Supernatants were collected and centrifuged at 1,000 x g for 10 
minutes at 4°C to remove cellular debris before analysis of cytokine expression by 
ELISA. Cell lysates were collected in protein lysis buffer, as described in in section 2.11. 
RNA was collected for qPCR analysis, as described in section 2.14. 
 
2.10 Inflammasome activation 
Primary bone marrow-derived macrophages were cultured, as described in section 
2.8, and plated the day prior to treatment in IMDM with 10% FBS and antibiotics with 
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10ng/mL M-CSF. Macrophages were plated at a density of 1 x 106 cells per 1mL media 
in 12-well dishes or 2.5 x 106 cells per 2mL media in 6-well dishes. Macrophages were 
primed with LPS (100ng/mL) from Aggregatibacter actinomycetemcomitans (strain Y4, 
serotype B), extracted by the hot phenol-water method (332), and diluted in PBS. After 
priming for 4 hours, cells were washed twice with serum-free IMDM before treatment 
with adenosine tri-phosphate (5mM ATP, Sigma-Aldrich) or nigericin (10µM, Sigma-
Aldrich) for 30 or 60 minutes, respectively, to induce inflammasome activation. 
Supernatants were collected and centrifuged at 1,000 x g for 10 minutes at 4°C to remove 
cellular debris before IL-1β detection by ELISA. Cell lysates were collected in protein 
lysis buffer, described in section 2.11. 
 
2.11 Protein isolation 
 Prior to protein collection, cell culture media was removed, and adherent cells 
were washed with PBS. Cell lysates were scraped in a 50µL volume of 
radioimmunoprecipitation assay (RIPA) buffer supplemented with phenylmethylsulfonyl 
fluoride (PMSF, 1mM), and the protease and phosphatase inhibitors cOmplete protease 
inhibitor cocktail and phosSTOP (Roche), according to manufacturer’s guidelines. 
Murine and human tissues, previously snap frozen, were thawed on ice and homogenized 
with a rotor stator homogenizer in the same lysis buffer in a 500µL volume in a 5mL 
round bottom tube. Following homogenization, tissue lysates were sonicated at 50% 
amplitude for five 1 second pulses. Cellular and tissue debris was removed by 
centrifugation at 14,000 x g for 15 minutes at 4°C and transferring the supernatant. 
Tissue samples and supernatants were filter-concentrated in a table-top centrifuge, 
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removing excess buffer and proteins smaller than 3kDa, following manufacturer’s 
protocol using a 30 minute centrifugation time (Millipore).  
 
2.12 Western blotting 
Protein samples were quantified by bicinchoninic acid assay immediately prior to 
electrophoresis. Samples from inflammasome experiments were analyzed on 15% 
acrylamide gels. All other samples were analyzed on 10% acrylamide gels. All 
acrylamide gels contained 4% acrylamide stacking phases and were prepared within 24 
hours prior to electrophoresis, using 30% acrylamide/bis solution (37.5:1), 
tetramethylethylenediamine, and ammonium persulfate (Bio-Rad). Protein samples of 30 
- 50µg were loaded into each well and electrophoresed before transfer in Towbin buffer 
onto polyvinyldiene fluoride membranes with 0.2µM pore size (Bio-Rad). Membranes 
were blocked from non-specific binding with 5% non-fat dry milk in Tris buffered saline, 
containing 0.1% Tween-20 (TBS-T), for 30 minutes. Membranes were then incubated in 
primary antibody, prepared in 5% bovine serum albumin in TBS-T, overnight at 4°C with 
gentle rocking.  
The following antibodies were used: DUSP1/MKP-1 (Millipore), caspase 1 p20 
(Millipore) and p10 (Santa Cruz), IL-1β (Abcam) at 1:500, β-actin, phospho- and total p-
38 MAPK GAPDH, phospho- and total-ERK1/2 MAPK, phospho- and total-
SAPK/JNK1/2 MAPK, GAPDH, and α-tubulin (Cell Signaling). All primary antibodies 
were used at 1:1000 dilutions unless stated otherwise and incubated overnight at 4°C with 
gentle agitation. Membranes were washed three times in TBS-T for 5 minutes before 
incubating in secondary antibodies, diluted 1:1000 in 5% non-fat dry milk in TBS-T. 
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Secondary antibodies were horseradish peroxidase-conjugated anti-rabbit and anti-biotin 
antibodies (Cell Signaling). After secondary antibody incubation for 1 hour at room 
temperature, membranes were washed five times for 5 minutes in TBS-T and incubated 
in prepared SuperSignal WestPico chemiluminescent substrate (Pierce) before exposing 
on X-ray film (ThermoScientific). Images of X-ray films were captured on a Gel Doc 
imaging systems and saved as TIFF files. 
 
2.13 Enzyme-linked immunosorbent assay 
Supernatants, previously collected with cellular debris removed by centrifugation, 
were thawed from -80°C for ELISA analysis. Single aliquots of supernatant were used to 
avoid freeze-thaw. Cytokine secretion in supernatants was detected using the Mouse IL-1 
beta/IL-1F2, IL-1RA, IL-12p40, and IL-10 DuoSet ELISAs (R&D Systems). Levels of 
IL-1β in tissue lysates and sera were detected using the Mouse IL-1β ELISA for Lysates 
(Ray Biotech). All samples were prepared in triplicate and analyzed alongside a standard 
curve, prepared in triplicate. Concentration was calculated from the standard curve using 
a 4-parameter logistic nonlinear regression model, per manufacturer’s recommendations. 
 
2.14 RNA isolation and quantitative PCR 
RNA isolation was performed using QIAprep RNeasy spin columns (Qiagen) for 
for quantitative PCR array analysis of tumor tissue lysates. Column eluents were assessed 
for RNA integrity on the Agilent Bioanalyzer using the RNA 6000 Pico chip, and only 
samples with RNA integrity > 7 were used for qPCR array analysis. TRIzol (Invitrogen) 
was used for preparation of all other samples. After addition of chloroform to TRIzol, the 
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aqueous phase was transferred, and isolated RNA was precipitated in isopropanol. All 
RNA for qPCR arrays were prepared with on-column DNase treatment, per 
manufacturer’s protocol (Qiagen). Isolated RNA was washed with 75% ethanol and 
resuspended in RNase and DNase-free water. Concentration was determined by Beer-
Lambert law, using absorbance at 260 and 280nm measured by NanoDrop 
spectrophotometer (ThermoScientific).  
Complementary DNA was prepared from 500ng of total RNA using random 
hexamers, according to manufacturer’s protocol (Applied Biosystems). Gene expression 
was determined using the following probe-primer TaqMan sets for delta-delta Ct 
calculations: Ptprc (Mm01293577_m1), Il1b (Mm00434228_m1), Cxcl1 
(Mm04207460_m1), Il12b (Mm00434174_m1), Nos2 (Mm00440502_m1), Il10 
(Mm00439614_m1), Arg1 (Mm00475988_m1), Gapdh (Mm99999915_g1), 16s rRNA 
(Mm04260181_s1), DUSP1 (Hs00610256_g1), and ACTB (Hs01060665_g1). 
Quantitation of primary Il1b mRNA was performed using the following SYBR Green 
primer pairs for delta-delta Ct calculations: Il1b exon 3 forward 5’-TGA CCT GTT CTT 
TGA AGT TGA CG-3’, Il1b intron 3 forward 5’-CCT TGG TGT TCT CTG GGG TTG-
3’, Il1b intron 3 reverse 5’-TAT CCC TTC CCG TTT GGG TT-3’, Il1b exon 4 reverse 
5’-CGA GAT TTG AAG CTG GAT GCT C-3’, Actb exon 2 forward 5’-CCA ACC GTG 
AAA AGA TGA CC-3’, Actb intron 2 reverse 5’-ATG GGA GAA CGG CAG AAG A-
3’. Samples were prepared in duplicate and amplified on the StepOnePlus PCR System 
(Applied Biosystems).  
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2.15 Quantitative PCR array 
RNA samples were prepared, as described in section 2.14, using the QIAgen 
RNeasy mini kit with on-column DNase digestion. After validation of RNA integrity on 
the Agilent Bioanalyzer RNA 6000 Pico chip, samples were prepared for qPCR array 
analysis using the RT2 Prolifer PCR array system (SA Biosciences). For each sample, 
1µg RNA was transcribed to cDNA using the RT First Strand synthesis kit and prepared 
for amplification using a SYBR Green qPCR master mix with ROX reference dye (SA 
Biosciences). Samples were amplified on the StepOnePlus PCR system (Applied 
Biosystems) using the following two arrays, Mouse MAP Kinase Signaling Pathway and 
Mouse Inflammatory Cytokine and Receptors (SA Biosciences).  
 
2.16 Nanostring 
Samples for Nanostring analysis were prepared by TRIzol extraction, as described 
in section 2.14. The nCounter analysis system (NanoString Technologies, Seattle, WA) 
was used to screen for gene expression using two specific probes (capture and reporter) 
for each gene of interest, in a custom panel. Total RNA, 250ng of each sample, was 
hybridized with customized Reporter and Capture ProbeSets according to the 
manufacturer’s instructions to directly label mRNAs with molecular barcodes without 
reverse transcription or amplification. Manufacturer probe sets were designed and 
validated for mRNA specificity to preclude the need for DNase treatment or RNA 
integrity > RIN 7 as in qPCR arrays. Hybridized samples were recovered in the 
NanoString Prep Station, and mRNA molecules were enumerated with the nCounter. For 
analysis of expression, each sample profile was normalized to the geometric mean of 4 
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reference genes, Eif4a2, Oaz1, Ncln, and Gfra2, chosen for their lowest variance among 
all experimental samples. 
 
2.17 mRNA decay 
 Primary bone marrow-derived macrophages from Dusp1-/- and Dusp1+/+ were 
cultured, as described in section 2.8, and plated the day prior to treatment in α-MEM 
with 10% FBS, antibiotics, and 10ng/mL M-CSF. Macrophages were plated at a density 
of 1.5 x 106 cells in 2mL media in a 6-well dish. Cells were treated in low serum media, 
consisting of complete α-MEM diluted 5-fold in serum-free α-MEM. Macrophages were 
stimulated with LPS (100ng/mL) for 4 hours, before the addition of ActD (5µg/mL, 
Sigma-Aldrich). Media was removed, and adherent cells were washed with PBS before 
collecting RNA by TRIzol extraction, as described in section 2.14. RNA was collected 
from cells treated with LPS for 4 hours alone, in addition to cells treated with 
actinomycin D for 15, 30, 45, 60, and 90 minutes. Relative quantification of mRNA 
expression by the 2^(-ΔΔCt) method was used to generate a semi-logarithmic curve of 
mRNA expression over time to calculate the mRNA half-life from the linear regression, 
under the assumption of first-order kinetics.  
 
2.18 Flow cytometry 
Spleens and cervical lymph nodes were isolated from tumor-bearing Dusp1-/- and 
Dusp1+/+ mice on a C57BL/6 genetic background 28 weeks after beginning 4NQO 
treatment. Organs were crushed through a 40µm nylon filter to generate a single cell 
suspension. Red blood cells from splenocyte preparations were lysed in ACK lysis buffer 
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for 2 minutes, and the concentration of remaining viable cells were counted on a 
hematocytometer prior to staining. Peripheral blood was collected from the lateral tail 
vein in 3mg/mL EDTA in PBS. The majority of red blood cells were separated in 1% 
dextran T500, and remaining red blood cells were lysed in ACK lysis buffer for 2 
minutes. Viable cells were enumerated by hematocytometer prior to staining.  
 Cells were prepared in 1x 105 – 1 x 106 cells per staining sample in PBS buffer 
containing 0.5% BSA and 2mM EDTA. Non-specific staining through Fc receptor 
binding was blocked by incubation with FcR blocking reagent (Miltenyi Biotec) for 10 
minutes on ice. Fluorescently-labeled antibodies diluted in staining buffer were added for 
an additional 30 minutes on ice. Samples were washed with staining buffer before 
resuspension in running buffer for analysis. Propidium iodide was added to each sample 
for dead cell exclusion. Samples stained for intracellular Foxp3 expression were stained 
with Fixable Viability Dye for dead cell exclusion (eBioscience). Prior to each flow 
cytometry experiment, calibration was performed, and instrument settings were adjusted 
for compensation of all necessary fluorophores using single antibody staining controls on 
the MACSQuant Analyzer (Miltenyi Biotec). 
 These murine-specific antibodies were used for staining at the following 
concentrations: CD45.1-APC (1:50), CD45.2-FITC (1:50), CD4-FITC (1:1500), CD62L-
PE (1:1000), CD69-eFluor450 (1:500), IgM-PE (1:200), IgD-eFluor450 (1:500), CD40-
APC (1:800), NK1.1-PE (1:500), CD3-FITC (1:2000), F4/80-PE (1:1000), MHCII-PE 
(1:500), PDCA-1-FITC (1:1000), CD4-FITC (1:1500), CD25-PE (1:1000), Foxp3-APC 
(1:500), rat IgG2a-APC (1:500) (eBioscience), Ly6C-FITC (1:500, Novus Biologicals), 
Ly6G-Pacific Blue (1:500, BioLegend), CD8-APC (1:10), B220-FITC (1:10), CD11b-
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APC (1:11), CD11c-APC (1:10) (Miltenyi Biotec). Intracellular staining with antibodies 
against Foxp3 or its isotype control was performed following staining with Fixable 
Viability dye and cell surface markers and incubation in permeabilization and fixation, 
according to manufacturer’s protocols (eBioscience). Flow cytometry data were collected 
from a live cell gate using either propidium iodide or Fixable Viability Dye to exclude 
dead cells. A total of 10,000 events were collected for each sample. Analysis was 
performed on MACSQuantify software (Miltenyi Biotec). 
 
2.19 Statistical analyses 
When comparing effect of genotype, a two-sample Student’s t-test was performed 
using the Satterthwaite method for unequal variances, Mann-Whitney U-test in absence 
of normal distribution, or pooled method for all other comparisons. For distributions of 
categorical scores, a Fischer’s Exact test was used. A repeated measures mixed model, 
with random intercept and time effect, was used to test effect of genotype on weight gain 
and inhibitor treatment by genotype interaction. Survival analyses (event = tumor volume 
> 1500mm3) with Kaplan-Meier estimates were performed using a log-rank test. Adjusted 
p-values using Tukey-Kramer multiple comparisons method are provided when 
comparing least square mean estimates. Analysis of human samples with matched tumor 
and adjacent tissues were assessed by paired Student’s t-test. Data analysis was 
performed using GraphPad Prism version 4.00 (GraphPad Software) with repeated 
measures mixed models using SAS 9.4; p values of < 0.05 were considered statistically 
significant. Error bars represent standard error of the mean. 




CHAPTER 3. Dusp1 deficiency enhances tumor growth and progression. 
 
3.1 Rationale & Hypothesis 
Although the expression of DUSP1 has been shown to be deregulated in a number 
of human cancers, with expression lost or increased depending on tumor type, the 
functional impact of this phosphatase on tumor development and progression has not 
been examined. As a negative regulator of MAPK signaling, DUSP1 has the potential to 
influence a broad array of cellular functions driven by MAPK activation. Despite 
extensive characterization by in situ hybridization and immunohistochemistry, there lacks 
an understanding of how DUSP1 gene and protein expression levels alter cancer 
phenotype.  
Previous studies have demonstrated DUSP1 is a crucial component to control 
inflammation in response to acute immune challenges, such as endotoxin. More recently, 
DUSP1 has also been shown to play a role in shaping the adaptive immune response to 
bacterial and fungal pathogens. The contribution of chronic inflammation to tumor 
progression has gained recognition, especially in oral cancer, where the tissue site is 
subjected to a highly dense array of microbial products. The following studies were 
designed to test the hypothesis that Dusp1 deficiency enhances tumor growth and 
progression, using two in vivo cancer models. 
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3.2 Results 
Dusp1 deficient mice are more susceptible to carcinogen-induced oral cancer. 
To understand how DUSP1 regulates tumor development and progression in oral 
cancer, Dusp1 wild-type and deficient mice were treated with 4-nitroquinoline 1-oxide 
(4NQO) in the drinking water. As a DNA adduct-forming agent, which generates 
successive DNA damage, 4NQO mimics chronic tobacco exposure, a risk factor for 
HNSCC, resulting in progressive epithelial neoplasia that culminates in the formation of 
oral squamous cell carcinomas (Figure 3-1). The development of oral lesions was 
monitored by weekly examinations performed under anesthesia, and the first onset of 
visible oral tumors was documented. Oral tumor-free survival curves show a significant 
enhancement of disease progression, by approximately 2-3 weeks, in Dusp1 deficient 
mice (Figure 3-2). Additional tumor sites were discovered on necropsy, primarily within 
the esophagus, as previously reported (333), with a minority of Dusp1 deficient animals 
demonstrating tumor invasion in the cervical lymph nodes. Studies from our laboratory 
have identified a gender bias in Dusp1 deficient mice in other models of inflammation, as 
well as skeletal homeostasis (334) (unpublished studies). However, no difference in 
disease onset was noted between Dusp1 deficient male and female mice (n = 19 per 
group, p = 0.4163) or wild-type male and female mice (n = 18 per group, p = 0.6824) 
(Figure 3-3).  
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Figure 3-1. Induction of squamous cell carcinoma by 4-nitroquinoline 1-oxide treatment. 
Animals were treated with 4-nitroquinoline 1-oxide (4NQO), a DNA-adduct-forming 
agent, chemical structure shown, in the drinking water for 16 weeks. After 4NQO 
treatment, animals were switched to regular drinking water and monitored for the 
development of oral lesions during biweekly examinations. A representative series of 
images depict the typical progression of disease. 
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Figure 3-2. Tumor-free survival is decreased in Dusp1 deficient animals. Following 
4NQO treatment, the development of oral tumors was monitored through biweekly oral 
examinations under anesthesia. Tumor-free survival was assessed as the time until the 
first visible oral lesion. n = 36. Log-rank test, p = 0.0137. 
 
Figure 3-3. Gender does not affect 4NQO progression in wild-type or Dusp1 deficient 
animals. Differences in tumor-free survival were assessed between male and female 
groups overall, n = 26, p = 0.428 (A), in wild-type mice, n = 18, p = 0.6824 (B), or in 
Dusp1 deficient animals, n = 19, p = 0.6607 (C).  
 
Weight gain was also monitored weekly as a surrogate for disease burden. Dusp1 
deficient mice ceased gaining weight at approximately 12-14 weeks, while wild-type 
mice continued weight gain until 15-16 weeks (Figure 3-4). Dusp1 deficient mice have 
been shown to be resistance to diet-induced obesity, and previous studies have identified 
a role for DUSP1 in regulating metabolism within adipocyte and skeletal muscle tissue 
A' B' C'
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(335, 336).  However, Dusp1 deficient and wild-type mice in vehicle treatment groups 

















Figure 3-4. Weight gain is decreased in Dusp1 deficient mice treated with 4NQO. As a 
surrogate marker of tumor burden, weight gain was monitored for wild-type and Dusp1 
deficient mice over the course of 4NQO treatment and tumor development. Dusp1 
deficient animals show significantly less weight gain than wild-type counterparts. n = 37, 
p < 0.05 at week 15. 
 
 

















Figure 3-5. Dusp1 deficiency does not affect weight gain in vehicle treatment groups. No 
differences were detected in weight gain between wild-type and Dusp1 deficient mice 
throughout the course of the model. n = 15-17. 
 
After 16 weeks of 4NQO treatment, animals were monitored for an additional 16 
weeks and then euthanized for tissue collection. Any animal that lost greater than 20% of 
its original weight before 32 weeks was also sacrificed, under the assumption of severe 
tumor burden.  At the time of tissue collection, full necropsies were performed, and major 
organs, including spleen, liver, lung, heart, esophagus, and cervical lymph nodes were 
collected for histological analysis. Total tumor burden on the tongue and esophagus were 
measured at that time with digital calipers. At the time of collection, nearly all animals 
had visible oral lesions. However, Dusp1 deficient animals had larger oral tumors, and 
only Dusp1 deficient animals had cases of cervical lymph node involvement or distant 
lung metastases (Figure 3-6). Furthermore, 4NQO treatment resulted in significantly 
enhanced esophageal tumor burden in Dusp1 deficient animals (Figure 3-7).  







Figure 3-6. Representative panel of tongue tissues at the time of collection. After 32 
weeks, animals were euthanized for tissue collection. By gross inspection, the majority of 
all animals had developed oral tumors. Views of the dorsal and ventral tongue from a 
representative panel of 4 wild-type and Dusp1 deficient animals are shown. Instances of 
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Figure 3-7. Enhanced esophageal tumor burden in Dusp1 deficient animals. Esophageal 
tumors were detected within both wild-type and Dusp1 deficient groups upon tissue 
collection. Images were taken at the 32 week timepoint. The heart and lungs were 
removed from the chest cavity to obtain a view of the esophagus. Male animals are 
shown on the left. Female animals are shown on the right. Wild-type animals are shown 
above. Dusp1 deficient animals are shown below. Yellow arrows indicate grossly visible 
esophageal tumors. 
 
Analysis of tumor burden at the model endpoint revealed significantly enhanced 
tumor burden, defined as cumulative tumor volume per individual animal, in Dusp1 
deficient mice (Figure 3-8). Histological tumor score, on a scale of normal, hyperplasia, 
dysplasia, in situ squamous cell carcinoma, and invasive squamous cell carcinoma, 
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in the invasive SCC category, compared to wild-type mice which were more evenly 


















Figure 3-8. Total tumor burden is increased in Dusp1 deficient animals. At the time of 
tissue collection, tumor burden of both oral cavity and esophageal tumors was calclulated 
as the total tumor volume per animal. n = 14-15, Mann-Whitney test, p = 0.0032. 
 
Figure 3-9. Dusp1 deficiency enhances histological disease progression. Tumor tissues 
were stained by hematoxylin and eosin and assessed for histological grade on a scale of 
epithelial neoplastic progression of normal, hyperplasia, dysplasia, in situ squamous cell 
carcinoma, and invasive squamous cell carcinoma. The majority of Dusp1 deficient 
animals had the most severe grade of disease, invasive SCC, whereas wild-type lesions 
were more evenly distributed across the spectrum of dysplasia, in situ SCC, and invasive 
SCC. n = 32-38. 
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Dusp1 deficient tumors contain higher levels of inflammation. 
 Histological examination of hematoxylin and eosin-stained tumor sections 
revealed marked inflammatory infiltrate in Dusp1 deficient samples (Figure 3-10A). 
Tissue sections were scored for inflammation on a scale of 0–4 (0, normal mucosa; 1, 
minimal inflammation (occasional scattered granulocytes and leukocytes); 2, mild 
inflammation (scattered granulocytes with occasional infiltrates); 3, moderate 
inflammation (scattered granulocytes with patchy infiltrates); and 4, severe inflammation 
(multiple extensive areas with abundant granulocytes and marked infiltrates), as 
previously described (330). Histologically scored inflammation was significantly 
enhanced in Dusp1 deficient tumor samples (Figure 3-10B). Levels of Ptprc, encoding 
the pan-leukocyte marker CD45, were quantified by qPCR in tumor tissues and also 
suggest an enhanced immune cell presence within Dusp1 deficient tumors (Figure 3-
10C).  
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Figure 3-10. Dusp1 deficient lesions have enhanced inflammatory infiltrate. (A) 
Hematoxylin and eosin-stained tissue sections show enhanced inflammatory infiltrate, 
indicated by the white arrow, surrounding the epithelial lesions in Dusp1 deficient mice. 
(B) A histological inflammation score was generated based on numbers of infiltrating 
leukocyte and granulocytes, demonstrating significantly enhanced inflammation in the 
Dusp1 deficient tumor tissues, compared to wild-type. n = 12-13 (vehicle), 31 (4NQO), 
Mann-Whitney test, p = 0.0005. (C) Expression of the pan-leukocyte marker Ptprc 
(CD45) by qPCR was performed as a measure of leukocyte infiltrate in tissues from wild-
type and Dusp1 deficient animals. In tumor-bearing mice, Ptprc was significantly 
elevated in Dusp1 deficient tissues. n = 7, Mann-Whitney test, p = 0.0175. 
 
Immunohistochemistry for the murine tissue macrophage marker F4/80 identified 
a notable macrophage presence within 4NQO-induced lesions. IHC analysis of a broader 
panel of tissue sections revealed enhanced macrophage infiltrate in tumor tissues, 
compared to vehicle control-treated animals, but no significant difference between wild-
type and Dusp1 deficient mice (Figure 3-11). Immunohistochemistry was also performed 
Dusp1 WT Dusp1 KO 
A 
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for the monocyte-macrophage lineage marker CD11b and the myeloid-derived suppressor 
cell marker Ly6G, which demonstrated no significant difference in CD11b-positive cells 
but increased numbers of Ly6G-positive cells in Dusp1 deficient tumors compared to 










Figure 3-11. Quantification of immunohistochemistry for macrophages in wild-type and 
Dusp1 deficient tissues. Macrophages were enumerated by counting F4/80+ cells in 10X 
fields of view by Viziopharm software. n = 4 (vehicle), n = 16-18 (4NQO). 
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Figure 3-12. Quantification of immunohistochemistry for monocyte-myeloid lineage 
infiltrate in tumor tissues. Macrophages, monocyte-derived cells, and granulocytic cells 
were enumerated by counting F4/80+, CD11b+, or Ly6G+ cells, respectively, by 
Viziopharm software in 10X field of view. No significant differences were detected in 
F4/80 or CD11b expression between wild-type and Dusp1 deficient tumor tissues, but 
significantly increased numbers of Ly6G+ cells were present in Dusp1 deficient tumor 
tissues, compared to wild-type. n = 17-18 (F4/80), 8 (CD11b), 8-9 (Ly6G). p = 0.0176 
(Ly6G). 
 
 To understand how Dusp1 deficiency alters the tumor environment, Nanostring 
analysis was performed on a set of tumor tissues from wild-type and Dusp1 deficient 
mice. This quantitative analysis of mRNAs revealed alterations in a number of gene sets. 
Markers of cellular infiltrate did not show any significant differences in Foxp3, indicative 
of T regulatory cells, but suggested a trend toward increased Cd11b and Gr1 expression. 
Similar to immunohistochemistry studies, no significant difference was detected in Emr1, 
encoding the murine macrophage marker F4/80 (Figure 3-13A). Markers of macrophage 
polarization, including Nos2, Ifng, Tnf, and Irf5, revealed no significant alterations in 
expression of M1-polarized macrophages, with the exception of decreased Il12a (Figure 
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3-13B). However, several markers of M2-polarization were significantly increased in 
Dusp1 deficient tumor tissues, including Arg1 and Il4ra, with a trend toward increased 
Cd163, Cd206, Ym1 and Fizz1 (Figure 3-13C). Most significant were increased levels of 
inflammatory cytokines, chemokines, and several receptors. In this panel, Il1b, Cxcl1, 
Cxcl2, Cxcl9, Cxcl10, Ccl2, and Ccr5 were all significantly elevated (Figure 3-13D). The 
receptor Cxcr5 was also significantly down-regulated.  
 
Figure 3-13. Gene expression from tumor tissues by Nanostring analysis. (A) Markers of 
cellular infiltrate suggested a trend toward increased monocyte lineage cells (Cd11b) and 
myeloid-derived suppressor cells (Gr1) but showed no difference in tissue macrophages 
(Emr, F4/80) or regulatory T cells (Foxp3). (B) Markers of macrophage M1 polarization 
revealed no significant differences except for decreased Il12a expression in Dusp1 
deficient tumor tissue. (C) Markers of macrophage M2 polarization revealed significant 
increases in Arg1, Ym1, and Il4ra expression in Dusp1 deficient tumor tissues with a 
trend toward increased Cd163 and Cd206 expression as well. (D) Significant increases in 
cytokine, chemokine, and receptor expression were detected in Dusp1 deficient tumor 
tissues, including Il1b, Cxcl1, Cxcl2, Cxcl9, Cxcl10, Ccl2, and Ccr5. The receptor Cxcr5 





	   70	  
 
 Flow cytometry analysis of immune cell populations within the spleen and 
draining cervical lymph nodes was performed to discern how Dusp1 deficiency alters the 
cellular constituents within the immune system in tumor-bearing mice. The number of 
CD4+ T helper and CD8+ cytotoxic T cells was assessed, in addition to activation status, 
as determined by CD69+ and CD62L- staining. No significant alteration in T cell numbers 
or activation was noted except for a moderate but significant increase in activated 
cytotoxic T cells within the spleen of Dusp1 deficient mice (Figure 3-14). No significant 
differences were detected in levels of T regulatory cells, defined as CD4+/CD25+/Foxp3+, 
in either spleen or draining lymph nodes from wild-type and Dusp1 deficient mice 
(Figure 3-15). Total number of B220+ B cells was significantly decreased in the spleen of 
Dusp1 deficient mice, but no differences in markers of B cell maturation or activation 
were detected in populations of B220+/IgM+/IgD-, B220+/IgM+/IgD+, or 
B220+/IgD+/CD40+ cells either tissue (Figure 3-16). 
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Figure 3-14. Flow cytometry analysis of T cells in tumor-bearing mice. Numbers and 
activation state of T cells in the spleen and draining lymph nodes were assessed using the 
markers CD4, CD8, CD62L, and CD69. Numbers of activated cytotoxic T cells were 
increased in the spleen of Dusp1 deficient mice. No other changes were detected. n = 6, 
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Figure 3-15. Flow cytometry analysis of T regulatory cells in tumor-bearing mice. 
Numbers of T regulatory cells in the spleen and draining lymph nodes were assessed 
using the markers CD4, CD25, and Foxp3. No changes were detected. n = 6. Gating 
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Figure 3-16. Flow cytometry analysis of B cells in tumor-bearing mice. Numbers and 
activation state of B cells in the spleen and draining lymph nodes were assessed using the 
markers B220, IgM, IgD, and CD40. There were significantly less total B cells in the 
spleens of Dusp1 deficient animals. No other changes were detected. n = 6. Gating 
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 No changes were detected in total levels of dendritic cells, CD11c+, or 
plasmacytoid dendritic cells, CD11c+/PDCA-1+, in either tissue, but there were 
significantly decreased levels of activated dendritic cells, CD11c+/MHCIIhi within the 
spleen of Dusp1 deficient mice. No changes in activated plasmacytoid dendritic cells 
were noted in either tissue (Figure 3-17). No changes in natural killer cell populations 
were detected within the spleen. However, natural killer cells, Cd11b+/Nk1.1+, and 
natural killer T cells, CD3+/Nk1.1+, were significantly elevated in Dusp1 deficient lymph 
nodes (Figure 3-18). The most abundant changes were noted in the cells of the myeloid 
lineage. Cells of interest were defined as monocytic myeloid derived suppressor cells, 
CD11b+/Ly6C+/Ly6G-, granulocytic myeloid-derived suppressor cells, CD11b+/Ly6C-
/Ly6G+, neutrophils, CD11b+/Ly6C+/Ly6G+, or macrophages, CD11b+/F4/80+. In the 
spleen, there was a trend toward increased levels of both myeloid derived suppressor cells 
with significant increase in neutrophils in the Dusp1 deficient mice. In the lymph node, 
all populations were elevated in Dusp1 deficient samples, with the exception of tissue 
macrophages (Figure 3-19).  
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Figure 3-17. Flow cytometry analysis of dendritic cells in tumor-bearing mice. Numbers 
and activation state of dendritic cells and plasmacytoid dendritic cells in the spleen and 
draining lymph nodes were assessed using the markers CD11c, PDCA-1, and MHCII. 
There were significantly less activated dendritic cells in the spleens of Dusp1 deficient 


































Figure 3-18. Flow cytometry analysis of natural killer cells in tumor-bearing mice. 
Numbers of natural killer cells and natural killer T cells in the spleen and draining lymph 
nodes were assessed using the markers CD11b and Nk1.1. There were significantly 
increased natural killer and natural killer T cells in the draining lymph nodes of Dusp1 






















Figure 3-19. Flow cytometry analysis of myeloid lineage cells in tumor-bearing mice. 
Numbers and activation state of myeloid-derived cells in the spleen and draining lymph 
nodes were assessed using the markers CD11b, Ly6C, Ly6G, and F4/80. There were 
significantly increased numbers of neutrophils in the spleens and significantly increased 
numbers of monocytic and granulocytic myeloid-derived suppressor cells and neutrophils 
in the draining lymph nodes of Dusp1 deficient animals. No changes were detected in 
tissue macrophages by F4/80 expression. n = 6. Student’s t-test, p < 0.05. Gating strategy 
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Effects of Dusp1 deficiency on MAPK activation in oral tumor epithelium. 
 To determine how the absence of Dusp1 affects MAPK activation, esophageal 
tumor tissue lysates were probed for levels of phosphorylated and total MAPK levels 
(Figure 3-20). Esophageal tumor tissues were chosen as their larger size enabled a 
sampling of increased tumor:epithelial ratio, compared to tongue tumors which were 
unable to be cleanly dissected from surrounding epithelium due to their small size. 
Western blot analysis revealed no significant changes in MAPK expression or activation 
in tissues from vehicle-treated mice. However, most striking were elevated levels of total 
MAPK expression, particularly p38 and ERK1/2, despite equal amounts of protein by 
bicinchoninic acid quantification and expression of the housekeeper glyceraldehyde 3-
phosphate dehydrogenase (GAPDH). Phospho-ERK1/2 MAPK expression was decreased 
in Dusp1 deficient tumor tissues compared to wild-type. No significant difference was 
seen in phospho-p38 MAPK expression between Dusp1 deficient tumor tissues compared 
to wild-type; however, densitometry analysis only revealed increases in total MAPK 
levels (Figure 3-21). 
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Figure 3-20. MAPK expression and activity in wild-type and Dusp1 deficient tissues. 
Western blots for phosphorylated and total forms of p38a, JNK1/2, and ERK1/2 MAPK 
in tissues show elevations in phospho-p38 in Dusp1 deficient tumor tissues compared to 
wild-type. More striking are elevations in total p38, JNK, and ERK MAPKs in Dusp1 
deficient tissue samples compared to wild-type. No significant changes are noted between 
wild-type and Dusp1 deficient tumor-free mice. 
 




















Figure 3-21. Densitometry analysis of Western blots for phosphorylated and total forms 
of p38α, JNK1/2, and ERK1/2 MAPK in tissues. Analysis demonstrates increased total 
p38, JNK, and ERK MAPKs, with no significant changes in phosphorylated forms 
between Dusp1 deficient and wild-type tumor tissues. 
 
 To address whether alterations in MAPK activation were due to tumor epithelial 
tissue, immunohistochemistry was performed to assess levels of phosphorylated MAPK 
expression in tumor epithelium (Figure 3-22). Only the tumor epithelium was assessed in 
scoring the staining percentage and positivity. No significant differences were detected in 
levels of phosphorylated JNK or ERK MAPK. Although levels of phospho-p38 MAPK 
were elevated in tumor tissues compared to vehicle-treated tissues, no differences were 
detected in wild-type, compared to Dusp1 deficient mice (Figure 3-23). 
Immunohistochemistry for the proliferation marker Ki67 also revealed no significant 
differences in proliferation rates between wild-type and Dusp1 deficient tumor tissues.  
Immunohistochemistry for markers of angiogenesis and proliferation, CD31 and TUNEL 
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sections due to physiologic epithelium turnover, and minimal CD31 positivity was 
detected in these tissues. The small size of many of the oral cancer tissues made it 
difficult obtain multiple serial sections to accurately assess angiogenesis by CD31 
expression.   
 
Figure 3-22. Immunohistochemistry of phosphorylated MAPK in oral tumor tissues. 
Immunohistochemistry was performed to detect phospho-p38, ERK1/2, and JNK1/2 
MAPK in oral tumor tissues in wild-type and Dusp1 deficient animals. Representative 
staining from serial sections for the three kinases and antibody isotype controls are shown 
from data in Figure 3-24. The majority of tissues showed phospho-p38 MAPK activation, 
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Figure 3-23. Quantification of MAPK and Ki67 immunohistochemistry staining. 
Immunohistochemistry scores were generated based on assessment of staining intensity 
and area within the tumor epithelium. Of the three MAPK, p38 was significantly 
increased in tumor tissues compared to vehicle-treated tissues. However, no differences 
were detected in MAPK activity between wild-type and Dusp1 deficient tumor 
epithelium. In addition, no significant differences in tumor proliferation, as assessed by 
Ki67 staining were detected. n = 12 (vehicle), 15 (4NQO). Kruskal-Wallis test, p = 0.006. 
 
Effect of hematopoietic Dusp1 deficiency in carcinogen-induced oral cancer.    
 To delineate the contribution of the immunologic constituents versus tumor 
epithelium to the advanced disease phenotype in Dusp1 deficient mice, bone marrow 
chimeras were generated with Dusp1 deficient and wild-type mice on a C57BL/6 
background and wild-type mice bearing the congenic allele CD45.1. Engraftment was 
assessed by expression of the CD45 alleles on peripheral blood at 6-8 weeks after 
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transplant. After transplant and engraftment, animals were treated with 4NQO at 
50µg/mL for 16 weeks, at a treatment dose and schedule as previously described (337). 
Earlier treatment of wild-type and Dusp1 deficient mice on a mixed C57/129 genetic 
background required a lower dose of 25µg/mL, due to enhanced susceptibility of Dusp1 
deficient mice to the carcinogen and were monitored for an extended period of 32 weeks 
to achieve sufficient tumor development on wild-type animals.  
After backcrossing to a C57BL/6 genetic background, the Dusp1 deficient mice 
and chimeras were treated with the originally described 50µg/mL dose and monitored for 
a total of 28 weeks, rather than 32 weeks. Weight gain was assessed as a surrogate 
measure of tumor burden (Figure 3-24). Comparison of wild-type and Dusp1 deficient 
mice both on a C57BL/6 genetic background demonstrates the same enhanced 
susceptibility of Dusp1 deficient animals to 4NQO-induced disease as previously seen on 
a mixed genetic background. Chimeric wild-type animals reconstituted with Dusp1 
deficient hematopoietic cells had similar changes in weight to wild-type animals. 
Surprisingly, chimeric Dusp1 deficient animals reconstituted with wild-type 
hematopoietic cells were more susceptible to 4NQO-induced weight loss than wild-type 
animals or wild-type animals with Dusp1 deficient hematopoietic cells.   These chimeric 
animals appeared to be more sensitive to 4NQO-induced weight loss early in the model, 
before returning to a similar pattern of weight change to the Dusp1 deficient animals by 
week 20. These results suggest Dusp1 deficiency in the radiation-resistant compartment 
is responsible for the increased disease burden described in Figure 3-4. At this time, 
additional analyses of histologic disease and inflammation scores from paraffin-
embedded tumor tissues as well as mRNA and protein analyses from snap frozen tissues 
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remain to be evaluated to assess how hematopoietic Dusp1 deficiency alters tumor-
associated inflammation.  
 
Figure 3-24. Weight gain in chimeric wild-type and Dusp1 deficient mice treated with 
4NQO. Wild-type and Dusp1 deficient mice were irradiated and reconstituted with either 
wild-type or Dusp1 deficient bone marrow, 6 weeks prior to enrollment in the 4NQO 
model of oral carcinogenesis. Weight gain was tracked over the duration of the 28 week 
model.  
 
Dusp1 deficient mice support enhanced syngeneic tumor growth. 
 To understand how Dusp1 expression within only the microenvironment affects 
tumor progression, wild-type and Dusp1 deficient mice were injected with syngeneic 
tumor cells to form subcutaneous allografts. Few murine oral cancer cell lines have been 
described, with SCCVII being the best characterized. Although SCCVII readily forms 
tumors in mice (338), the cell line was derived from a mouse on the C3H/HeJ genetic 
background, which is protected from endotoxin challenge due to a spontaneous Tlr4 
mutation (339). Murine cancer cell lines on a C57BL/6 background are limited to other 
Weight Loss
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tissue origins, including colorectal, breast, and prostate adenocarcinomas, melanoma, 
lymphoma, and lung carcinomas.  
 Previous studies have demonstrated DUSP1 expression is lost in advanced stages 
of human breast and prostate cancer (174, 176, 340). Furthermore, analysis of DUSP1 
gene expression in publicly available databases has revealed the same trend, with loss of 
DUSP1 expression in metastatic lesions compared to adjacent non-tumor tissue and 
primary prostate cancer tissues (Figure 3-25). In breast cancer, patients stratified as 
having high DUSP1 expression compared to those with low DUSP1 expression have 
significantly enhanced progression-free survival (Figure 3-26). Based on these data 
suggesting these malignancies mirror the trend seen in HNSCC, the murine prostate 
adenocarcinoma cell line TRAMP-C2 and the murine breast adenocarcinoma cell line 
EO771 were selected for subcutaneous allografts. In contrast, DUSP1 expression has not 
been well characterized in melanoma, and no reports have identified a consistent 
correlation between expression levels and disease stage or survival. In that regard, the 
murine B16F10 melanoma cell line was used for comparison. 
 
Figure 3-25. Expression of DUSP1 by microarray analysis in prostate cancer. Microarray 
data from the NCBI GEO dataset GDS2545 demonstrate significant loss of DUSP1 
mRNA in metastatic tissues compared to samples from adjacent non-tumor tissue and 
primary tumors. n = 18 (normal), 63 (adjacent), 65 (primary), 25 (metastatic). Kruskal-
Wallis with Dunn’s post-test, p < 0.001. 
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Figure 3-26. Effect of DUSP1 expression on progression-free survival in breast cancer. 
Previously generated microarray data was used to stratify patients based on high versus 
low DUSP1 expression. Patients with low levels of DUSP1 expression had significantly 
decreased time to disease progression. Data generated from model described in Gyorffy 
et al. 2010 (341). 
 
 Measurements of allografts were taken with digital calipers every other day after 
the formation of palpable tumors, usually occurring after ~ 3-5 days for EO771 and 
B16F10 cell lines and after ~14-16 days for TRAMP-C2 cells.  For both EO771 and 
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TRAMP-C2 cell lines, implanted tumors in Dusp1 deficient mice were significantly 
larger than wild-type mice. However, B16F10 allografts grew at the same rate in wild-
type and Dusp1 deficient mice (Figure 3-27). Histological analysis of inflammatory 
infiltrate was scored as previously described for 4NQO-induced tumors on a 0-4 scale. 
No differences in distribution of inflammation scores were detected in either EO771 or 
TRAMP-C2 tumors (Figure 3-28). To determine whether enhanced p38α MAPK 
activation was responsible for the increase in tumor growth, the small molecule inhibitor 
SB203580 was injected intraperitoneally daily following establishment of subcutaneous 
tumors 7 days after initial tumor cell injection (Figure 3-29). SB203580 did not have an 
effect on EO771 tumor growth in wild-type mice, and no difference was seen between 
SB203580 versus vehicle treatment in wild-type mice. However, in Dusp1 deficient mice, 
SB203580 injection abrogated the enhanced tumor growth seen in Dusp1 deficient mice 
compared to wild-type mice, suggesting enhanced tumor growth in Dusp1 deficient mice 
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Figure 3-27. Subcutaneous syngeneic tumor growth in wild-type and Dusp1 deficient 
animals. The growth of subcutaneous allografts using C57BL/6 syngeneic tumor cell 
lines from prostate cancer (TRAMP-C2), breast cancer (EO771), and melanoma 
(B16F10) were measured in wild-type and Dusp1 deficient animals. Significant tumor 
growth was evidence in Dusp1 deficient mice bearing TRAMP-C2 and EO771 tumors 
but not B16F10 tumors. Student’s unpaired t-test. n = 11, p = 0.0396 at day 25 (TRAMP-
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  Figure 3-28. Inflammation scores of syngeneic subcutaneous tumors in wild-type and 
Dusp1 deficient animals. Histological scores of inflammatory infiltrate within tumors of 
injected syngeneic TRAMP-C2, EO771, and B16F10 cells were performed on a 0-4 
scale, as previously described. n = 6-7, p = 0.6585 (TRAMP-C2), n = 7, p = 0.6747 
(EO771). Fisher’s exact test.  
 
 
Figure 3-29. Inhibition of p38α MAPK in wild-type and Dusp1 deficient mice with 
subcutaneous syngeneic EO771 tumors. Wild-type and Dusp1 deficient mice were 
injected subcutaneously with syngeneic EO771 cells, as previously described. Starting on 
day 7, mice received daily intraperitoneal injections of SB203580 (5mg/kg) or vehicle 
control. Rate of tumor growth is increased in Dusp1 deficient vehicle-treated animals (p < 
0.0001) and Dusp1 deficient SB203580-treated animals (p = 0.0098). Dusp1 deficient 
animals had decreased survival compared to wild-type animals (p = 0.0123). Survival 
was enhanced in Dusp1 deficient animals treated with SB203580 compared to vehicle 














































	   90	  
3.3 Summary & Discussion 
Although the mechanisms of pro-tumorigenic inflammation in gastric and 
colorectal cancer have been well described, only recently has there been an appreciation 
of the contribution of chronic inflammation to other processes of tumorigenesis. The 
development of cancer is now better understood as the interplay between genomic 
alterations, such as those induced by carcinogen exposure, and a supportive tumor 
microenvironment. To understand how Dusp1 deficiency alters the development and 
progression of oral cancer, wild-type and Dusp1 deficient mice were subjected to a 
carcinogen-induced oral cancer model, previously optimized to generate heterogeneous 
oral lesions that evolve into squamous cell carcinomas (337). This carcinogen-induced 
model of oral cancer has previously been described, in wild-type animals, as generating 
little inflammation with low levels of COX-2 expression and stromal infiltrate (337, 342). 
Results from these studies demonstrate the immense alteration of the inflammatory 
milieu within these tumors that develops in the absence of Dusp1 negative regulation.  
In this model system designed to mirror human disease progression from 
hyperplasia to dysplasia to in situ and invasive squamous cell carcinoma, Dusp1 deficient 
mice demonstrated accelerated oral tumorigenesis with associated inflammation and 
provides the first evidence for a mechanistic link between loss of DUSP1 expression and 
advanced disease progression in human cancers. Furthermore, this is the first 
experimental evidence to demonstrate the pro-tumorigenic effect of enhanced 
inflammatory cytokine expression in oral cancer. The particularly enhanced tumor burden 
within esophageal tissues (Figure 3-7) suggests the same mechanism lies true for 
esophageal squamous cell carcinoma. Whether the dramatic increase in esophageal tumor 
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volume in Dusp1 deficient animals is due to tissue-specific effects of Dusp1 regulation or 
characteristics of the esophageal tissue architecture that might render it more susceptible 
to rapid tumor proliferation and expansion requires further investigation. 
The panel of increased cytokines and chemokines identified by Nanostring 
analyses suggests a wide-scale activation of immune signaling. Although IL-1β was one 
of the most highly elevated mRNAs, it is unclear if this cytokine is sufficient to generate 
the development of the pro-inflammatory microenvironment that promotes tumor 
progression. The gradual process of tumorigenesis in the 4NQO model makes antibody 
blockade of IL-1β prohibitively expensive. Repeating the model with Casp1-/- and Casp1-
/-Dusp1-/- double knockout animals or Il1r-/- animals could better address the functional 
role of elevated IL-1β in oral tumorigenesis and tumor progression.  
Although the identification of a precise cytokine driver has not been identified in 
this model, these studies highlight the potential of targeting an upstream regulator of the 
pro-tumorigenic inflammatory response rather than single, secreted factors with 
biologics, which have not yielded significant improvement in clinical trials (343, 344).  
Pharmaceutical methods of increasing DUSP1 expression have been described in a 
number of in vitro studies (345-347) and merit further investigation, particularly in 
cancer models.  
The loss of DUSP1 expression has implications on the biologic activities of many 
cellular constituents within the tumor, which have yet to be clearly dissected in these 
experiments. A recent survey of over 400 human HNSCC tissues revealed p38 MAPK 
activity to be highly elevated in nearly 80% of cases studied by immunohistochemistry, 
with significant impact on cancer cell growth, lymphangiogenesis, and angiogenesis in 
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xenograft studies (348). The discrepancy between elevated phosphorylated p38 MAPK in 
immunoblotting whole tissue lysates versus equal immunohistochemical staining of 
tumor epithelium suggests a more critical role for Dusp1-mediated p38 regulation in the 
supporting stromal and immune cells.  
 Results from the bone marrow chimeric model suggest hematopoietic-derived 
cells alone cannot recapitulate the enhanced disease progression in the long-term model 
of carcinogenesis and tumor progression driven by 4NQO exposure. An initial hypothesis 
for advanced disease progression in Dusp1 deficient mice centered on inflammatory cells 
driving an enhanced immune response that promoted tumor growth. Although Dusp1 
hematopoietic deficiency did not recapitulate the original phenotype, the possibility 
remains increased immune activation with infiltrating leukocytes and cytokine production 
are still necessary for the enhanced disease production seen in Dusp1 deficient animals, 
both with wild-type and Dusp1 deficient bone marrow. Although the 4NQO model 
produces heterogeneous tumors of the oral cavity, bearing numerous molecular 
alterations similar to human HNSCC, the slow, carcinogen-driven disease process 
encompasses a wide spectrum of tumor biology, including carcinogenesis and neoplastic 
transformation, immune escape, tumor proliferation, and early local invasion, which 
makes identification of specific points of regulation difficult. More specific models to 
address immune escape, e.g. MCA-induced fibrosarcoma, or suppression of anti-tumor 
responses, e.g. adoptive transfer of pmel-1 T cells against B16 melanoma, could begin to 
more precisely answer how Dusp1 deficiency enhances tumor progression through 
immune modulation. 
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These initial findings from the chimer and syngeneic subcutaneous tumor models 
suggest non-hematopoietic, non-epithelial tissues within the tumor microenvironment, 
including endothelium, lymphatic vessels, and cancer-associated fibroblasts, may also be 
a driving force. Xenograft studies with a small molecular inhibitor of p38α MAPK 
demonstrated a crucial role for p38-mediated regulation of tumor-promoting secreted 
factors from cancer-associated fibroblasts (349). Inactivation of the RNA decay factor 
AUF1 increased expression of a panel of cytokines and chemokines, including IL-1β, 
CXCL1, and GM-CSF, validated in larger datasets of stromal-specific factors present in 
human breast cancer. In a murine hindlimb ischemia model, Dusp1 expression in 
endothelial cells promoted angiogenesis by modulating histone H3 dephosphorylation to 
induce expression of the proangiogenic chemokine fractalkine (350). As DUSP1 is 
ubiquitously expressed, the potential impact it has on tumorigenesis may vary across 
different cell types.  
DUSP1 is capable of regulating activation of multiple MAPKs, although it has 
greatest affinity for p38. In HNSCC, p38α activation fails to inactivate ERK1/2 
signaling, as in normal oral keratinocytes, due to a failure to inactivate MEK1/2 (351). 
The enhanced p38α and p38δ activity promoted tumor cell proliferation and survival, 
both in vitro and in vivo (351). In peripheral blood mononuclear cells isolated from 83 
HNSCC patients, p38α MAPK was significantly elevated compared to healthy donors 
(352). Levels of p38α were also found to be elevated in sera from HNSCC patients, with 
significant decreases during and after radiation therapy in the group of responders (70 
patients), not seen in the non-responders (11 patients) (353). Based on these previous 
characterizations of human HNSCC samples and the MAPK activation profile in Dusp1 
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deficient 4NQO-induced tumor tissues, the candidate MAPK target responsible for the 
enhancement of tumor progression in Dusp1 deficient animals is p38α, as suggested by 
small molecule inhibition of subcutaneous syngeneic tumor cell growth (Figure 3-29). 
Already, several orally available p38 MAPK inhibitors are in phase II and III 
clinical trials for inflammatory conditions with no signs of clinical toxicity (354, 355). A 
xenograft model of tumor progression using co-injected cancer-associated fibroblasts and 
preneoplastic cell lines demonstrated oral p38 inhibitor treatment could preferentially 
target stromal production of pro-inflammatory mediators (349). However, xenograft 
studies using a systemically administered p38 inhibitor blocked HNSCC tumor cell 
growth (356), suggesting inhibition of p38 signaling within tumor epithelium may also 
have beneficial effects.  
However, the tumor-promoting effect of Dusp1 deficiency may be through 
increased activation of other pathways, such as JNK1/2. Small molecular inhibitors of 
JNK1/2 were effective at targeting in vitro HNSCC cell lines and in xenograft models, 
reducing tumor proliferation and microvasculature, EGFR expression, and secretion of 
IL-6, IL-8, and VEGF (357). In rat tongue cancers, resulting from 4NQO treatment, of all 
the AP-1 family members, JunB and cfos mRNA and protein were elevated in cancerous 
tissue compared to normal control, although only cfos was elevated during the dysplastic 
stage (358). In addition, a targeted qPCR array described in Chapter 4.2 revealed cfos to 
be highly elevated in the Dusp1 deficient tumor sample, although this result was not 
selected for further validation.   
 Histological scores, flow cytometry, immunohistochemistry, and Nanostring 
analyses describe a highly inflammatory tumor tissue in Dusp1 deficient mice subjected 
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to 4NQO. The panel of cytokines and chemokines suggest a mechanism by which 
recruited myeloid-derived immune cells traffick to the tumor site to promote tumor 
progression in Dusp1 deficient animals. Potential cellular mediators include myeloid-
derived suppressor cells, tumor-associated macrophages, neutrophils, and other 
granulocytes. In a murine model of rhabdomyosarcoma, the recruitment of Cxcr2+ 
granulocytic myeloid derived suppressor cells (CD11b+/Ly6G+), via Cxcl1/2 expression, 
inhibited anti-PD1 therapy. Tumor regression after anti-PD1 treatment was restored on 
Cxcr2 deficient mice or with a CXCR2 neutralizing antibody (359). Genetic deletion of 
eosinophils in Balb/c mice challenged with 4-nitroquinoline 1-oxide resulted in reduced 
disease burden (360).  
A similar association between increased numbers of myeloid-derived 
granulocytes and disease progression has been described in HNSCC. A study of HNSCC 
patients revealed high levels of neutrophilic infiltrate in HNSCC tissue with greater 
infiltrate correlating to poorer survival in advanced disease (361). Furthermore, HNSCC 
cell line conditioned medium enhanced neutrophil survival and increased chemotaxis and 
secretory function (361). A later study of neutrophils isolated from peripheral blood of 
HNSCC patients identified impairment of HNSCC-conditioned neutrophilic inducible 
ROS production but not cytokine secretion, with elevated cytokine levels in HNSCC 
serum compared to controls. Similar to previous studies, these cells had enhanced 
survival with lower rates of spontaneous apoptosis. Importantly, HNSCC patients had 
increased numbers of immature PMNs, suggesting a systemic response engaging 
hematopoietic precursors to traffick to the tumor site (362). 
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Little changes were detected in members of the adaptive immune response, with 
low levels of activation markers in T cell subsets, suggesting T cell exhaustion may be 
occurring, as described in other characterizations of the 4NQO model (342). Slight 
decreases in expression of dendritic cell activation markers may be signs of impaired 
recruitment of an anti-tumor immune response. A dendritic cell-based vaccination 
strategy using 4NQO-treated animals suggests these cells are capable of promoting an 
immune response to premalignant and HNSCC lesions (363). In previous 
characterizations of 4NQO-induced lesions on wild-type mice, cervical lymph nodes 
contained higher levels of immunosuppressive T regulatory cells but also conventional T 
cells, albeit with decreased proliferative capacity (342). A study of circulating and 
intratumoral T regulatory cells isolated from HNSCC patients found higher levels of 
immune checkpoint markers (CTLA-4 and PD-1) in intratumoral cells with 
corresponding greater immunosuppressive ability (364). The development of such a 
potent immunosuppressive microenvironment may result, in part, from the enhanced 
secretion of cytokines within earlier premalignant lesions (365). In a small study of 11 
patients and 10 healthy donors, peripheral blood-isolated regulatory T cells from HNSCC 
patients were significantly elevated with increased TLR expression and enhanced 
immunosuppressive effect following LPS and Hsp60 stimulation (366). However, no 
differences in effector T cell proliferative ability were detected. At this time, it is unclear 
how these immunosuppressive mechanisms develop in HNSCC, but Dusp1 deficiency 
does not appear to immediately affect these pathways in the 4NQO model. 
Although 4NQO treatment generated lymph node metastases only in Dusp1 
deficient animals, whether loss of DUSP1 protein promotes metastasis is still unclear. A 
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previous group’s modification of the 4NQO delivery model, using a higher dose with 
prolonged monitoring period, has been used to establish lymph node metastasis with 
complete penetrance in Balb/c mice (367). This and other more rapid models of could be 
used to address this question, especially if DUSP1 is postulated to be a regulator of the 
supporting soil for tumor initiation and development.  
 The subcutaneous allogeneic tumor model was performed to address whether an 
equivalent tumor burden, with wild-type Dusp1 expression, would progress more rapidly 
in a Dusp1 deficient tumor microenvironment compared to wild-type. A limitation of this 
model is the tissue-specific effects of the oral cavity, in particular, potential sources of 
innate immune activation in the microflora. The syngeneic murine oral squamous cell 
line SCCVII can be used on a C3H/HeJ genetic background to model oral squamous cell 
carcinoma with local invasion into the local muscle and mandible, and cervical lymph 
node and pulmonary metastases (368). Unfortunately, the C3H/HeJ genetic background 
necessary for a syngeneic transplant contains a spontaneous mutation in Tlr4, rendering 
these mice resistant to endotoxin challenge (339).   
Due to supporting evidence from human tissue datasets, breast and prostate 
adenocarcinoma cell lines were selected for allogeneic tumor cell experiments, results of 
which support the role of Dusp1 in the microenvironment as a suppressor of tumor 
growth. This effect was not seen across all tumor cell lines, with no statistical difference 
in the growth curves of B16F10 allografts. The spontaneous murine B16 melanoma cell 
line is highly tumorigenic and rapidly growing but has generally been described as poorly 
immunogenic (369, 370). Furthermore, the characterization of DUSP1 in human 
melanoma samples is not consistent, with much smaller sample sizes available in public 
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databases such as NCBI Gene Expression Omnibus and Oncomine. Thus, in future 
investigation of DUSP1 as a target of therapeutic induction, careful consideration of the 
tumor type and molecular patterns of MAPK and cytokine expression should be made. 




CHAPTER 4. Dusp1 regulates inflammatory mediators ex vivo.  
 
4.1 Rationale & Hypothesis 
Animal models of tumor progression, both carcinogen-induced and transplanted 
tumors, suggest Dusp1 deficiency enhances disease progression and generates a more 
inflammatory phenotype than in wild-type animals. Although DUSP1 is well described as 
a negative regulator of the innate immune response to acute endotoxin stimuli in models 
of sepsis and other bacterial-driven disease processes (143, 144, 150, 153, 334, 371), how 
it affects tumor-associated inflammation has not been addressed. Within the oral cavity, 
tissues are constantly exposed to pathogen-associated molecular patterns (PAMPs) 
through the diverse microbiota (372). Correlations between altered microbiota and cancer 
development have been made, in patients with periodontitis or poor oral hygiene (373, 
374). However, the functional impact of these bacterial triggers and host inflammatory 
responses on HNSCC carcinogenesis are not well characterized. 
In HNSCC, IL-1β has been identified as a potential diagnostic biomarker, through 
mRNA and protein studies of tumor tissue and patient saliva samples (375, 376). IL-1β 
was initially discovered as a secreted cytokine from activated monocytes (377) and has 
been shown to be expressed primarily by innate myeloid cells. A study of cytokine 
secretion from well-established UMSCC cell lines revealed varying levels of IL-6, 
VEGF, and IL-8 secretion but no detectable IL-1β (378), suggesting an alternative 
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cellular source of IL-1β within the microenvironment is driving transcription of these 
cytokines and growth factors.   
 Due to the highly elevated levels of IL-1β mRNA and increase in myeloid-lineage 
cells within Dusp1 deficient tumor tissues, we hypothesize Dusp1 negatively regulates 
expression of IL-1β in macrophages. Of the elevated cytokines and chemokines identified 
by Nanostring analysis in the 4NQO tumor model, IL-1β had previously been shown to 
upregulated in human HNSCC. Furthermore, IL-1β signaling has been described as an 
activator of a number of inflammatory mediators, making it an attractive candidate for 
validation as a downstream target of Dusp1 for future therapeutic targeting. 
 
4.2 Results 
Macrophage polarization is not skewed in Dusp1 deficient primary cells. 
Immunohistochemistry previously identified similar numbers of infiltrating 
F4/80+ tumor-associated macrophages within 4NQO-induced lesions in wild-type and 
Dusp1 deficient mice. However, Nanostring analysis suggested the phenotype of these 
macrophages might differ between wild-type and Dusp1 deficient animals, based on 
expression of macrophage polarization genes, such as Il12a, Arg1, and Il4ra. To 
determine whether Dusp1 deficiency generated an intrinsic defect in M1 polarization, 
primary bone marrow-derived macrophages from wild-type and Dusp1 deficient mice 
were treated ex vivo to classic M1 (LPS and IFN-γ) or M2 (IL-4) polarizing conditions 
and assessed for cytokine response.  
There have been conflicting reports of whether IL-12 is within a group of 
cytokines negatively regulated by DUSP1 (142, 379). In this study, Dusp1 deficient 
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macrophages express less Il12b mRNA and IL-12p40 protein following stimulation, 
although the difference was not statistically significant. Levels of Nos2 mRNA and IL-23 
protein were also decreased in Dusp1 deficient macrophages. However, examination of 
markers of M2 polarization did not reveal a consistent trend. There were no significant 
changes in Il10 mRNA and no detectable IL-10 protein secreted. There was a trend 
toward decreased Arg1 mRNA and no significant difference in IL-1RA expression 
(Figure 4-1). These data suggest Dusp1 deficient macrophages may have impaired M1 
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Figure 4-1. Effect of Dusp1 deficiency on macrophage polarization. Primary bone 
marrow-derived macrophages from wild-type and Dusp1 deficient mice were treated with 
LPS and IFN-γ to induce M1 polarization or IL-4 to induce M2 polarization. Il12b and 
Nos2 gene expression and IL-12p40 and IL-23 cytokine secretion were assessed as 
measures of M1 polarization. Il10 and Arg1 gene expression and IL-1RA and IL-10 
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Dusp1 deficient tumor tissues express significantly higher levels of inflammatory 
chemokines and cytokines. 
 A targeted qPCR array was used to assess a panel of 89 inflammatory cytokines, 
chemokines, and receptors comparing expression between a pair of wild-type and Dusp1 
deficient tumor tissues matched for sex, tumor grade, and inflammation score. Fifteen 
targets were expressed greater than 5-fold in the Dusp1 deficient sample, with the three 
highest being Il20, Il1b, and Cxcl1 (Appendix A). Of these three targets, Il1b was 
validated in a larger panel of 4NQO and vehicle-treated tissue samples with significant 
increased in Il1b in Dusp1 deficient tumor tissues (Figure 4-2). Il1b was also selected for 
further investigation, due to the supportive evidence that IL-1β is up-regulated in human 
HNSCC. A similar qPCR array targeted towards members of the MAPK signaling family 
identified 6 genes up-regulated greater than 5-fold in at the Dusp1 deficient tumor tissue 
sample compared to a wild-type match, but validation of the most highly expressed gene, 
p16INK4A, in a larger panel of tissue samples was unsuccessful (Appendix B). 
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Figure 4-2. Increased Il1b gene expression in Dusp1 deficient tumor tissues. Validation 
of Il1b as an upregulated gene in Dusp1 deficient tumor tissues was performed by qPCR 
in a panel of wild-type and Dusp1 deficient tumor and control-treated tissues. Il1b mRNA 
was significantly increased in Dusp1 deficient tumor tissues, with no differences between 
tumor-free animals. n = 7-8, Mann-Whitney test, p = 0.0003. 
 
Dusp1 deficient macrophages express more Il1b mRNA after stimulation. 
 Stimulation of primary bone marrow-derived macrophages with LPS confirmed 
enhanced expression of Il1b mRNA in Dusp1 deficient cells compared to wild-type 
(Figure 4-3). The same trend was seen when conditioned media from a premalignant cell 
line obtained from a 4NQO-induced lesion was used as an activation stimulus, although 
to a much lesser extent than with LPS (Figure 4-4). IL-1β expression is carefully 
controlled at both the mRNA and protein level. To understand whether the increase in 
steady-state mRNA was due to increased de novo transcription or enhanced mRNA 
stability, levels of primary mRNA transcripts were quantified by qPCR using primers 
targeting the exon-intron junction present only in unprocessed mRNA compared to 
amplicons generated from primers targeting exon-exon junctions of mature, fully 
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processed mRNA. These data revealed increases in both primary transcripts as well as 
mature mRNA after LPS stimulation, both with greater levels in Dusp1 deficient cells 
(Figure 4-5). However, mature mRNA appeared to constitute the majority of Il1b mRNA 
present after LPS stimulation. The expression levels of mature mRNA detected by exon-
exon primer pairs were identical to that detected by TaqMan assays using fluorescent 
probes specific for exon-exon junctions performed in independent experiments (Figure 4-
3).   
 
Figure 4-3. Il1b mRNA is increased in Dusp1 deficient macrophages after stimulation 
with LPS. Primary bone marrow-derived macrophages from wild-type and Dusp1 
deficient mice were treated with LPS (100ng/mL) for 4h. Il1b expression was assessed by 
qPCR, normalized to the housekeeping gene Gapdh. n = 4, Student’s unpaired t-test, p = 
0.0122. 
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Figure 4-4. Il1b expression is increased after stimulation with 4NQO-derived conditioned 
media. Primary bone marrow-derived macrophages from wild-type and Dusp1 deficient 
mice were treated with conditioned media from a cell line derived from a 4NQO-induced 
premalignant lesion, diluted 5-fold in serum-free media for 4h. Il1b expression was 
assessed by qPCR, normalized to the housekeeping gene Gapdh. n = 3, Student’s 
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Figure 4-5. Il1b primary transcripts are increased in Dusp1 deficient macrophages after 
LPS stimulation. Primary bone marrow-derived macrophages from wild-type and Dusp1 
deficient mice were treated with LPS (100ng/mL) for 4h and assessed for gene 
expression by qPCR. (A, B) Unprocessed primary transcripts of Il1b were detected with 
primer pairs flanking intron-exon junctions, revealing increased Il1b primary mRNA in 
Dusp1 deficient macrophages. (C) Mature Il1b mRNA was detected with primer pairs 
flanking exon-exon junctions, revealing increased Il1b primary mRNA in Dusp1 
deficient macrophages, as previously shown in Figure 4-3. The majority of Il1b transcript 
after LPS stimulation is mature, processed mRNA rather than de novo transcription. n = 4 
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Il1b mRNA stability is enhanced in Dusp1 deficient macrophages. 
 The 3’ untranslated region of Il1b mRNA, like many other cytokines, contains 
multiple AU-rich elements capable of interacting with RNA binding proteins, such as 
AUF1, HuR, and TTP (Figure 4-6) (380). The activity of these RNA binding proteins can 
be regulated by p38MAPK-mediated phosphorylation downstream of DUSP1, affecting 
their cellular localization or targeting them for degradation (381-383). To determine 
whether enhanced Il1b expression after stimulation was due to increased mRNA stability 
following LPS stimulation, primary bone marrow-derived macrophages were treated with 
actinomycin D to inhibit de novo transcription. After actinomycin D treatment, levels of 
Il1b mRNA were quantified to assess rates of mRNA decay. In these experiments, LPS 
stimulation revealed enhanced Il1b stability in Dusp1 deficient macrophages with a half-
life of approximately 45 minutes in wild-type macrophages compared to greater than 60 
minutes in Dusp1 deficient cells (Figure 4-7A). However, treatment with conditioned 
media from the 4NQO-derived cell line did not reveal significant differences in mRNA 
half-life, both between 30-35 minutes (Figure 4-7B), possibly due to the low levels of 
induction as seen in steady-state experiments.  
 
Figure 4-6. The 3’ untranslated region of IL1B contains AU-rich elements. The 3’ 
untranslated region of the human IL1B gene contains several AU-rich elements enabling 
interaction with mRNA binding proteins. Images adapted from AREsite. Gruber et al. 
2011 (384).  
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Figure 4-7. Dusp1 deficiency differentially affects Il1b mRNA stability. Primary bone 
marrow-derived macrophages from wild-type and Dusp1 deficient mice were treated with 
LPS (100ng/mL) or conditioned media from a 4NQO-derived cell line for 4h followed by 
actinomycin D (5ug/mL). Il1b expression was assessed by qPCR, normalized to the 
housekeeping gene Gapdh at time 0, 15, 30, 45, and 60 minutes. n = 3. 
 
Dusp1 deficiency does not affect inflammasome activation. 
 After transcription of Il1b mRNA, the message must be translated as a 34kDa 
protein and then cleaved by the inflammasome protein complex before being secreted in 
its active 17kDa form. Examination of tumor tissues from the 4NQO model revealed the 
proform of IL-1β to be elevated only in Dusp1 deficient tumor samples. Furthermore, 
these samples contained highly elevated levels of procaspase-1, the enzyme within the 
inflammasome complex responsible for cleavage and activation of IL-1β (Figure 4-8). 
These data support increased production of IL-1β within the 4NQO-induced tumor 
microenvironment, with both elevated transcriptional and translational products. 
However, the increased levels of procaspase-1 within Dusp1 deficient tumor tissues 





































	   110	  
suggested Dusp1 could potentially modulate an additional point of post-translational 
regulation by the inflammasome.  
Figure 4-8. IL-1β and caspase-1 expression in 4NQO tissues. The proforms of caspase-1 
and IL-1β were detected in tissue samples from wild-type and Dusp1 deficient animals 
treated with vehicle or 4NQO. Gapdh was used as a loading control. Cleaved isoforms of 
caspase-1 and IL-1β were unable to be detected in these samples. 
 
 To determine whether this was the case, primary bone marrow-derived 
macrophages from wild-type and Dusp1 deficient mice were treated with LPS for 4 hours 
to prime these cells to express Il1b mRNA. Following this treatment, cells were 
stimulated with either adenosine tri-phosphate (ATP) or nigericin to induce formation of 
the Nlrp3 inflammasome complex necessary to cleave Il1b to its mature, secreted form. 
Activation of inflammasomes requires this secondary treatment to recruit members of the 
complex with subsequent cleavage of procaspase-1 into active p10 and p20 subunits. 
ELISA of supernatants collected revealed enhanced IL-1β secretion by Dusp1 deficient 
macrophages after ATP or nigericin treatment, although this was not statistically 
significant (Figure 4-9). Western blotting showed similar increases of IL-1β protein in 
lysates as well as supernatants in Dusp1 deficient samples. However, no changes were 
Pro Il-1b 
31kDa 
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seen in procaspase-1 expression or its cleaved caspase 1 p20 subunit (Figure 4-10), 
suggesting enhanced IL-1β secretion is due to increased influx of Il1b mRNA and its 
translational product rather than increased inflammasome recruitment or activation.  
 
Figure 4-9. IL-1β secretion by wild-type and Dusp1 deficient macrophages after 
inflammasome activation. Primary bone marrow-derived macrophages from wild-type 
and Dusp1 deficient mice were treated with LPS (100ng/mL) for 4h or primed with LPS 
under the same conditions, followed by ATP (5mM) for 30 minutes or nigericin (10uM) 
for 60 minutes to activate the inflammasome complex. Secreted IL-1β in the supernatant 
was quantified by ELISA. ATP stimulation resulted in a trend toward increased IL-1β 
from Dusp1 deficient macrophages. Nigericin stimulation resulted in detectable IL-1β 
secretion only in Dusp1 deficient cells. n = 4, p = 0.4555 (ATP), p = 0.1036 (nigericin), 
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Figure 4-10. IL-1β expression in increased in Dusp1 deficient macrophages. Primary 
bone marrow-derived macrophages from wild-type and Dusp1 deficient mice were 
treated with LPS (100ng/mL) for 4h or primed with LPS under the same conditions, 
followed by ATP (5mM) for 30 minutes. Lysates and supernatants were probed for 
caspase-1 and IL-1β expression. LPS followed by ATP treatment resulted in increased 
mature IL-1β expression by Dusp1 deficient macrophages. Increased IL-1β expression 
was not accompanied by increased caspase-1 cleavage, detected as caspase-1 p20. 
Loading control for lysates was α-tubulin. Western blots shown are representative of 4 
independent experiments. 
 
4.3 Summary & Discussion 
 Immunohistochemistry and flow cytometry analysis did not suggest alterations in 
macrophage numbers within Dusp1 deficient tumor tissues. However, the phenotype of 
infiltrating macrophages was only indirectly assessed by Nanostring analysis. These gene 
expression results suggest a skewing toward M2 polarization, which would promote 
tumor progression through immunosuppressive effects on other immune cells and 
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enhancing angiogenesis (287, 385, 386).  Macrophage polarization was assessed ex vivo 
using primary bone marrow-derived macrophages and revealed no intrinsic bias toward 
M2 polarization but did demonstrate decreased IL-12 expression, which could lead to a 
less effective anti-tumor immune response. Dusp1 deficient dendritic cells have been 
shown to express lower levels of IL-12, rescued by p38 but not JNK inhibition, which 
impaired effective recruitment of Th1 and Th17 but not Th2 responses (387).  
Dusp1 deficient macrophages have been well characterized as expressing 
enhanced levels of IL-10 after LPS challenge (143, 144, 151, 371), but this effect was not 
seen in M2-polarized primary cells. Enhanced IL-10 may promote the development of an 
immunosuppressive tumor microenvironment (286, 388). It is unclear whether 
recombinant IL-4 treatment can sufficiently mimic the conditions that promote the 
development of tumor-associated macrophages. Furthermore, debate continues as to 
whether M2 polarized macrophages from primary cells can accurately recapitulate these 
cells or whether tumor-associated macrophages are a truly distinct entity (389).  
The inflammatory component of 4NQO-induced tumors in Dusp1 deficient mice 
was characterized by qPCR array to identify cytokine mediators for more in-depth 
validation. Both Nanostring analyses, performed in Chapter 3.2, and targeted qPCR array 
results, described in Chapter 4.3, found Il1b mRNA to be significantly elevated in Dusp1 
deficient tumor tissues. To address the mechanism of IL-1β regulation by Dusp1, primary 
bone marrow-derived macrophages were used for an ex vivo culture model, based on 
these observations. A previous study of 4NQO-induced lesions in Balb/c mice revealed 
Il1b mRNA was elevated in HNSCC lesions but not in epithelial-enriched samples 
examined by laser-capture microdissection, with prominent CD11b+ cells in the 
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underlying stroma (390). Examination of secreted supernatants from HNSCC cell lines 
compared to supernatants from freshly derived tumors and tumor-draining lymph nodes 
from HNSCC patients found similar results with elevated levels of IL-1β only in the 
tumor lysates and lymph nodes but not isolated cell lines (391). 
Results from the experiments detailed in this chapter demonstrate multiple points 
of regulation of IL-1β expression by Dusp1, both transcriptionally and post-
transcriptionally. Transcriptional regulation of IL-1β has been shown to be mediated by 
NF-κB and AP-1 (392), both key members of the TLR-MAPK innate immune signaling 
pathway, suggesting similar mechanisms may be increased in Dusp1 deficient cells. 
Identifying the MAPK responsible for increased transcription by inhibitor treatment, 
followed by chromatin immunoprecipitation of the putative transcription factor and 
promoter region will more clearly delineate this pathway. 
Following stimulation, the majority of Il1b mRNA was determined to be mature, 
processed transcript suggesting enhanced mRNA stability as the main mechanism by 
which IL-1β is rapidly elevated following stimulation. Like other cytokines rapidly 
induced following TLR4 activation, the 3’ UTR of IL-1β contains several ARE sites for 
interactions with RNA binding proteins to regulate its stability (393). Specifically in 
HNSCC tissues, the RNA binding protein tristetraprolin down-regulates expression of IL-
6, VEGF, and PGE2 by decreasing mRNA stability, with an inverse correlation between 
TTP and IL-6 expression, serving as a biomarker for poor prognosis (394). More 
recently, the tumor-promoting effects of p38α MAPK activity in senescent and cancer-
associated fibroblasts was found to be mediated through post-transcriptional regulation of 
secretory products known collectively as the senescence-associated secretory phenotype, 
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which includes IL-1β, by RNA binding protein AUF1 (349). As the ARE sites within IL-
1β have been identified to bind to at least three RNA binding proteins (395-399), more 
thorough ribonucleoprotein immunoprecipitation reactions with 3’ UTR mutation screens 
are needed to dissect the regulatory pathway involved. 
Functionally, IL-1β may have several distinct roles within the tumor 
microenvironment. In Epstein Barr virus-associated nasopharyngeal carcinoma, tumor-
derived IL-1β was shown to recruit neutrophils to generate an anti-tumor immune 
response, associated with increased survival (400). Other knockout studies have also 
suggested hematopoietic-derived IL-1β may have beneficial anti-tumor effects (325, 
401). IL-1β has the potential to induce dendritic cell-mediated activation of adaptive 
immune cells (401). However, the effects of IL-1β may vary greatly depending upon the 
cellular constituents of the microenvironment. In a xenograft model, tumor cells 
engineered to overexpress IL-1β were shown to preferentially induce expansion of a 
Ly6C- MDSC population, particular immunosuppressive against NK cell function (402). 
Il1r and Myd88 deficiency protected mice from topical skin carcinogenesis, but 
orthotopic tumor growth was only inhibited in Myd88 deficient keratinocytes and not Il1r 
deficient cells (403). Deficiency in IL-1β but not IL-1α was shown to protect mice from 
3-methylcholanthrene-induced fibrosarcoma, an effect reversed with addition of 
recombinant IL-1RA, an endogenous inhibitor of IL-1β signaling (300). In mouse models 
of obesity, inflammasome activation in adipose tissue macrophages occurs in response to 
secreted factors from adipocytes; the increase in circulating IL-1β then promotes the 
expansion and recruitment of bone marrow-derived myeloid progenitors (404).  Data 
from the Dusp1 deficient animals challenged with 4NQO, described in chapter 3, suggest 
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IL-1β may play a similar role in recruiting myeloid lineage immune cells to the tumor 
microevironment. Understanding the direct contribution of IL-1β in these models of 
tumor progression could be better addressed in the future with Casp1-/- or Il1b-/- animals.  
In addition to tumor-associated macrophages, other cellular sources of IL-1β 
could further modulate the immune response. Sublethal doses of radiation and 
chemotherapeutics 5-fluourouracil and cisplatin were shown to increase levels of IL-1β 
in a panel of HNSCC cell lines (405). Surprisingly, enhanced tumorigenesis in colitis-
associated cancer through Nlrc4 inflammasome activation has been attributed to caspase-
1 regulation of colonic epithelium (406). However, Nlrp3 has been shown in the same 
model of colitis-associated cancer to regulate tumorigenesis through the hematopoietic 
compartment (325). Whether these complex regulatory pathways impact HNSCC 
development are exciting avenues for future investigation. 
 
 




CHAPTER 5. Assessment of DUSP1 expression in human HNSCC 
 
5.1 Rationale & Hypothesis 
 DUSP1 gene and protein expression have been shown to be lost in a number of 
human malignancies, including prostate, breast, and colon, with increasing tumor grade 
(174, 176, 340). Based on characterization of the knockout animal, Dusp1 has been 
shown to be necessary for timely inactivation of immune responses to bacterial 
challenges, including LPS, peptidoglycan, and other innate immune stimuli (144, 153, 
407). The oral microenvironment contains a unique complement of dense bacterial 
pathogens and constant immune surveillance, with important implications in head and 
neck cancer (374, 408).  Animal studies presented in Chapter 3 suggest Dusp1 may have 
a tumor suppressive role in head and neck cancer, due in part to alterations of the 
immunologic milieu. Thus, we hypothesize expression of DUSP1 is decreased in human 
HNSCC tissues.  
 
5.2 Results 
Decreased DUSP1 expression in human HNSCC 
Expression of DUSP1 mRNA and protein levels were examined in tumor tissue 
from patients diagnosed with HNSCC in comparison to matched adjacent non-tumor 
tissue. RNA and protein were isolated from snap frozen tissues and assessed by qPCR 
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and immunoblotting. DUSP1 mRNA was significantly decreased in ten pairs of HNSCC 
tissues compared to non-tumor controls (Figure 5-1). Protein levels of DUSP1 were also 
down-regulated in tumor tissues in 8 of the 11 pairs of tissue samples. Expression of IL1B 
mRNA was also examined to determine if there was a similar inverse relationship as seen 
in the 4NQO animal model and in ex vivo macrophage experiments. A linear regression 
of IL1B and DUSP1 gene expression from each patient, using fold change of gene 
expression in the tumor tissue normalized to the adjacent non-tumor tissue sample did not 
detect an inverse linear relationship between fold change of DUSP1 versus fold change of 
IL1B for each patient sample pair. However, this method of comparison is not well suited 
for these data, in which a single patient provides two pairs of (x, y) data. Using an 
alternative statistical test, an association (β = 1.34, p = 0.011) was detected between IL1B 
and DUSP1 in this sample set. However, the available sample size limits the 
interpretation that can be made from this comparison. As expression of IL-1β is regulated 
at multiple points, both in gene expression and post-translational processing, protein 
expression of IL-1β by Western blotting was assessed (Figure 5-2). These blots 
demonstrate increased levels of 35kD proform and cleaved 17kD IL-1β in eight of eleven 
pairs of these HNSCC tumor tissues, likely a more appropriate measure of IL-1β 
expression within the tumor microenvironment than mRNA.  
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Figure 5-1. DUSP1 mRNA is decreased in human HNSCC. Tissues from patients 
diagnosed with HNSCC were assessed for DUSP1 expression by qPCR. DUSP1 
expression was significantly decreased in tumor tissues compared to matched adjacent 
non-tumor tissue. n = 10, Student’s paired t-test, p = 0.0378. 
 
Figure 5-2. DUSP1 and IL-1β expression in human HNSCC. Tissues from patients 
diagnosed with HNSCC were assessed for DUSP1 and IL-1β expression by Western 
blotting. DUSP1 expression was decreased in nine of the eleven tumor tissues compared 
to matched adjacent non-tumor tissue. IL-1β expression was increased eight of the eleven 
tumor tissues. n = 11. 
 
DUSP1 expression in other HNSCC datasets 
 Previously generated microarray data from a set of 22 patients diagnosed with 
HNSCC were also examined for DUSP1 expression. Five of the 22 pairs of patient 
samples were obtained from a hospital in Shanghai, China, and the remainder during 
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surgical resection at New York University. Thirteen of the 22 tumors were located within 
the oral cavity. Three of the tumor samples were located within the oropharynx. Nine 
patients were diagnosed with stage T1 or T2 disease with no nodal involvement, and none 
of the patients had any distant metastatic disease (409). In this sample set, comparing 
HNSCC expression with that of non-tumor adjacent tissue revealed significantly 
decreased DUSP1 and significantly increased IL1B mRNA (Figure 5-3).   
Figure 5-3. DUSP1 and IL1B mRNA in HNSCC from available microarray datasets. 
Previous microarray analysis of human HNSCC and matched adjacent non-tumor tissues 
show significantly decreased DUSP1 expression and increased IL1B expression. n = 22, 
Wilcoxon signed-rank test, p =0.0005 (DUSP1), 0.047 (IL1B). 
 
Correlation between DUSP1 expression and cytokine levels in HNSCC 
 Linear regression analysis of DUSP1 and IL1B mRNA expression from the ten 
sample sets obtained from the Hollings Cancer Center did not reveal a significant 
correlation. This analysis was performed using a linear regression of IL1B and DUSP1 
gene expression from each patient, comparing fold change of gene expression in the 
tumor tissue normalized to the adjacent non-tumor tissue sample, for both DUSP1 and 
IL1B gene levels, which did not detect an inverse linear relationship between fold change 
of DUSP1 versus fold change of IL1B for each patient sample pair. As previously 
discussed, this statistical method is not well suited for these data, in which a single 
patient provides two pairs of (x, y) data. Although an association (β = 1.34, p = 0.011) 
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was detected between IL1B and DUSP1 using an alternative statistical test, the available 
sample size limits the interpretation that can be made from this comparison. 
 
5.3 Summary & Discussion 
 These experiments demonstrated that DUSP1 gene and protein expression is 
reduced in human HNSCC compared to adjacent non-tumor tissue, as previously 
described in other tumor types (88, 174, 182). The interpretation of these results is 
limited by a disease-free tissue sample to account for potential changes in gene 
expression due to a tumor field effect. Although adjacent non-tumor tissue samples were 
used as controls, the field of precancerous epithelium, seen early in the progression of 
OSCC (410), has likely already begun to accumulate genomic and epigenetic alterations. 
An alternative option for control tissues from cancer-free patients includes samples from 
uvulopharyngoplasty for obstructive sleep apnea. These tissues offer similar anatomical 
location but often are complicated by long-standing inflammation and hypoxia (411). In 
the available tissue pairs, the difference between HNSCC and adjacent non-tumor tissue 
was significant, even in a small sample size, suggesting loss of DUSP1 is a common 
molecular occurrence. Searches of available genome-wide association studies and copy 
number variation analyses have not identified sites of mutation or deletion to explain its 
loss. Recently, an unbiased promoter hypermethylation screen identified DUSP1 (89), 
suggesting its down-regulation can be mediated by epigenetic means. The upstream 
epigenetic modifiers responsible and whether loss of expression can be reversed with 
pharmaceutical inhibitors, such as azacytidine and decitabine, should be addressed in 
future studies. 
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 A shortcoming of these studies is the inability to address whether regulation of 
IL-1β is deregulated by loss of DUSP1 expression, as seen in murine macrophages ex 
vivo. Correlation analysis suggests a trend toward increasing IL-1β mRNA expression 
with decreasing DUSP1 mRNA expression, but analysis of IL-1β gene levels may not be 
sufficient as its expression is highly regulated post-translationally by inflammasome 
activation. Furthermore, the small sample size limits the associations that could be drawn 
to understand whether DUSP1 and/or IL-1β expression may have prognostic or 
predictive value in HNSCC. In future studies with a larger sample set, ideally these 
tissues can be stratified based on tissue site, stage, grade, patient sex, exposure to 
tobacco, alcohol, and chemotherapeutic and radiotherapeutic treatments.  The tissues 
used for these analyses did not include tumors from the oropharynx, limiting likelihood 
of HPV-positive status. However, in future studies with larger datasets, stratification of 
HPV-positive versus negative tissues will be an important distinction, as pathophysiology 
of these tumors, particularly with respect to immune involvement, differs dramatically. In 
addition, analysis of tissues from primary tumors versus lymph node or distant metastases 
might answer whether DUSP1 expression level is involved in metastatic progression. 
 Immunohistochemical studies were not performed due to non-specific background 
staining in testing of several commercially available DUSP1 antibodies. The 
consequences of altered subcellular localization must be considered, as DUSP1 
immunohistochemistry has been characterized as cytoplasmic in certain cancers (184) 
(182). With a more specific antibody for immunohistochemistry, subcellular localization 
can be assessed as well as identifying which cells within the tumor express DUSP1 and 
whether these colocalize with specific cytokines, such as IL-1β. The latter question can 
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be addressed by laser-capture microdissection of epithelial versus stromal expression 
within HNSCC tissues, but delineating key immune cell players will require more precise 
techniques.  
 Already a recombinant form of IL-1RA, an endogenous antagonist to IL-1R1, 
approved for use in rheumatoid arthritis, is showing signs of efficacy in clinical trials for 
smoldering myeloma and numerous murine cancer models (412, 413). A dose-escalation 
phase I clinical trial of a monoclonal antibody against IL-1α demonstrated 29% stable 
disease and 3% partial response in a group of 34 patients with metastatic disease of 18 
tumor types. Furthermore, 70% of patients with cancer-associated cachexia demonstrated 
reduced IL-6 plasma levels with increased lean body mass (414). Before expanding these 
to other disease models, additional studies must be done to better understand the cellular 
constituents and downstream mechanisms targeted by these inhibitors. 
 




CHAPTER 6. General Discussion & Future Directions 
Although previous reports have identified down-regulation of DUSP1 across a 
diversity of tumor tissues, this is the first study to demonstrate a tumor suppressive role 
for this MAPK phosphatase. Results from these in vivo and ex vivo studies also highlight 
a potential mechanism for up-regulation of the pro-inflammatory cytokine IL-1β in oral 
cancer, previously shown to be elevated both as mRNA in salivary exosomes (376) and 
secreted protein (375). Using a model that closely mimics the genetic heterogeneity of 
HNSCC following long-term carcinogen exposure, these findings support the role of IL-
1β as a potential biomarker for human disease. However, additional work must be done 
to address the functional impact of IL-1β on tumor progression. 
The implications of these findings may extend well beyond HNSCC, as DUSP1 
expression has been shown to be dysregulated in a number of other cancers and may even 
be predictive of response to targeted therapies, such as cetuximab (174, 415). Genomic 
studies have not identified common mutation or deletions, but a recent DNA methylation 
screen identified significantly increased promoter hypermethylation in over 80% of oral 
cancer tissues compared to normal samples (89). Furthermore, aberrant ERK signaling in 
cancer cells may enhance DUSP1 degradation through the proteasomal pathway (136, 
137). The delineation of regulatory mechanisms in different cell types will enhance the 
understanding of expression changes in pathologic states and enhance development of 
specific therapeutic agents.    
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Bone marrow chimeric and subcutaneous syngeneic tumor experiments suggest 
the loss of DUSP1 expression in the tumor microenvironment, but not hematopoietic 
cells, supports tumor progression. Additional studies must be performed to address how 
Dusp1 deficiency in non-hematopoietic cells alters tumor-associated inflammation and 
the specific cell types involved. This finding presents an opportunity to design 
therapeutics with the benefit of targeting cell types with decreased heterogeneity, 
compared to tumor cells, with the goal of generating a consistent anti-tumor response. In 
addition, modulation of an immune regulator, such as DUSP1, has the potential to go 
beyond simply reducing inflammation and shifts the immune response to reprogram it 
toward a less immunosuppressive phenotype. 
An unanswered question remains the potential inflammatory trigger that initiates 
the inflammatory response seen in the 4NQO model of oral cancer. Although tumor-
associated inflammation is commonly referred to as “sterile inflammation,” possibly 
driven, in this scenario, by the interleukin-1 response to necrotic tissue, the context of the 
oral cavity brings up potential involvement of the abundant and diverse microflora.  
Recent studies of germ-free mice have identified crucial roles of the gut microbiome in 
shaping immune system development with broad-reaching effects on metabolism, 
autoimmunity, and cancer. Additional work must be done to address how the complex 
biodiversity in the oral cavity may interact with the immune cells within the head and 
neck tumor microenvironment and its effects on tumor growth and progression.  
Pharmaceutical intervention to induce DUSP1 expression, with agents such as 
rosiglitazone and mapracorat, are currently being explored with promising results, 
suppressing MMP-2 and CXCR4 expression and xenograft growth in NSCLC cells and 
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LPS-induced activation in macrophages, respectively (345, 347). Additional agonists of 
DUSP1 include aurothiomalate and auranofin, which increase DUSP1 expression and 
inhibit p38 MAPK phosphorylation, are anti-rheumatic gold compounds (416). 
Phosphodiesterase 4 (PDE4) inhibitors, recently used to treat chronic obstructive 
pulmonary disease, plaque psoriasis, and psoriatic arthritis (417-419), inhibit the cyclic 
AMP (cAMP) degradation pathway regulating the signaling through this second 
messenger in a number of cell types (420). DUSP1 has been shown to mediate the anti-
inflammatory effect of the PDE4 inhibitor rolipram through transcriptional activation by 
the cAMP-PKA-CREB pathway (421-424). Vitamin D has also been shown to induce 
DUSP1 expression and inhibit p38 MAPK phosphorylation in macrophages (83), as one 
of a number of mechanisms for its role as an endogenous anti-inflammatory agent. The 
use of thiazolidinediones as an anti-diabetic agent was previously shown in a 
retrospective study to be associated with reduced risk of lung, prostate, and colon cancer 
(425). Concerns over adverse cardiovascular events associated with rosiglitazone use 
have dampened enthusiasm over its potential as a chemopreventive agent. However, on 
November 25, 2013, the Food and Drug Administration released an update removing 
prescribing restrictions on the drug following evaluation of the Rosiglitazone Evaluated 
for Cardiovascular Outcomes and Regulation of Glycemia in Diabetes (RECORD) 
clinical trial when no increase in risk of heart attack or death was found. Within the same 
family of thiazolidinediones, pioglitazone was recently examined in a Phase IIa clinical 
trial for prevention of head and neck cancer in patients with oral leukoplakia, with partial 
or complete responses in 15 out of 21 patients, as reported to clinicaltrials.gov 
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(NCT00099021). Given these promising early findings, additional investigation as to 
whether these agents could enhance current therapies is needed. 
In summary, these studies demonstrate DUSP1 plays an important role within the 
tumor microenvironment, regulating key cytokines such as IL-1β. Loss of DUSP1 
expression, as shown here in head and neck cancer, alters the inflammatory milieu of the 
tissue, with enhanced expression of pro-tumorigenic cytokines that enhance immune cell 
recruitment and activation while promoting suppression of anti-tumor immunity. In 
animal tumor models, down regulation of Dusp1 leads to enhanced disease progression 
through increased activation of MAPK-driven signaling pathways. Thus, restoring 
DUSP1 expression represents a promising target of pharmacological intervention and 
merits further investigation as a suppressor of tumor-promoting inflammation. 
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Appendix A. Comparison of inflammatory cytokine, chemokine and receptor expression 
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Appendix B. Comparison of the expression levels of MAPK signaling pathway members 
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Appendix C. Nanostring gene counts from wild-type and Dusp1 deficient tumor tissues. 
Gene counts are shown for individual tumor tissue lysates, after normalization against 
positive and negative in-assay controls and housekeeping genes. n = 6. 
 
a-SMA Activin AB Acvr2a ADAM17 ALK-1 
WT 11775.74 13.16 1266.01 2303.91 3407.61 
WT 12400.28 13.23 1284.19 2389.29 3476.07 
WT 1489.83 5.02 1696.78 2935.46 561.58 
WT 12312.11 11.72 1529.42 2195.55 1032.76 
WT 6367.13 22.76 1473.21 3544.08 892.31 
WT 9517.23 25.36 1483.79 3163.57 900.42 
KO 9980.18 12.16 1087.9 3462.71 1265.9 
KO 2372.75 14.97 1468 4034.42 794.35 
KO 2283.04 11.14 1426.2 3961.06 728.7 
KO 2861.85 7.53 1308.97 4579.52 720.41 
KO 6599.72 8.93 1275.89 2604.37 804.63 













WT 1203.72 6603.78 4139.32 1946.83 644.85 
WT 1333.04 6820.87 4136.48 2029.06 706.2 
WT 1018.67 6231.58 4353.97 2206.12 343.58 
WT 1130.81 6497.11 4368.71 2282.94 751.39 
WT 1389.37 6224.6 4418.42 2003.8 476.7 
WT 1292.41 6240.68 4883.71 1776.63 537.25 
KO 1478.18 6724.21 5472.68 2340.54 357.11 
KO 1414.67 6384.71 4170.08 2917.28 188.06 
KO 1325.92 6384.49 4227.36 2959.37 172.7 
KO 1520.86 7440.42 4582.34 2873.15 136.55 
KO 1061.59 5700.84 3225.45 1787.84 335.34 




(Acvr1C) Alpl AMH APRIL Arg-1 
WT 23.69 206.18 7.02 108.79 6703.8 
WT 31.55 194.36 5.09 123.13 6988.77 
WT 52.24 239.1 5.02 164.76 12976.52 
WT 62.88 313.35 9.59 181.19 7331.63 
	   131	  
WT 141.33 267.09 7.19 179.66 13404.98 
WT 29.98 198.3 6.92 227.12 14945.11 
KO 17.69 504.15 4.42 135.99 39627.73 
KO 165.61 145.96 14.97 130.05 160061.26 
KO 171.59 122.56 11.14 141.51 155674.57 
KO 5.65 542.42 5.65 80.99 86303.61 
KO 49.61 200.41 7.94 84.33 9542.4 
KO 9.5 38.87 6.91 50.1 24022.86 
 
 Arginase Atf4 Axin2 Bad Bax 
WT 89.49 9329.7 420.25 364.1 1262.5 
WT 86.49 9760.67 423.32 401.95 1297.42 
WT 25.12 10790.5 301.38 459.11 1477.78 
WT 38.37 7856.01 510.52 363.44 1170.25 
WT 22.76 10674.16 352.13 420.4 1143.83 
WT 42.66 9732.83 408.13 447.33 1127.54 
KO 160.31 13104.58 375.9 509.68 1451.64 
KO 236.71 12309.09 245.13 589.44 1963.88 
KO 240.67 12043.62 222.84 563.8 1896.4 
KO 367.27 12590.61 344.66 543.36 1777 
KO 33.73 11155.62 278.79 373.04 1116.16 
KO 126.12 16403.09 188.31 597.76 2265.8 
 
 Bcl2 Bcl2l1 Bcl2l11 Bcl6 Bglap 
WT 310.58 1706.44 485.17 914.19 6679.24 
WT 345.98 1722.77 528.13 936.18 6835.11 
WT 115.53 1423.53 318.46 798.66 20252.9 
WT 262.19 1164.92 447.64 840.92 12957.99 
WT 222.78 1349.84 421.6 1002.5 11506.58 
WT 249.03 1254.36 469.23 832.4 9053.76 
KO 192.37 1795.48 724.16 1072.42 1460.49 
KO 109.47 2055.57 747.57 906.62 1217.25 
KO 93.59 2089.17 726.47 915.89 1246.81 
KO 113 1618.79 761.84 741.12 459.55 
KO 70.44 907.81 299.63 872.09 1088.38 
KO 155.49 1161.84 694.51 1102.24 251.37 
 
 Bmp-1 Bmp2 Bmp4 BMPR-II C-fos 
WT 1547.64 450.96 1898.58 2263.55 1444.11 
	   132	  
WT 1502.97 487.42 1953.76 2269.21 1507.04 
WT 816.75 744.41 888.07 2799.84 958.4 
WT 962.42 820.67 1606.16 2940.54 1289.62 
WT 1052.8 589.28 958.18 2617.04 1913.97 
WT 1215.16 645.63 1423.84 2712.79 1165.59 
KO 1822.02 674.41 1223.89 2672.22 3153.15 
KO 2170.65 1007.67 712.01 3360.77 10835.48 
KO 2071.34 947.09 677.45 3295.87 10536.08 
KO 2058.57 730.76 1280.72 2608.53 2936.24 
KO 714.34 369.08 1018.93 2352.36 1433.64 
KO 5028.3 1921.14 1224.9 3905.33 15322.45 
 
 C1qa C1qb C3ar1 C5ar1 Calcr 
WT 1712.58 3354.09 547.46 374.63 37.73 
WT 1821.48 3395.68 590.2 365.31 38.67 
WT 1819.35 3333.29 494.27 339.56 31.14 
WT 2550.46 4242.95 940.04 331.46 28.78 
WT 1948.71 3287.77 1203.72 406.03 41.92 
WT 2526.02 4613.93 1035.31 440.41 24.21 
KO 3147.62 5973.51 1169.72 705.37 16.58 
KO 4553.69 9327.25 1756.17 1274.32 8.42 
KO 4507.03 9220.18 1644.59 1331.49 17.83 
KO 3254.54 5420.46 2217.72 921.93 11.3 
KO 1494.16 3338.55 540.72 303.59 26.79 
KO 2101.68 4063.41 1591.16 446.6 10.37 
 
 CCL2 CCR5 Cd 44 Cd 47 Cd 9 
WT 504.47 106.16 11211.61 3898.05 13505.87 
WT 525.07 135.34 11338.94 4029.63 14243.13 
WT 445.04 115.53 11416.37 5073.27 20856.67 
WT 540.36 185.45 10892.47 4500.87 13942.79 
WT 1366.61 209.6 15350.1 4525.02 15465.08 
WT 840.47 228.28 14834.43 4949.42 14910.52 
KO 794.92 256.5 24304.22 5984.57 22548.55 
KO 2137.91 377.06 39415.11 8776.17 50118.67 
KO 2152.68 384.41 38495.24 8796.78 49367.81 
KO 1214.8 509.46 32803.39 8977.29 39992.38 
KO 655.8 157.75 10609.95 3605.44 11283.61 
KO 3063.11 332.57 50665.68 9912.34 56344.44 
 
	   133	  
 CD105  CD109 CD11b CD16 CD163 
WT 1759.08 2347.78 423.76 219.34 959.82 
WT 1926.29 2419.82 443.67 241.17 979.93 
WT 697.2 3527.18 546.51 341.57 882.05 
WT 1316.26 3418.02 653.34 274.98 1108.43 
WT 1234.86 2327.19 450.35 202.42 945.01 
WT 1378.87 2361.15 737.86 319.35 1265.89 
KO 1670.55 2546.18 740.75 479.83 1678.29 
KO 1156.43 3188.61 1442.74 1424.02 4221.54 
KO 1080.79 3221.21 1520.91 1352.66 4169.42 
KO 1244.94 2830.77 833.41 838.12 1554.76 
KO 1149.89 1676.72 536.75 302.6 540.72 
KO 801.63 8969.92 404.27 374.03 375.76 
 
 CD32 CD40lg CD46 CD55 CD56  
WT 1473.06 13.16 26.32 3350.59 1350.24 
WT 1490.76 21.37 18.32 3506.6 1374.76 
WT 1403.44 9.04 12.06 2343.75 931.27 
WT 1303.47 29.84 22.38 3080.16 1235.26 
WT 1353.43 34.73 28.75 2421.81 983.34 
WT 1596.77 29.98 18.45 2588.27 990.35 
KO 3138.78 38.7 23.22 2640.15 885.58 
KO 6517.57 27.13 12.16 2264.21 786.86 
KO 6138.25 23.4 20.06 2184.99 699.73 
KO 4228.26 32.02 14.13 1438.93 431.3 
KO 1097.31 26.79 21.83 2690.68 882.01 
KO 2521.49 16.41 20.73 567.53 1844.26 
 
 Col10a1 Col1a1 CD86 Cdh1 CEBPb 
WT 4.39 4788.56 296.54 9626.24 8791.89 
WT 6.11 4880.33 306.29 9845.13 9098.22 
WT 4.02 3398.59 240.1 10433.86 11097.91 
WT 4.26 4995.4 436.98 8474.17 8942.06 
WT 11.98 4413.63 554.55 11681.45 12782.17 
WT 13.83 7221.8 526.88 12096.28 10289.68 
KO 12.16 9460.55 671.09 15243.9 11820.99 
KO 11.23 12267.93 265.72 20376.06 11453.93 
KO 21.17 11987.91 269.64 20265.46 11015.19 
KO 19.78 9013.07 652.6 15222.68 10204.33 
KO 6.94 4705.72 326.41 8153.41 9482.88 
	   134	  
KO 244.46 4910.82 310.98 14060.41 6772.35 
 
 Chordin Col10a1 Col1a1 Col1A2 Col2a1 
WT 163.19 4.39 4788.56 3107.56 11.41 
WT 180.11 6.11 4880.33 3231.85 14.25 
WT 112.52 4.02 3398.59 1482.8 14.06 
WT 187.58 4.26 4995.4 3731.36 20.25 
WT 135.34 11.98 4413.63 3260.22 25.15 
WT 177.55 13.83 7221.8 4853.73 16.14 
KO 127.14 12.16 9460.55 5199.6 13.27 
KO 78.59 11.23 12267.93 3752.8 25.26 
KO 60.17 21.17 11987.91 3613.42 31.2 
KO 65.92 19.78 9013.07 5009.88 25.43 
KO 99.21 6.94 4705.72 1886.06 10.91 
KO 50.97 244.46 4910.82 2074.03 38.01 
 
 Cpt1a Crim1 CSF1 CSF2 CSF3 
WT 3472.54 1612.56 1067.73 21.93 35.97 
WT 3613.44 1801.12 1120.36 36.63 46.81 
WT 4810.06 1114.11 894.1 14.06 8.04 
WT 3208.06 1711.67 1187.3 27.71 24.51 
WT 3630.32 1206.11 1269.59 22.76 69.47 
WT 3637.42 1324.69 1207.09 25.36 13.83 
KO 4412.42 1556.67 1055.84 16.58 202.32 
KO 3428.13 1882.48 880.42 55.2 152.51 
KO 3387.23 1908.66 817.84 46.8 134.82 
KO 3594.49 1573.59 823.05 61.21 259.91 
KO 3341.53 1323.52 929.64 12.9 7.94 
KO 4144.61 2888.62 848.27 55.28 119.21 
 
 Ctla4 Ctnnb1 Ctsk CXCL1 CXCL10 
WT 129.85 20536.04 464.99 100.02 42.11 
WT 121.09 20424.95 436.54 98.71 42.74 
WT 97.45 22674.01 259.19 48.22 53.24 
WT 228.08 23931.46 699.16 106.58 121.5 
WT 231.16 24639.68 492.27 332.97 415.61 
WT 244.42 25083.76 707.88 103.76 198.3 
KO 464.35 26059.9 824.77 1174.14 456.61 
KO 178.7 32609.37 1959.2 1250.93 246.07 
	   135	  
KO 193.87 32197.66 1808.38 1128.71 233.99 
KO 836.24 27795.4 747.71 1544.4 457.67 
KO 81.36 19792.21 353.2 78.38 101.2 
KO 199.54 38908.22 344.66 2392.78 374.03 
 
 CXCl11 CXCL13 CXCL2 CXCL9 CXCR5 
WT 23.69 202.67 48.25 41.24 35.97 
WT 31.55 202.5 49.86 42.74 58 
WT 47.22 589.7 11.05 120.55 49.23 
WT 105.51 344.25 35.17 160.94 96.99 
WT 79.05 1245.64 38.33 168.88 80.25 
WT 117.6 1065.28 62.26 387.38 99.15 
KO 26.53 547.27 906.59 347.16 35.38 
KO 31.81 2408.3 1215.38 364.89 27.13 
KO 25.63 2313.12 1270.21 324.24 33.43 
KO 48.03 433.18 2536.96 1107.45 30.13 
KO 31.75 104.17 11.91 128.98 15.87 
KO 32.83 31.1 610.72 377.49 26.78 
 
 Decorin Dermatopontin Dkk1 DMP-1 Dspp 
WT 66434.41 25010.51 15.79 9.65 8.77 
WT 67027.26 25073.28 13.23 20.35 3.05 
WT 75432 20581.41 8.04 10.05 11.05 
WT 97661.33 25296.75 30.91 19.18 24.51 
WT 57691.02 26109.3 20.36 10.78 20.36 
WT 77477.54 26981.44 21.91 12.68 17.29 
KO 67276.37 26277.71 14.37 14.37 12.16 
KO 49692.03 9735.19 8.42 25.26 11.23 
KO 49153.88 9468.65 10.03 20.06 10.03 
KO 30450.07 11938.01 11.3 26.37 11.3 
KO 48463.07 19216.76 7.94 5.95 16.87 
KO 7776.11 7115.29 11.23 13.82 9.5 
 
 Erbin Ets1 Eif4a2 Elastase  Emr1 
WT 7349.53 1823.13 32873.28 10.53 294.79 
WT 7390.72 1888.64 33172.23 9.16 317.49 
WT 7451.18 1031.73 30200.53 12.06 654 
WT 7525.61 1393 30605.49 12.79 597.91 
WT 7033.07 1569.03 28751.49 15.57 601.26 
	   136	  
WT 6968.16 1468.8 30991.24 12.68 718.26 
KO 7233.89 1817.59 30459.05 15.48 372.58 
KO 8424.38 1714.07 20233.85 14.97 813.06 
KO 8280.89 1608.94 20080.5 15.6 821.18 
KO 7404.64 1756.28 32189.4 5.65 483.1 
KO 4855.53 1248.11 31393.3 11.91 383.96 
KO 9261.02 1652.49 33940.38 11.23 301.47 
 
 EOMES Erbin Ets1 Factor B Fgf2 
WT 10.53 7349.53 1823.13 214.95 1156.34 
WT 17.3 7390.72 1888.64 178.08 1098.99 
WT 5.02 7451.18 1031.73 294.35 585.69 
WT 21.32 7525.61 1393 401.81 1165.98 
WT 15.57 7033.07 1569.03 328.18 722.23 
WT 25.36 6968.16 1468.8 457.7 780.52 
KO 5.53 7233.89 1817.59 637.93 657.83 
KO 22.46 8424.38 1714.07 946.85 277.88 
KO 31.2 8280.89 1608.94 937.06 287.47 
KO 13.18 7404.64 1756.28 657.31 152.56 
KO 9.92 4855.53 1248.11 529.8 640.92 
KO 32.83 9261.02 1652.49 343.8 101.07 
 
 Fgf23 Fgf4 Fgf8 Fizz1 FKBP51 
WT 8.77 14.91 5.26 16235.29 1137.92 
WT 8.14 18.32 8.14 16512.34 1097.97 
WT 17.08 28.13 13.06 40055.73 655 
WT 38.37 30.91 6.39 33439.46 690.64 
WT 63.48 39.53 11.98 27507.05 839.61 
WT 38.05 39.2 5.76 34869.62 667.53 
KO 49.75 15.48 7.74 15194.15 1911.57 
KO 34.62 14.97 7.49 33161.39 1698.16 
KO 55.71 18.94 8.91 32078.44 1598.91 
KO 68.74 15.07 6.59 12470.07 606.46 
KO 16.87 24.8 4.96 23334.15 459.36 
KO 21.6 18.14 12.09 2810.01 324.8 
 
 FLT3L Follistatin Foxo1 FoxP3 Fstl3 
WT 372.87 599.23 1208.98 34.22 67.56 
WT 387.7 579.01 1231.28 31.55 89.55 
	   137	  
WT 211.97 503.31 1023.7 28.13 36.17 
WT 339.99 522.24 1470.8 103.38 93.79 
WT 396.45 352.13 1143.83 140.13 85.04 
WT 317.05 499.21 1062.98 136.04 83.01 
KO 302.93 1060.26 1166.4 107.24 89.55 
KO 244.2 1091.88 1409.05 31.81 130.05 
KO 226.19 1021.74 1372.72 26.74 123.68 
KO 285.34 1488.84 747.71 122.42 77.22 
KO 218.27 376.02 749.07 31.75 40.68 




(PACE) G6pd2 Gata3 GDF1 
WT 16.67 4412.17 3260.22 135.11 52.64 
WT 29.51 4404.11 3490.31 129.23 68.18 
WT 15.07 5261.13 3367.45 95.44 31.14 
WT 40.5 4466.77 3253.89 266.45 77.8 
WT 17.97 5180.18 3833.93 173.67 68.27 
WT 34.59 5080.85 3300.77 279 48.42 
KO 22.11 8414.66 3599.81 174.68 32.06 
KO 17.78 12194.01 4503.17 105.73 16.84 
KO 18.94 12311.03 4518.17 114.76 18.94 
KO 12.24 10256.12 3330.81 184.57 22.6 
KO 7.94 4822.79 2152.94 94.25 40.68 













WT 5.26 8.77 14.04 366.73 28.95 
WT 8.14 6.11 11.19 391.77 39.69 
WT 11.05 13.06 12.06 278.28 16.07 
WT 19.18 22.38 29.84 395.41 49.03 
WT 34.73 19.16 13.18 346.14 37.13 
WT 23.06 21.91 29.98 386.22 35.74 
KO 13.27 11.06 44.22 392.49 38.7 
KO 14.97 9.36 14.97 422.9 16.84 
KO 17.83 17.83 20.06 441.23 12.26 
KO 21.66 10.36 20.72 358.79 11.3 
KO 8.93 13.89 28.77 403.8 31.75 
KO 14.68 11.23 30.23 214.23 10.37 




alpha-1 Gfra4 Gli1 GP49A Gprasp1 
WT 215.83 286.89 251.8 541.32 529.92 
WT 253.38 296.12 276.78 623.78 533.21 
WT 240.1 181.83 57.26 203.94 371.71 
WT 222.75 311.21 142.82 341.06 525.44 
WT 198.82 194.03 82.64 519.81 516.22 
WT 168.32 250.18 129.13 515.35 500.36 
KO 123.83 208.96 105.03 1902.72 286.35 
KO 69.24 151.57 50.52 3142.77 174.03 
KO 62.4 141.51 55.71 3132.08 192.76 
KO 52.74 154.44 57.44 5239.65 144.08 
KO 92.27 90.28 64.49 375.03 312.52 
KO 63.06 67.38 59.6 1760.47 187.45 
 
 Gprasp2 Gr1 Gremlin GusB GzmB 
WT 131.6 6.14 660.64 626.43 10.53 
WT 117.02 10.18 668.55 641.08 13.23 
WT 67.31 3.01 44.2 619.84 22.1 
WT 229.15 12.79 474.28 614.97 33.04 
WT 156.9 11.98 457.53 606.05 22.76 
WT 157.95 25.36 600.66 722.87 38.05 
KO 50.86 17.69 1656.18 986.19 33.17 
KO 29 56.14 1370.69 1136.79 101.05 
KO 28.97 49.03 1422.86 1184.42 90.25 
KO 36.73 34.84 1699.78 946.41 117.71 
KO 24.8 7.94 147.83 667.71 16.87 
KO 21.6 18.14 501.88 1208.49 87.25 
 
 HAVCR2 Hk2 Hmgb1 Hmox1 Ibsp 
WT 149.15 7147.74 5464.99 3448.85 6.14 
WT 161.8 7405.98 5522.43 3514.74 6.11 
WT 83.38 6423.46 6713.8 3909.93 15.07 
WT 101.25 6575.98 6591.97 3053.52 11.72 
WT 152.11 8646.41 5792.22 3734.52 3.59 
WT 142.96 6512.76 5622.72 2597.5 8.07 
KO 280.82 8892.27 5513.59 5964.67 3.32 
KO 185.25 8276.55 6671.01 6017.01 18.71 
	   139	  
KO 162.68 7965.57 6554.96 5825.15 11.14 
KO 334.31 5998.67 6074 5559.83 10.36 
KO 82.35 8668.33 5609.56 3558.81 9.92 
KO 225.46 4083.28 8817.88 2154.37 19.87 
 
 IFNG Ift122 Ift139 Ift140 Ift172 
WT 19.3 634.32 455.34 735.22 858.92 
WT 17.3 674.66 447.74 742.84 845.61 
WT 15.07 516.37 355.63 575.64 730.35 
WT 27.71 609.64 448.7 685.31 882.48 
WT 29.94 528.2 424 842 887.52 
WT 21.91 510.74 455.4 902.72 760.92 
KO 15.48 636.82 382.53 719.74 623.55 
KO 29 682.07 510.85 918.78 705.46 
KO 13.37 667.42 547.08 929.26 601.68 
KO 11.3 550.9 513.23 765.61 387.98 
KO 22.82 437.53 311.53 502.02 626.04 
KO 12.09 1047.81 1015.85 1267.23 743.75 
 
 Ift88 Igsf1 Ihh IL-10 IL-12a 
WT 259.69 24.57 9.65 14.91 566.77 
WT 252.36 23.4 19.33 12.21 565.78 
WT 223.02 15.07 8.04 5.02 713.27 
WT 249.4 25.58 10.66 13.86 563.81 
WT 289.85 37.13 13.18 26.35 455.14 
WT 257.1 20.75 12.68 13.83 348.18 
KO 243.23 24.32 6.63 15.48 241.02 
KO 331.21 19.65 10.29 21.52 58.01 
KO 373.26 13.37 10.03 24.51 42.34 
KO 247.67 14.13 10.36 24.48 78.16 
KO 162.71 19.84 8.93 18.85 421.66 
KO 574.44 9.5 19.87 19 33.69 
 
 IL-13 IL-15 IL-15Ra IL-17a IL-1B 
WT 7.9 241.27 269.35 16.67 304.44 
WT 12.21 257.45 317.49 10.18 290.01 
WT 13.06 321.47 184.85 15.07 42.19 
WT 25.58 379.42 301.62 44.76 88.46 
WT 14.37 376.09 337.76 34.73 332.97 
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WT 33.43 522.27 325.12 57.65 244.42 
KO 12.16 319.52 430.08 27.64 2276.41 
KO 24.33 222.68 226.42 25.26 4731.46 
KO 18.94 197.22 203.9 33.43 4423.46 
KO 31.08 271.21 351.26 48.97 8111.86 
KO 13.89 456.38 191.48 19.84 71.43 
KO 29.37 125.25 248.78 27.64 3077.79 
 
 IL-2 IL-21r IL-2RB IL-2Rg IL-4 
WT 7.02 102.65 493.07 206.18 14.91 
WT 5.09 78.35 493.53 237.1 5.09 
WT 8.04 56.26 178.82 148.68 16.07 
WT 23.45 156.67 442.31 211.03 21.32 
WT 14.37 179.66 582.1 261.1 29.94 
WT 23.06 234.04 575.3 270.93 27.67 
KO 13.27 175.79 799.34 407.96 17.69 
KO 4.68 107.6 272.27 234.84 110.4 
KO 12.26 124.79 283.01 280.78 147.08 
KO 7.53 328.66 882.38 440.72 80.05 
KO 9.92 64.49 210.33 213.31 8.93 
KO 4.32 182.27 241.87 245.33 106.25 
 
 IL-4Ra IL-6 IL-7 IL-7Ra IL18r1 
WT 1589.75 38.6 129.85 573.78 634.32 
WT 1594.55 32.56 132.29 594.27 658.38 
WT 1135.21 15.07 124.57 317.46 271.24 
WT 944.3 31.97 150.28 516.91 429.52 
WT 1922.36 45.51 136.54 837.21 469.51 
WT 1965.7 35.74 168.32 866.98 534.95 
KO 6754.06 116.09 171.37 1408.52 604.76 
KO 15117.84 227.36 205.84 459.39 469.68 
KO 14708.84 230.64 215.04 452.37 473.54 
KO 10327.69 199.64 239.19 1182.78 637.54 
KO 1830.5 17.86 149.81 421.66 274.82 
KO 11254.72 205.59 107.98 440.55 376.63 
 
 IL1RL1 IL2ra IL9R iNOS Irf-5 
WT 200.91 62.29 18.42 45.62 784.35 
WT 206.57 52.91 16.28 51.9 800.84 
	   141	  
WT 236.08 93.43 17.08 44.2 1287.91 
WT 325.07 165.2 38.37 66.08 1406.86 
WT 318.6 141.33 37.13 65.88 1237.25 
WT 436.95 197.15 26.52 59.95 1407.7 
KO 453.29 179.11 18.8 63.02 1089.01 
KO 758.79 105.73 15.91 87.95 1351.98 
KO 698.62 114.76 14.48 76.88 1322.58 
KO 655.43 277.8 14.13 59.33 1482.25 
KO 193.47 75.4 8.93 53.58 802.64 
KO 152.9 112.3 12.09 63.92 1058.18 
 
 Lag3 Ldha Lef1 Lefty Lilrb4 
WT 82.47 56098.39 114.93 441.31 327.25 
WT 82.42 56527.83 117.02 460.97 320.54 
WT 81.37 65711.42 27.12 308.41 155.71 
WT 124.7 52390.43 36.24 442.31 187.58 
WT 147.32 69859.95 46.71 255.12 194.03 
WT 134.89 56214.51 47.27 403.52 219.05 
KO 142.62 72462.7 54.17 613.6 728.59 
KO 158.12 92997.47 43.97 541.73 1445.54 
KO 154.88 91134.4 37.88 463.52 1368.26 
KO 305.11 63465.35 105.47 549.01 1505.79 
KO 67.47 70321.91 56.55 275.81 228.19 
KO 243.6 84590.51 47.51 900.1 777.44 
 
 LRRC32 MCP-1 Amhr2 Mmp1 MMP2 
WT 898.4 75.45 1559.92 5.26 3649.76 
WT 907.69 86.49 1607.78 7.12 3851.56 
WT 233.07 102.47 1530.02 14.06 3437.77 
WT 478.54 296.29 1236.33 12.79 4824.87 
WT 444.36 366.51 1337.86 7.19 3379.99 
WT 519.96 220.2 1207.09 13.83 4751.12 
KO 835.83 143.73 1279.17 7.74 5301.31 
KO 569.8 597.86 796.22 10.29 3776.19 
KO 583.85 533.71 750.99 10.03 3583.34 
KO 521.71 155.38 667.67 16.01 2862.79 
KO 383.96 87.31 1655.88 7.94 2793.87 
KO 456.96 209.04 752.39 16.41 1146.29 
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 MMP9 Msx1 Msx2 MMP14 MMP16 
WT 172.84 60.54 64.92 1708.19 71.94 
WT 181.13 76.32 61.06 1613.89 73.27 
WT 245.12 34.16 47.22 1320.06 53.24 
WT 193.98 60.75 69.28 1873.68 95.92 
WT 247.93 64.68 49.11 2115.19 55.1 
WT 216.75 65.72 42.66 2185.91 71.48 
KO 1049.21 61.91 100.61 2723.07 46.43 
KO 1126.49 63.62 83.27 4303.88 36.49 
KO 1181.07 34.54 65.74 4162.73 39 
KO 2314.71 48.97 108.3 4210.37 19.78 
KO 60.52 38.69 52.58 1176.68 60.52 
KO 12239.48 112.3 266.06 6945.12 21.6 
 
 Nanog ND4 Nfatc1 Nfkb NGF 
WT 12.28 2772.41 705.39 2198.63 64.92 
WT 10.18 2733.23 738.77 2349.6 71.23 
WT 21.1 2584.86 500.29 2282.47 72.33 
WT 29.84 2851.01 613.9 2208.34 81 
WT 37.13 3177.58 613.24 3100.92 92.23 
WT 38.05 2858.05 545.32 2644.76 86.47 
KO 11.06 2836.95 538.42 4059.73 106.14 
KO 15.91 2635.66 445.36 5718.55 214.26 
KO 16.71 2405.6 425.63 5583.36 168.25 
KO 10.36 3291.26 448.25 4574.81 151.61 
KO 11.91 3911.02 497.06 2141.04 97.23 
KO 15.55 2899.85 407.72 5806.6 72.56 
 
 Nicalin Noggin Nox1 Oaz1 Ocstamp 
WT 1521.32 318.48 59.66 20699.23 21.93 
WT 1440.9 329.7 56.98 20273.33 19.33 
WT 1797.24 262.2 32.15 25134.29 18.08 
WT 1531.55 394.35 67.15 20482.53 19.18 
WT 1825.34 267.09 41.92 20897.98 22.76 
WT 1642.89 145.27 44.96 19305.4 20.75 
KO 1585.42 234.39 40.91 20030.01 19.9 
KO 2042.47 117.89 52.4 21721.49 55.2 
KO 2056.85 112.54 40.11 20831.48 42.34 
KO 1443.64 115.83 30.13 22769.51 27.31 
KO 1376.1 340.3 22.82 21762.6 30.76 
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KO 1939.28 296.29 19 26923.57 46.65 
 
 Pcx Pdcd1 PDGFA Pdlim7 Pfkl 
WT 1108.09 78.96 1868.75 12937.35 3024.21 
WT 1136.64 67.16 1931.38 13029.15 3208.44 
WT 2005.2 33.15 1287.91 11025.57 4440.37 
WT 2612.27 99.12 1611.49 12334.5 4143.83 
WT 1939.12 130.55 1426.5 11130.5 5715.56 
WT 1706.3 176.39 1472.26 10747.38 4006.35 
KO 1247.11 385.85 1520.19 10987.37 5939.24 
KO 2622.56 112.28 1928.32 8305.55 11006.7 
KO 2514.8 119.22 1928.72 8378.95 10774.52 
KO 873.9 384.22 1782.65 7723.87 5629.52 
KO 1793.79 54.57 1128.06 13943.54 2891.1 
KO 609.86 61.33 3615.09 9393.19 11751.42 
 
 PGAM1 Pgd PGE2 Pilrb1 Plasmin 
WT 3025.09 6594.13 936.13 63.17 28.95 
WT 2983.56 6657.04 999.27 63.09 26.46 
WT 3839.61 6177.34 964.42 55.25 14.06 
WT 3690.86 5509.12 1081.79 75.67 116.17 
WT 5662.86 6625.84 1036.04 105.4 15.57 
WT 4827.21 6100.02 1039.92 127.97 17.29 
KO 6761.8 6921 1197.36 91.76 21.01 
KO 9174.75 8307.42 1276.19 84.21 23.39 
KO 9242.47 7854.15 1260.18 83.57 17.83 
KO 8034.64 6219.97 1010.45 108.3 16.95 
KO 2970.47 4384.27 1208.43 50.6 13.89 
KO 10763.21 4754.47 1094.46 58.74 11.23 
 
 POSTN Pou5f1 PPARG Ppargc1a Prdm1 
WT 7610.1 4.39 308.83 930.86 1229.16 
WT 7680.73 7.12 302.22 932.11 1275.03 
WT 3219.77 6.03 183.84 632.9 3584.44 
WT 8961.24 14.92 295.23 830.26 2244.57 
WT 5194.55 20.36 361.71 656.36 3285.37 
WT 7742.91 20.75 216.75 589.13 2707.02 
KO 7176.4 12.16 152.57 864.57 2326.17 
KO 9714.6 11.23 499.62 574.47 2921.96 
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KO 9327.15 8.91 454.6 592.77 2774.41 
KO 4733.02 8.48 65.92 227.89 3090.68 
KO 2307.72 6.94 155.77 1312.6 1566.59 
KO 4148.93 6.91 52.69 121.8 2600.96 
 
 Prf1 Ptch1 Ptgs2 Pth1r Pthlh 
WT 44.74 378.14 994.91 216.7 363.22 
WT 49.86 402.96 989.09 212.68 360.22 
WT 12.06 192.88 267.23 171.79 140.65 
WT 35.17 278.17 376.23 330.4 214.23 
WT 50.3 258.71 445.56 362.91 118.58 
WT 56.49 270.93 624.87 264.02 446.17 
KO 23.22 235.49 3923.75 213.38 1760.1 
KO 28.07 175.9 4411.48 272.27 5590.36 
KO 28.97 198.33 4434.6 269.64 5512.05 
KO 33.9 213.77 5877.19 124.31 2865.61 
KO 20.83 141.88 203.39 232.16 90.28 
KO 19.87 226.32 8461.99 77.74 5651.98 
 
 PTPRC RGM-A RGM-B RGM-C Rorc 
WT 1354.62 1128.27 4772.76 6072.99 1337.95 
WT 1355.42 1196.68 4601.52 6284.6 1364.58 
WT 841.86 767.52 4069.67 4287.67 2123.74 
WT 1243.79 1018.9 5389.75 3634.38 1566.73 
WT 1509.14 1020.47 3995.62 3235.07 1469.61 
WT 1684.39 951.15 4009.8 3298.46 1242.83 
KO 1473.75 933.12 3379.79 3567.74 1202.88 
KO 1241.58 878.55 2409.24 1279.94 1048.84 
KO 1189.99 824.52 2347.66 1257.96 1062.97 
KO 2681.04 644.13 1834.44 1487.9 717.58 
KO 849.27 805.62 3305.81 9342.98 1960.47 
KO 1012.4 1916.82 3149.49 843.95 539.02 
 
 Runx2 SCF SDF-1 Serpinb9 Shh 
WT 216.7 2075.8 1771.36 321.11 64.92 
WT 216.75 2031.1 1943.59 366.33 49.86 
WT 112.52 1425.54 1736.97 166.76 6.03 
WT 102.32 2206.2 2596.29 308.02 14.92 
WT 178.46 1182.16 1752.28 253.92 5.99 
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WT 189.08 1570.26 2129.42 314.74 16.14 
KO 298.51 1741.31 3003.89 228.86 3.32 
KO 310.63 2058.38 1880.61 208.64 10.29 
KO 301.95 1958.8 1851.84 231.76 2.23 
KO 351.26 1167.72 1433.28 261.79 2.83 
KO 80.36 1430.67 2812.72 155.77 2.98 
KO 638.36 2226.07 513.97 348.98 6.05 
 
 Slc2a1 Slc2a4 Smad3 SOCS1 SOST 
WT 2145.11 5058.78 4678.01 193.89 7.02 
WT 2212.23 5110.31 4899.67 163.83 4.07 
WT 3740.16 3894.87 4719.65 237.09 11.05 
WT 1977.06 5627.42 4630.9 276.04 19.18 
WT 3781.23 4460.34 4310.63 323.39 13.18 
WT 3140.51 3947.55 3553.25 359.71 12.68 
KO 9818.76 3681.62 3125.51 718.63 1.11 
KO 26045.95 2644.08 1991.95 606.29 29.94 
KO 25275 2688.62 1924.26 518.11 28.97 
KO 17462.06 960.54 2048.21 646.01 1.88 
KO 3281.01 7544.23 3975.51 241.09 2.98 
KO 27263.05 1069.41 2555.18 1445.17 6.91 
 
 Sox9 Sp7 Sparc Sphk1 SPON-1 
WT 205.3 7.02 1319.53 479.91 615.9 
WT 198.43 13.23 1331 515.92 625.81 
WT 146.67 9.04 805.7 125.58 67.31 
WT 224.88 18.12 999.72 160.94 321.87 
WT 155.7 15.57 919.86 149.72 155.7 
WT 259.4 14.99 1065.28 200.61 249.03 
KO 329.47 12.16 1208.41 417.91 517.42 
KO 1055.39 20.58 1075.03 430.39 804.64 
KO 1044.03 22.28 1007.26 426.75 729.82 
KO 523.59 20.72 872.02 412.47 602.69 
KO 199.42 9.92 1066.55 178.59 121.04 
KO 2585.42 28.51 862.09 398.22 133.89 
 
 Spp1 Sprouty2 Sprouty4 Stat1 Stk36 
WT 200.91 951.04 516.76 1331.81 40.36 
WT 220.82 965.69 466.05 1363.56 39.69 
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WT 118.54 725.33 168.77 1809.3 19.09 
WT 72.47 755.65 280.31 2491.84 25.58 
WT 389.26 968.96 287.45 2304.43 31.14 
WT 118.75 642.17 230.58 1876.93 27.67 
KO 552.8 621.34 379.22 2184.65 23.22 
KO 2186.56 875.75 208.64 2184.69 29.94 
KO 2130.39 854.61 249.59 2211.73 37.88 
KO 2250.68 524.53 180.81 2448.44 20.72 
KO 93.26 610.17 192.48 1407.85 11.91 
KO 3178.86 1433.08 182.27 2515.45 41.46 
 
 Tbx21 Tceb1 Tcf7 
Tdgf1 
(Cripto) TFAM 
WT 9.65 3018.07 261.45 10.53 1519.56 
WT 14.25 3150.44 263.55 10.18 1497.88 
WT 12.06 4039.53 112.52 14.06 1670.66 
WT 35.17 3351.94 219.55 18.12 1621.08 
WT 22.76 3366.82 212 35.93 1545.07 
WT 26.52 3230.44 277.85 25.36 1506.85 
KO 17.69 3768.96 379.22 12.16 1688.24 
KO 16.84 4554.63 422.9 25.26 1969.49 
KO 18.94 4683.07 408.92 21.17 1937.63 
KO 15.07 4862.03 408.7 16.01 1844.8 
KO 6.94 3765.17 212.32 9.92 1880.11 




2 TGF-b 3 TGFb R II TGFBRIII 
WT 1374.8 353.57 1455.52 3700.65 3624.32 
WT 1397.14 374.47 1466.34 3753.87 3740.64 
WT 1107.08 215.99 1014.65 2870.17 2023.28 
WT 1268.3 289.9 1257.64 3808.1 3557.64 
WT 1451.65 222.78 1031.24 3637.5 2267.3 
WT 1525.29 231.73 1148.29 3856.47 2471.83 
KO 2715.33 390.27 1276.96 4290.8 2234.4 
KO 4829.7 443.49 874.81 5343.36 1375.37 
KO 4644.08 411.15 909.2 5408.43 1401.69 
KO 3245.12 353.14 1018.93 4556.92 666.73 
KO 926.66 236.13 1522.94 2929.79 1421.74 
KO 6773.22 2646.75 1123.83 4268.14 523.48 
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 TNF Tnfrsf11a Tnfrsf11b TNFRSF4 Tnfsf11 
WT 24.57 200.03 43.87 71.07 15.79 
WT 22.39 203.52 53.93 63.09 24.42 
WT 35.16 132.61 39.18 36.17 28.13 
WT 60.75 292.03 74.61 74.61 30.91 
WT 101.81 233.56 63.48 85.04 33.54 
WT 102.61 254.79 101.46 66.87 33.43 
KO 96.19 195.69 116.09 80.71 54.17 
KO 87.01 181.51 126.31 93.56 75.79 
KO 92.48 187.19 99.17 67.97 74.65 
KO 150.67 183.63 160.09 153.5 50.85 
KO 29.76 126 58.54 29.76 14.88 
KO 209.91 142.53 85.52 115.75 20.73 
 
 Tnfsf13b Tubb4a VEGF VHL Wnt5a 
WT 204.42 189.51 4428.84 395.68 2276.71 
WT 209.62 194.36 4524.18 397.88 2254.97 
WT 86.4 79.36 2129.77 342.57 1554.13 
WT 192.91 139.62 2533.41 670.39 1926.97 
WT 177.26 94.62 2584.7 904.29 1816.96 
WT 193.69 86.47 2079.84 968.44 2097.13 
KO 290.77 70.76 4689.92 687.68 1772.26 
KO 223.61 26.2 8483.32 281.62 1964.81 
KO 198.33 30.08 8409.03 330.92 1930.95 
KO 290.05 24.48 5273.55 558.43 2692.34 
KO 115.09 49.61 3283.98 305.58 1316.57 
KO 112.3 10.37 11494 641.82 4409.81 
 
 Wnt7a Ym1 
WT 23.69 122.83 
WT 17.3 102.78 
WT 12.06 95.44 
WT 25.58 92.72 
WT 22.76 59.89 
WT 21.91 92.23 
KO 23.22 1054.73 
KO 17.78 54121.28 
KO 15.6 53186.25 
	   148	  
KO 22.6 1001.03 
KO 12.9 46.63 
KO 20.73 887.14 
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